

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
17 March 2005 (17.03.2005)

PCT

(10) International Publication Number
WO 2005/023814 A1

(51) International Patent Classification⁷: **C07D 487/04**

(21) International Application Number:
PCT/GB2004/003873

(22) International Filing Date:
10 September 2004 (10.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0321295.8 11 September 2003 (11.09.2003) GB

(71) Applicant (for all designated States except US):
SPIROGEN LIMITED [GB/GB]; 79 George Street,
Ryde, Hampshire PO33 2JF (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HOWARD, Philip**
[GB/GB]; School of Pharmacy, University of London,
29/39 Brunswick Square, London, Greater London WC1N
1AX (GB). **MASTERSON, Luke** [GB/GB]; School of
Pharmacy, University of London, 29/39 Brunswick Square,
London, Greater London WC1N 1AX (GB).

(74) Agents: **WATSON, Robert** et al.; Mewburn Ellis LLP,
York House, 23 Kingsway, London, Greater London
WC2B 6HP (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:




— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: SYNTHESIS OF PROTECTED PYRROLOBENZODIAZEPINES



(57) Abstract: A method of synthesis of a N-10 protected PBD compound of formula (I) via an intermediate of formula (II) or formula (V).

WO 2005/023814 A1

Synthesis of Protected Pyrrolobenzodiazepines

The present application relates to methods of making pyrrolobenzodiazepine (PBD) compounds, and in particular, PBDs having a N-10 protecting group, as well as intermediates in these methods.

Background


A large number of both synthetic and naturally occurring low molecular weight ligands are known that interact with DNA via a number of different mechanisms, including covalent or non-covalent interaction in the minor or major grooves, intercalation between base pairs or other types of non-specific interactions.

A particular class of compounds which interacts with the minor groove are the pyrrolobenzodiazepines (PBDs). PBDs have the ability to recognise and bond to specific sequences of DNA; the most preferred sequence is PuGpu (Purine-Guanine-Purine). The first PBD antitumour antibiotic, anthramycin, was discovered in 1965 (Leimgruber, et al., *J. Am. Chem. Soc.*, **87**, 5793-5795 (1965); Leimgruber, et al., *J. Am. Chem. Soc.*, **87**, 5791-5793 (1965)). Since then, a number of naturally occurring PBDs have been reported, and over 10 synthetic routes have been developed to a variety of analogues (Thurston, et al., *Chem. Rev.* **1994**, 433-465 (1994)). Family members include abbeymycin (Hochlowski et al., 1987 *J. Antibiotics*, **40**, 145-148), chicamycin (Konishi et al., 1984 *J. Antibiotics*, **37**, 200-206), DC-81 (Japanese Patent 58-180 487; Thurston et al., 1990, *Chem. Brit.*, **26**, 767-772; Bose et al., 1992 *Tetrahedron*, **48**, 751-758), mazethramycin (Kunimoto et al., 1980 *J. Antibiotics*, **33**, 665-667), neothramycins A and B (Takeuchi et al., 1976 *J. Antibiotics*, **29**, 93-96), porothramycin (Tsunakawa et al., 1988 *J. Antibiotics*, **41**, 1366-1373), prothracarcin (Shimizu et al., 1982 *J. Antibiotics*, **35**, 972-978; Langley and Thurston, 1987 *J. Org. Chem.*, **52**, 91-97), sibanomycin (DC-102) (Hara et al., 1988 *J. Antibiotics*, **41**, 702-704; Itoh et al., 1988 *J. Antibiotics*, **41**, 1281-1284), sibiromycin (Leber et

al., 1988 *J. Am. Chem. Soc.*, **110**, 2992-2993) and tomamycin (Arima et al., 1972 *J. Antibiotics*, **25**, 437-444).


PBDs are of the general structure:

5




10 They differ in the number, type and position of substituents, in both their aromatic A rings and pyrrole C rings, and in the degree of saturation of the C ring. There is either an imine (N=C), carbinolamine (NH-CH(OH)) or a carbinolamine methyl ether (NH-CH(OMe)) at the N10-C11 position which is the electrophilic
15 centre responsible for alkylating DNA. These forms may exist in equilibrium in solution. All of the known natural products have an (S)-configuration at the chiral C11a position which provides them with a right-handed twist when viewed from the C ring towards the A ring. This gives them the appropriate three-
20 dimensional shape for isohelicity with the minor groove of B-form DNA, leading to a snug fit at the binding site (Kohn, 1975 In *Antibiotics III*. Springer-Verlag, New York, pp. 3-11; Hurley and Needham-VanDevanter, 1986 *Acc. Chem. Res.*, **19**, 230-237). Their ability to form an adduct in the minor groove enables them to
25 interfere with DNA processing, hence their use as antitumour agents.

The present inventors have previously disclosed that PBDs can be employed as prodrugs by protecting them at the N10 position with
30 a nitrogen protecting group which is removable *in vivo* (WO 00/12507). Many of these protecting groups are carbamates, and are, for example, of the structure:



where * indicates the attachment point to the N10 atom of the PBD. These protecting groups are described as being added to the compound at two different stages in the synthesis route. One stage is addition of the corresponding chloroformate to a precursor structure as follows, which precursor is then cyclised to form the desired final compound:




An alternative route discussed involves adding the corresponding chloroformate to a carboxy aniline precursor of the starting material in the above route.

These routes employ a chloroformate reacting with an (aromatic) amine to form the carbamate. The present inventors have discovered that the use of the chloroformate has disadvantages, and have therefore developed an alternative synthesis route, which does not employ a chloroformate.


Summary of the Invention

Accordingly, a first aspect of the present invention provides a method of synthesis of a compound of formula (I):




comprising the step of either:

(a) reacting a compound of formula (II) with a compound of formula (III) to yield a compound of formula (IV):



(b) reacting a compound of formula (V) with a compound of formula (III) to yield a compound of formula (VI):



wherein

the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3;

R^2 and R^3 are independently selected from -H, -OH, =O, =CH₂, -CN, -R, OR, =CH-R, O-SO₂-R, CO₂R and COR;

R^6 , R^7 and R^9 are independently H, R, OH, OR, SH, SR, NH₂, NHR,

NRR', nitro, Me₃Sn and halo;

R^8 is either selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR', nitro, Me₃Sn and halo or the compound is a dimer with each monomer being the same or different and being of the relevant formula,

where the R^8 groups of each monomer form together a bridge having the formula $-X-R''-X-$, where R'' is a C_{3-12} alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, NH, and/or aromatic rings, e.g. benzene or pyridine, and each X

5 is independently selected from O, S and NH;

R^{10} is such that $R^{10}-OC(=O)-$ forms a nitrogen protecting group;

R^{11} is either H or R;

R^{12} is an optionally substituted C_{1-4} alkyl group;

P and Q are such that $-CPQ$ is a masked aldehyde group;

10 wherein R and R' are independently selected from optionally substituted C_{1-20} alkyl, C_{3-20} heterocyclyl, and C_{5-20} aryl.


Reaction conditions

The reactions above should be carried in an anhydrous and non-
15 hydroxylic organic solvent, which is preferably non-polar.

Suitable solvents include anhydrous dichloromethane and anhydrous toluene. The reaction should be carried out in the presence of a base is present, and suitable bases include pyridine or TEA. The reaction may be carried out at 0°C , or at a higher temperature to
20 increase the rate of reaction.

Further Reaction Steps

If the method of synthesis of the first aspect of the invention comprises step (a), then the synthesis of the compound of formula
25 (I) from the compound of formula (IV) will be according to the following scheme:



wherein T is O or S, and each R^{ac} is independently selected from C₁₋₁₀ alkyl or together can be a C₁₋₃ alkylene group.

Thus the synthesis further comprise the following steps:

- 5 (i) hydrolysis of the ester -C(=O)OR¹²;
(ii) (a) coupling of resulting acid with hydroxymethyl pyrrole, followed by oxidation; or
(b) coupling of resulting acid with acetalmethyl pyrrole, followed by palladium mediated unmasking; and
10 (iii) (a) if XR¹¹ is OR¹¹, direct etherification;
(b) if XR¹¹ is SR¹¹, treatment with R¹¹SH and a catalyst, such as a Lewis Acid, e.g. Al₂O₃)
(c) if XR¹¹ is NHR¹¹, treatment with R¹¹NH and a catalyst, such as a Lewis Acid, e.g. Al₂O₃).

15

The ester hydrolysis is usually carried out under mild conditions, for example at 0°C with lithium hydroxide or under non-basic conditions, if the carbamate is sensitive to these. In this situation suitable R¹² groups would include allyl, butyl and
20 benzyl.


The coupling reaction is preferably carried out under mild conditions, with preferred conditions being DCC or HOBT in DCM at low temperature. Oxalyl chloride and thionyl chloride may be
25 used, but are less preferred.

Oxidation of the deprotected primary alcohols provokes spontaneous PBD B-ring closure. A number of oxidizing agents/conditions can be employed to achieve ring closure
30 including; Swern Oxidation, SO₃-Pyridine/DMSO, pyridinium dichromate, TPAP/NMO, Dess-Martin Periodinane and TEMPO-DAIB. The TEMPO/DAIB system is particularly favoured as it does not require rigorous anhydrous conditions, reaction is easily monitored by TLC, and there is no evidence of over-oxidation to
35 the PBD dilactam species.

The palladium mediated demasking can be carried out under literature conditions, such as using bisacetonitrile palladium chloride, $(\text{CH}_3\text{CN})_2\text{PdCl}_2$, in acetone (Lipshutz, B.H., et al., *Tetrahedron Letters*, **26**, 705 (1985)).

5

The compound of formula (II) can be synthesised according to the following scheme:



10 Thus the synthesis further comprise the following steps:


- (i) esterification, by reaction with R^{12}OH ; and
- (ii) reaction with triphosgene to form isocyanate.

15 The esterification is carried out under normal conditions. Often the ester is commercially available itself.

The conversion to the isocyanate can be carried out by the action of phosgene, trichloromethyl chloroformate or triphosgene, of which triphosgene is the preferred agent as it is an easy to handle crystalline solid rather than a toxic gas. The reaction should be carried in an anhydrous and non-hydroxylic organic solvent, which is preferably non-polar. Suitable solvents include anhydrous dichloromethane and anhydrous toluene. The reaction may be carried out at room temperature, and is conveniently monitored by infrared spectroscopy at about 2260 cm^{-1} .

If the method of synthesis of the first aspect of the invention comprises step (b), then the synthesis of the compound of formula

(I) from the compound of formula (VI) will be according to the following scheme:



5

Thus the synthesis comprises the following steps:

- (i) (a) if -CPQ represents a protected alcohol group,
deprotection followed by oxidation; or
- (b) if -CPQ represents an acetal or thioacetal,
palladium mediated unmasking; and
- (ii) (a) if XR^{11} is OR^{11} , direct etherification;
- (b) if XR^{11} is SR^{11} , treatment with R^{11}SH and a catalyst,
such as a Lewis Acid, e.g. Al_2O_3)
- (c) if XR^{11} is NHR^{11} , treatment with R^{11}NH and a catalyst,
such as a Lewis Acid, e.g. Al_2O_3).

15


The hydroxyl protecting groups (if present) must be removed to allow B-ring cyclization to take place. Removal is under standard conditions. For example, an acetate protecting group can be removed under extremely mild conditions with potassium carbonate. A silyl ether protecting group can be removed by fluoridolysis using TBAF or with mild acid. If these conditions are unsuitable for a particular carbamate, alternative hydroxyl protecting groups can be selected as long as they are capable of surviving the reduction of the nitro group.

20

25

The conditions for the remaining reactions are as described above in relation to the first method.

The compound of formula (IV) can be synthesised according to the following scheme:



5

Thus the synthesis comprises the following steps:

- (i) (a) coupling of acid with hydroxymethyl pyrrole; or
- (b) coupling of acid with acetalmethyl pyrrole;
- (ii) reduction of aromatic nitro group to form aromatic amine
- 10 group; and
- (ii) reaction with triphosgene to form isocyanate.

15

Commercially available nitrobenzoic acids are converted to acid chlorides and coupled to pyrrolidinemethanol and its derivatives under literature conditions. Free hydroxyl groups may be protected as silyl ethers or acetates (other protectings groups, including acetals such as MEM or MOM, can be employed as long as they are stable to the conditions requires to reduced the aromatic nitro group) in order to prevent the formation of a bridging carbamate in the isocyanate formation step.

20


The reduction of the nitro group can be carried out under standard conditions. Preferred methods include hydrogenation over a palladium on charcoal catalyst in a Parr hydrogenator, and using sodium dithionite, tin(II) chloride or Raney Nickel and hydrazine, depending on the requirements of the hydroxyl protecting group.

25

The isocyanate forming step is carried out as described above.

30


A second aspect of the invention is a compound of formula (IV):



(IV)

, wherein R⁶, R⁷, R⁸, R⁹, R¹⁰ and R¹² are as defined in the first aspect of the invention.

- 5 A third aspect of the present invention is a compound of formula (VI):



(VI)

- 10 , wherein R², R³, R⁶, R⁷, R⁸, R⁹, R¹⁰, P and Q are as defined in the first aspect of the invention, and the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3.


Definitions

- 15 Masked aldehyde group (-CPQ): The term masked aldehyde group pertains to a group which can be chemically converted into an aldehyde group, and includes in particular, a protected alcohol group (-CH₂OProt), wherein the alcohol protecting group is orthogonal to the nitrogen protecting group, acetal groups (-
- 20 C(OR^{ac})₂), thioacetal groups (-C(SR^{ac})₂), where each R^{ac} can be independently selected from C₁₋₁₀ alkyl or together can be a C₁₋₃ alkylene group.

Alcohol Protecting Group: This term pertains to a group which is removable leave an alcohol group, without affecting the remainder of the compound to which the alcohol group is attached. Of particular interest are ethers and esters, numerous examples of which are described in Greene and Wuts, "Protective Groups in Organic Synthesis", 3rd edition, John Wiley & Sons (1999), which is incorporated herein by reference. Examples include ethers, in particular silyl ethers (e.g. tert-butyl-dimethyl-silyl ether), esters, for examples acetates and carbonates.










Orthogonal: Protecting groups are orthogonal to one another, if one protecting group can be removed from a molecule in which the other protecting group is present, without the other protecting group being removed. For example, the alcohol protecting group acetate is orthogonal to the nitrogen protecting group Teoc, and the alcohol protecting group TBDMS is orthogonal to the nitrogen protecting group benzyloxy carbamate.


Nitrogen Protecting Group: This term pertains to a group which is removable from the N10 position of the PBD moiety to leave an N10-C11 imine bond. This application is only concerned with those nitrogen protecting groups which are carbamate, i.e. those which have the structure:



The nature of R¹⁰ can vary widely, and is chosen dependent on the conditions by which the whole group is eliminated from the molecule. A large number of suitable groups are described in Greene and Wuts, "Protective Groups in Organic Synthesis", 3rd edition, John Wiley & Sons (1999), which is incorporated herein by reference. These groups include many well know groups such as fmoc (9-fluorenylmethylcarbamate), Troc (2,2,2-trichloroethyl carbamate) and Alloc (allyl carbamate) which can be removed under varying conditions. Also described are carbamate based nitrogen protecting groups which can be cleaved photolytically, such as o-nitrobenzyl carbamate and Nvoc (6-nitroveratryl carbamate).



Also of interest are groups which can be cleaved by the action of enzymes. These include the following:



Group	Removable by
 <p style="text-align: center;">n=0 to 3</p>	nitroreductase
 <p style="text-align: center;">n=0 to 3</p>	Glutathione/glutathione transferase
 <p style="text-align: center;">R =   </p>	β -lactamase
 <p style="text-align: center;">R = </p>	β -lactamase
	α -galactosidase

 <p style="text-align: center;">Q=NH, O</p>	carboxypeptidase
--	------------------

These groups, and others, are described in, for example, Jungheim, L. and Shepherd, T., *Chem. Rev.*, **94**, 1553-1566 (1994), WO 00/64864 and Niculescu-Duvaz, D., et al., *J. Med. Chem.*, **41**, 5297-5309 (1998).

Further enzyme labile groups include the following:


Group	Removable by
	β-Glucuronidase
 <p>R¹ & R² selected from optionally substituted C₁₋₄ alkyl (e.g. methyl, iso-propyl, benzyl)</p>	<p>Plasmin</p> <p>(see de Groot, F.M.H., et al., <i>J. Med. Chem.</i>, 43, 3093-3102 (2000) & Groot, F.M.H., et al., <i>Bioorganic & Medicinal Chem. Lett.</i>, 12, 2371-2376 (2002)</p>

 <p>R is, for example,</p> <p>or</p>	<p>Cathepsin B</p> <p>(see Duboschik, G.M., et al., <i>Bioorganic & Medicinal Chem. Lett.</i>, 8, 3341-3346 and 3347-3352 (1998))</p>
 <p>where n is 0 to 3</p>	<p>Prostate Specific Antigen</p> <p>(see Garsky, V.M., et al., <i>J. Med. Chem.</i>, 44, 4216-4224 (2001); Mhaka, A., et al., <i>Bioorganic & Medicinal Chem. Lett.</i>, 12, 2459-2461 (2002); Jakobsen, C.M., et al., <i>J. Med. Chem.</i>, 44, 4696-4703 (2001))</p>

Prodrugs with such protecting groups are also reviewed Dubowchik, G.M. and Walker, M.A., *Pharmacology & Therapeutics*, **83**, 67-123 (1999).

5

A number of nitrogen protecting groups (including some of the enzyme labile groups discussed above) can be classed as containing a 'self-immolative linker'. Such groups usually has a structure:



10

where Y is NH or O, n is 0 to 3 and R'¹⁰ is such that the whole moiety is a nitrogen protecting group (and may be defined as for R¹⁰ below). The self-immolative linker will allow for release of the protected compound when a remote site is activated,


15

proceeding along the lines shown below (for n=0):



These groups have the advantage of separating the site of activation from the compound being protected.

- 5 A further class of nitrogen protecting groups are those where R^{10} essentially forms a cleavable link to another moiety, whether it be physical in nature, for example a solid support, or biological in nature. Examples of these protecting groups are disclosed in WO 00/12509, and include:



10 where O represents a resin bead.

The R^{10} group can be described as an optionally substituted C_{1-30} alkyl group, C_{3-30} heterocyclyl group or a C_{5-30} aryl group or a
 15 divalent version of one of these groups linked to another moiety. It is preferred that R^{10} is not a silane group or is substituted by a silyl group (e.g. $-CH_2-Si(Me)_3$).

The present invention allows the synthesis of N-10 protected PBD
 20 compounds where the appropriate chloroformate is not available or is unstable. This for example applies to the Moz (methoxybenzyl carbamate) group which cannot be introduced via the chloroformate as it is too unstable, and other derivatives such as Moz-ON are not sufficiently active to react with a PBD-precursor aniline
 25 group. However, the *p*-methoxybenzyl alcohol is commercially available and reacts smoothly with the isocyanate to give the Moz carbamate (see examples, compound 17). The case of the Teoc

carbamate reinforces the point; again the required chloroformate is not very stable and not commercially available. A *p*-nitrophenyl carbonate derivative of Teoc is available but, again, is not sufficiently active to protect an aromatic amine such as compound 5. Trimethylsilylethanol is commercially available and reacts with isocyanates to afford the Teoc carbamate in good yields (see examples, compound 18).

The method of the invention is particularly useful for complex protecting groups, such as those shown in the examples as alcohols 35 and 42. Such protecting groups are required to prepare PBD prodrugs for ADEPT approaches to cancer chemotherapy, and the alcohols are not commercially available and give rise to extremely unstable chloroformates. However, these alcohols react with isocyanates to furnish carbamates in moderate to good yields.

Alkyl: The term "alkyl" as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from a carbon atom of a hydrocarbon compound having from 1 to 20 carbon atoms (unless otherwise specified), which may be aliphatic or alicyclic, and which may be saturated or unsaturated (e.g., partially unsaturated, fully unsaturated). Thus, the term "alkyl" includes the sub-classes alkenyl, alkynyl, cycloalkyl, cycloalkylenyl, cycloalkynyl, etc., discussed below.

In the context of alkyl groups, the prefixes (e.g., C₁₋₄, C₁₋₇, C₁₋₂₀, C₂₋₇, C₃₋₇, etc.) denote the number of carbon atoms, or range of number of carbon atoms. For example, the term "C₁₋₄ alkyl" as used herein, pertains to an alkyl group having from 1 to 4 carbon atoms. Examples of groups of alkyl groups include C₁₋₄ alkyl ("lower alkyl"), C₁₋₇ alkyl, C₁₋₂₀ alkyl and C₁₋₃₀ alkyl. Note that the first prefix may vary according to other limitations; for example, for unsaturated alkyl groups, the first prefix must be at least 2; for cyclic and branched alkyl groups, the first prefix must be at least 3; etc.

Examples of saturated alkyl groups include, but are not limited to, methyl (C₁), ethyl (C₂), propyl (C₃), butyl (C₄), pentyl (C₅), hexyl (C₆), heptyl (C₇), octyl (C₈), nonyl (C₉), decyl (C₁₀),
5 undecyl (C₁₁), dodecyl (C₁₂), tridecyl (C₁₃), tetradecyl (C₁₄),
pentadecyl (C₁₅), and eicoddecyl (C₂₀).

Examples of saturated linear alkyl groups include, but are not limited to, methyl (C₁), ethyl (C₂), n-propyl (C₃), n-butyl (C₄),
10 n-pentyl (amyl) (C₅), n-hexyl (C₆), and n-heptyl (C₇).

Examples of saturated branched alkyl groups include iso-propyl (C₃), iso-butyl (C₄), sec-butyl (C₄), tert-butyl (C₄), iso-pentyl (C₅), and neo-pentyl (C₅).

15

Alkenyl: The term "alkenyl" as used herein, pertains to an alkyl group having one or more carbon-carbon double bonds. Examples of groups of alkenyl groups include C₂₋₄ alkenyl, C₂₋₇ alkenyl, C₂₋₂₀ alkenyl.

20

Examples of unsaturated alkenyl groups include, but are not limited to, ethenyl (vinyl, -CH=CH₂), 1-propenyl (-CH=CH-CH₃), 2-propenyl (allyl, -CH=CH-CH₂), isopropenyl (1-methylvinyl, -C(CH₃)=CH₂), butenyl (C₄), pentenyl (C₅), and hexenyl (C₆).

25

Alkynyl: The term "alkynyl" as used herein, pertains to an alkyl group having one or more carbon-carbon triple bonds. Examples of groups of alkynyl groups include C₂₋₄ alkynyl, C₂₋₇ alkynyl, C₂₋₂₀ alkynyl.

30

Examples of unsaturated alkynyl groups include, but are not limited to, ethynyl (ethinyl, -C≡CH) and 2-propynyl (propargyl, -CH₂-C≡CH).

35 Cycloalkyl: The term "cycloalkyl" as used herein, pertains to an alkyl group which is also a cyclyl group; that is, a monovalent

moiety obtained by removing a hydrogen atom from an alicyclic ring atom of a carbocyclic ring of a carbocyclic compound, which carbocyclic ring may be saturated or unsaturated (e.g., partially unsaturated, fully unsaturated), which moiety has from 3 to 20 carbon atoms (unless otherwise specified), including from 3 to 20 ring atoms. Thus, the term "cycloalkyl" includes the sub-classes cycloalkenyl and cycloalkynyl. Preferably, each ring has from 3 to 7 ring atoms. Examples of groups of cycloalkyl groups include C₃₋₃₀ cycloalkyl, C₃₋₂₀ cycloalkyl, C₃₋₁₀ cycloalkyl, C₃₋₇ cycloalkyl.

Examples of cycloalkyl groups include, but are not limited to, those derived from:

saturated monocyclic hydrocarbon compounds:

cyclopropane (C₃), cyclobutane (C₄), cyclopentane (C₅), cyclohexane (C₆), cycloheptane (C₇), methylcyclopropane (C₄), dimethylcyclopropane (C₅), methylcyclobutane (C₅), dimethylcyclobutane (C₆), methylcyclopentane (C₆), dimethylcyclopentane (C₇), methylcyclohexane (C₇), dimethylcyclohexane (C₈), menthane (C₁₀);

unsaturated monocyclic hydrocarbon compounds:

cyclopropene (C₃), cyclobutene (C₄), cyclopentene (C₅), cyclohexene (C₆), methylcyclopropene (C₄), dimethylcyclopropene (C₅), methylcyclobutene (C₅), dimethylcyclobutene (C₆), methylcyclopentene (C₆), dimethylcyclopentene (C₇), methylcyclohexene (C₇), dimethylcyclohexene (C₈);

saturated polycyclic hydrocarbon compounds:

thujane (C₁₀), carane (C₁₀), pinane (C₁₀), bornane (C₁₀), norcarane (C₇), norpinane (C₇), norbornane (C₇), adamantane (C₁₀), decalin (decahydronaphthalene) (C₁₀);

unsaturated polycyclic hydrocarbon compounds:

camphene (C₁₀), limonene (C₁₀), pinene (C₁₀);

polycyclic hydrocarbon compounds having an aromatic ring:

indene (C₉), indane (e.g., 2,3-dihydro-1H-indene) (C₉), tetraline (1,2,3,4-tetrahydronaphthalene) (C₁₀), acenaphthene (C₁₂), fluorene (C₁₃), phenalene (C₁₃), acephenanthrene (C₁₅), aceanthrene (C₁₆), cholanthrene (C₂₀).

Heterocyclyl: The term "heterocyclyl" as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from a ring atom of a heterocyclic compound, which moiety has from 3 to 20 ring atoms (unless otherwise specified), of which from 1 to 10 are ring heteroatoms. Preferably, each ring has from 3 to 7 ring atoms, of which from 1 to 4 are ring heteroatoms.

In this context, the prefixes (e.g., C₃₋₂₀, C₃₋₇, C₅₋₆, etc.) denote the number of ring atoms, or range of number of ring atoms, whether carbon atoms or heteroatoms. For example, the term "C₅₋₆ heterocyclyl" as used herein, pertains to a heterocyclyl group having 5 or 6 ring atoms. Examples of groups of heterocyclyl groups include C₃₋₃₀ heterocyclyl, C₃₋₂₀ heterocyclyl, C₅₋₂₀ heterocyclyl, C₃₋₁₅ heterocyclyl, C₅₋₁₅ heterocyclyl, C₃₋₁₂ heterocyclyl, C₅₋₁₂ heterocyclyl, C₃₋₁₀ heterocyclyl, C₅₋₁₀ heterocyclyl, C₃₋₇ heterocyclyl, C₅₋₇ heterocyclyl, and C₅₋₆ heterocyclyl.

Examples of monocyclic heterocyclyl groups include, but are not limited to, those derived from:

N₁: aziridine (C₃), azetidine (C₄), pyrrolidine (tetrahydropyrrole) (C₅), pyrroline (e.g., 3-pyrroline, 2,5-dihydropyrrole) (C₅), 2H-pyrrole or 3H-pyrrole (isopyrrole, isoazole) (C₅), piperidine (C₆), dihydropyridine (C₆), tetrahydropyridine (C₆), azepine (C₇);

O₁: oxirane (C₃), oxetane (C₄), oxolane (tetrahydrofuran) (C₅), oxole (dihydrofuran) (C₅), oxane (tetrahydropyran) (C₆), dihydropyran (C₆), pyran (C₆), oxepin (C₇);

S₁: thiirane (C₃), thietane (C₄), thiolane (tetrahydrothiophene) (C₅), thiane (tetrahydrothiopyran) (C₆), thiepane (C₇);

O₂: dioxolane (C₅), dioxane (C₆), and dioxepane (C₇);

O₃: trioxane (C₆);

N₂: imidazolidine (C₅), pyrazolidine (diazolidine) (C₅),

imidazoline (C₅), pyrazoline (dihydropyrazole) (C₅), piperazine (C₆);

- N₁O₁: tetrahydrooxazole (C₅), dihydrooxazole (C₅),
tetrahydroisoxazole (C₅), dihydroisoxazole (C₅), morpholine (C₆),
tetrahydrooxazine (C₆), dihydrooxazine (C₆), oxazine (C₆);
N₁S₁: thiazoline (C₅), thiazolidine (C₅), thiomorpholine (C₆);
5 N₂O₁: oxadiazine (C₆);
O₁S₁: oxathiole (C₅) and oxathiane (thioxane) (C₆); and,
N₁O₁S₁: oxathiazine (C₆).

Examples of substituted monocyclic heterocyclyl groups include
10 those derived from saccharides, in cyclic form, for example,
furanoses (C₅), such as arabinofuranose, lyxofuranose,
ribofuranose, and xylofuranse, and pyranoses (C₆), such as
allopyranose, altropyranose, glucopyranose, mannopyranose,
gulopyranose, idopyranose, galactopyranose, and talopyranose.

15

Aryl: The term "aryl" as used herein, pertains to a monovalent
moiety obtained by removing a hydrogen atom from an aromatic ring
atom of an aromatic compound, which moiety has from 3 to 20 ring
atoms (unless otherwise specified). Preferably, each ring has
20 from 5 to 7 ring atoms.

In this context, the prefixes (e.g. C₃₋₂₀, C₅₋₇, C₅₋₆, etc.) denote
the number of ring atoms, or range of number of ring atoms,
whether carbon atoms or heteroatoms. For example, the term
25 "C₅₋₆aryl" as used herein, pertains to an aryl group having 5 or 6
ring atoms. Examples of groups of aryl groups include C₃₋₃₀ aryl,
C₃₋₂₀ aryl, C₅₋₂₀ aryl, C₅₋₁₅ aryl, C₅₋₁₂ aryl, C₅₋₁₀ aryl, C₅₋₇ aryl, C₅₋₆
aryl, C₅ aryl, and C₆ aryl.

30 The ring atoms may be all carbon atoms, as in "carboaryl groups".
Examples of carboaryl groups include C₃₋₂₀ carboaryl, C₅₋₂₀
carboaryl, C₅₋₁₅ carboaryl, C₅₋₁₂ carboaryl, C₅₋₁₀ carboaryl, C₅₋₇
carboaryl, C₅₋₆ carboaryl and C₆ carboaryl.

35 Examples of carboaryl groups include, but are not limited to,
those derived from benzene (i.e., phenyl) (C₆), naphthalene (C₁₀),

azulene (C₁₀), anthracene (C₁₄), phenanthrene (C₁₄), naphthacene (C₁₈), and pyrene (C₁₆).

5 Examples of aryl groups which comprise fused rings, at least one of which is an aromatic ring, include, but are not limited to, groups derived from indane (e.g., 2,3-dihydro-1H-indene) (C₉), indene (C₉), isoindene (C₉), tetraline (1,2,3,4-tetrahydronaphthalene (C₁₀), acenaphthene (C₁₂), fluorene (C₁₃), phenalene (C₁₃), acephenanthrene (C₁₅), and aceanthrene
10 (C₁₆).

Alternatively, the ring atoms may include one or more heteroatoms, as in "heteroaryl groups". Examples of heteroaryl groups include C₃₋₂₀ heteroaryl, C₅₋₂₀ heteroaryl, C₅₋₁₅ heteroaryl,
15 C₅₋₁₂ heteroaryl, C₅₋₁₀ heteroaryl, C₅₋₇ heteroaryl, C₅₋₆ heteroaryl, C₅ heteroaryl, and C₆ heteroaryl.

Examples of monocyclic heteroaryl groups include, but are not limited to, those derived from:

20 N₁: pyrrole (azole) (C₅), pyridine (azine) (C₆);
O₁: furan (oxole) (C₅);
S₁: thiophene (thiole) (C₅);
N₁O₁: oxazole (C₅), isoxazole (C₅), isoxazine (C₆);
N₂O₁: oxadiazole (furazan) (C₅);
25 N₃O₁: oxatriazole (C₅);
N₁S₁: thiazole (C₅), isothiazole (C₅);
N₂: imidazole (1,3-diazole) (C₅), pyrazole (1,2-diazole) (C₅), pyridazine (1,2-diazine) (C₆), pyrimidine (1,3-diazine) (C₆) (e.g., cytosine, thymine, uracil), pyrazine (1,4-diazine) (C₆);
30 N₃: triazole (C₅), triazine (C₆); and,
N₄: tetrazole (C₅).

Examples of heteroaryl groups which comprise fused rings, include, but are not limited to:

35 C₉ heteroaryl groups (with 2 fused rings) derived from benzofuran (O₁), isobenzofuran (O₁), indole (N₁), isoindole (N₁),

indolizine (N_1), indoline (N_1), isoindoline (N_1), purine (N_4)
(e.g., adenine, guanine), benzimidazole (N_2), indazole (N_2),
benzoxazole (N_1O_1), benzisoxazole (N_1O_1), benzodioxole (O_2),
benzofurazan (N_2O_1), benzotriazole (N_3), benzothiofuran (S_1),
5 benzothiazole (N_1S_1), benzothiadiaazole (N_2S);

C_{10} heteroaryl groups (with 2 fused rings) derived from
chromene (O_1), isochromene (O_1), chroman (O_1), isochroman (O_1),
benzodioxan (O_2), quinoline (N_1), isoquinoline (N_1), quinolizine
(N_1), benzoxazine (N_1O_1), benzodiazine (N_2), pyridopyridine (N_2),
10 quinoxaline (N_2), quinazoline (N_2), cinnoline (N_2), phthalazine
(N_2), naphthyridine (N_2), pteridine (N_4);

C_{11} heteroaryl groups (with 2 fused rings) derived from
benzodiazepine (N_2);

C_{13} heteroaryl groups (with 3 fused rings) derived from
15 carbazole (N_1), dibenzofuran (O_1), dibenzothiophene (S_1),
carboline (N_2), perimidine (N_2), pyridoindole (N_2); and,

C_{14} heteroaryl groups (with 3 fused rings) derived from
acridine (N_1), xanthene (O_1), thioxanthene (S_1), oxanthrene (O_2),
phenoxathiin (O_1S_1), phenazine (N_2), phenoxazine (N_1O_1),
20 phenothiazine (N_1S_1), thianthrene (S_2), phenanthridine (N_1),
phenanthroline (N_2), phenazine (N_2).

Heteroaryl groups which have a nitrogen ring atom in the form of
an -NH- group may be N-substituted, that is, as -NR-. For
25 example, pyrrole may be N-methyl substituted, to give N-
methylpyrrole. Examples of N-substitutents include, but are not
limited to C_{1-7} alkyl, C_{3-20} heterocyclyl, C_{5-20} aryl, and acyl
groups.

30 Heterocyclic groups (including heteroaryl groups) which have a
nitrogen ring atom in the form of an -N= group may be substituted
in the form of an N-oxide, that is, as -N(\rightarrow O)= (also denoted
-N⁺(\rightarrow O⁻)=). For example, quinoline may be substituted to give
quinoline N-oxide; pyridine to give pyridine N-oxide;
35 benzofurazan to give benzofurazan N-oxide (also known as
benzofuroxan).

Cyclic groups may additionally bear one or more oxo (=O) groups on ring carbon atoms.

5 The above groups, whether alone or part of another substituent, may themselves optionally be substituted with one or more groups selected from themselves and the additional substituents listed below.

10 Halo: -F, -Cl, -Br, and -I.

Hydroxy: -OH.

15 Ether: -OR, wherein R is an ether substituent, for example, a C₁₋₇ alkyl group (also referred to as a C₁₋₇ alkoxy group, discussed below), a C₃₋₂₀ heterocyclyl group (also referred to as a C₃₋₂₀ heterocyclyloxy group), or a C₅₋₂₀ aryl group (also referred to as a C₅₋₂₀ aryloxy group), preferably a C₁₋₇alkyl group.

20 Alkoxy: -OR, wherein R is an alkyl group, for example, a C₁₋₇ alkyl group. Examples of C₁₋₇ alkoxy groups include, but are not limited to, -OMe (methoxy), -OEt (ethoxy), -O(nPr) (n-propoxy), -O(iPr) (isopropoxy), -O(nBu) (n-butoxy), -O(sBu) (sec-butoxy), -O(iBu) (isobutoxy), and -O(tBu) (tert-butoxy).

25

Acetal: -CH(OR¹)(OR²), wherein R¹ and R² are independently acetal substituents, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group, or, in the case of a "cyclic" acetal group, R¹ and R², taken together
30 with the two oxygen atoms to which they are attached, and the carbon atoms to which they are attached, form a heterocyclic ring having from 4 to 8 ring atoms. Examples of acetal groups include, but are not limited to, -CH(OMe)₂, -CH(OEt)₂, and -CH(OMe)(OEt).
35

Hemiacetal: $-\text{CH}(\text{OH})(\text{OR}^1)$, wherein R^1 is a hemiacetal substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of hemiacetal groups include, but are not limited to, $-\text{CH}(\text{OH})(\text{OMe})$ and $-\text{CH}(\text{OH})(\text{OEt})$.

Ketal: $-\text{CR}(\text{OR}^1)(\text{OR}^2)$, where R^1 and R^2 are as defined for acetals, and R is a ketal substituent other than hydrogen, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples ketal groups include, but are not limited to, $-\text{C}(\text{Me})(\text{OMe})_2$, $-\text{C}(\text{Me})(\text{OEt})_2$, $-\text{C}(\text{Me})(\text{OMe})(\text{OEt})$, $-\text{C}(\text{Et})(\text{OMe})_2$, $-\text{C}(\text{Et})(\text{OEt})_2$, and $-\text{C}(\text{Et})(\text{OMe})(\text{OEt})$.

Hemiketal: $-\text{CR}(\text{OH})(\text{OR}^1)$, where R^1 is as defined for hemiacetals, and R is a hemiketal substituent other than hydrogen, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of hemiacetal groups include, but are not limited to, $-\text{C}(\text{Me})(\text{OH})(\text{OMe})$, $-\text{C}(\text{Et})(\text{OH})(\text{OMe})$, $-\text{C}(\text{Me})(\text{OH})(\text{OEt})$, and $-\text{C}(\text{Et})(\text{OH})(\text{OEt})$.

Oxo (keto, -one): $=\text{O}$.

Thione (thioketone): $=\text{S}$.

Imino (imine): $=\text{NR}$, wherein R is an imino substituent, for example, hydrogen, C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably hydrogen or a C_{1-7} alkyl group. Examples of ester groups include, but are not limited to, $=\text{NH}$, $=\text{NMe}$, $=\text{NEt}$, and $=\text{NPh}$.

Formyl (carbaldehyde, carboxaldehyde): $-\text{C}(=\text{O})\text{H}$.

Acyl (keto): $-\text{C}(=\text{O})\text{R}$, wherein R is an acyl substituent, for example, a C_{1-7} alkyl group (also referred to as C_{1-7} alkylacyl or C_{1-7} alkanoyl), a C_{3-20} heterocyclyl group (also referred to as C_{3-20} heterocyclylacyl), or a C_{5-20} aryl group (also referred to as C_{5-20}

arylacyl), preferably a C₁₋₇ alkyl group. Examples of acyl groups include, but are not limited to, -C(=O)CH₃ (acetyl), -C(=O)CH₂CH₃ (propionyl), -C(=O)C(CH₃)₃ (t-butyryl), and -C(=O)Ph (benzoyl, phenone).

5

Carboxy (carboxylic acid): -C(=O)OH.

Thiocarboxy (thiocarboxylic acid): -C(=S)SH.

10

Thiolocarboxy (thiolocarboxylic acid): -C(=O)SH.

Thionocarboxy (thionocarboxylic acid): -C(=S)OH.

Imidic acid: -C(=NH)OH.

15

Hydroxamic acid: -C(=NOH)OH.

Ester (carboxylate, carboxylic acid ester, oxycarbonyl):

20

-C(=O)OR, wherein R is an ester substituent, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group. Examples of ester groups include, but are not limited to, -C(=O)OCH₃, -C(=O)OCH₂CH₃, -C(=O)OC(CH₃)₃, and -C(=O)OPh.

25

Acyloxy (reverse ester): -OC(=O)R, wherein R is an acyloxy substituent, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group. Examples of acyloxy groups include, but are not limited to, -OC(=O)CH₃ (acetoxy), -OC(=O)CH₂CH₃, -OC(=O)C(CH₃)₃, -OC(=O)Ph, and

30

-OC(=O)CH₂Ph.

35

Oxycarboxyloxy: -OC(=O)OR, wherein R is an ester substituent, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group. Examples of ester groups include, but are not limited to, -OC(=O)OCH₃, -OC(=O)OCH₂CH₃, -OC(=O)OC(CH₃)₃, and -OC(=O)OPh.


Amino: $-NR^1R^2$, wherein R^1 and R^2 are independently amino substituents, for example, hydrogen, a C_{1-7} alkyl group (also referred to as C_{1-7} alkylamino or di- C_{1-7} alkylamino), a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably H or a C_{1-7} alkyl group, or, in the case of a "cyclic" amino group, R^1 and R^2 , taken together with the nitrogen atom to which they are attached, form a heterocyclic ring having from 4 to 8 ring atoms. Amino groups may be primary ($-NH_2$), secondary ($-NHR^1$), or tertiary ($-NHR^1R^2$), and in cationic form, may be quaternary ($-^+NR^1R^2R^3$). Examples of amino groups include, but are not limited to, $-NH_2$, $-NHCH_3$, $-NHC(CH_3)_2$, $-N(CH_3)_2$, $-N(CH_2CH_3)_2$, and $-NHPh$. Examples of cyclic amino groups include, but are not limited to, aziridino, azetidino, pyrrolidino, piperidino, piperazino, morpholino, and thiomorpholino.

Amido (carbamoyl, carbamyl, aminocarbonyl, carboxamide): $-C(=O)NR^1R^2$, wherein R^1 and R^2 are independently amino substituents, as defined for amino groups. Examples of amido groups include, but are not limited to, $-C(=O)NH_2$, $-C(=O)NHCH_3$, $-C(=O)N(CH_3)_2$, $-C(=O)NHCH_2CH_3$, and $-C(=O)N(CH_2CH_3)_2$, as well as amido groups in which R^1 and R^2 , together with the nitrogen atom to which they are attached, form a heterocyclic structure as in, for example, piperidinocarbonyl, morpholinocarbonyl, thiomorpholinocarbonyl, and piperazinocarbonyl.

Thioamido (thiocarbamyl): $-C(=S)NR^1R^2$, wherein R^1 and R^2 are independently amino substituents, as defined for amino groups. Examples of amido groups include, but are not limited to, $-C(=S)NH_2$, $-C(=S)NHCH_3$, $-C(=S)N(CH_3)_2$, and $-C(=S)NHCH_2CH_3$.

Acylamido (acylamino): $-NR^1C(=O)R^2$, wherein R^1 is an amide substituent, for example, hydrogen, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably hydrogen or a C_{1-7} alkyl group, and R^2 is an acyl substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group,

preferably hydrogen or a C₁₋₇ alkyl group. Examples of acylamide groups include, but are not limited to, -NHC(=O)CH₃, -NHC(=O)CH₂CH₃, and -NHC(=O)Ph. R¹ and R² may together form a cyclic structure, as in, for example, succinimidyl, maleimidyl, and phthalimidyl:




Aminocarbonyloxy: -OC(=O)NR¹R², wherein R¹ and R² are independently amino substituents, as defined for amino groups. Examples of aminocarbonyloxy groups include, but are not limited to, -OC(=O)NH₂, -OC(=O)NHMe, -OC(=O)NMe₂, and -OC(=O)NEt₂.

Ureido: -N(R¹)CONR²R³ wherein R² and R³ are independently amino substituents, as defined for amino groups, and R¹ is a ureido substituent, for example, hydrogen, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably hydrogen or a C₁₋₇ alkyl group. Examples of ureido groups include, but are not limited to, -NHCONH₂, -NHCONHMe, -NHCONHEt, -NHCONMe₂, -NHCONEt₂, -NMeCONH₂, -NMeCONHMe, -NMeCONHEt, -NMeCONMe₂, and -NMeCONEt₂.

Guanidino: -NH-C(=NH)NH₂.

Tetrazolyl: a five membered aromatic ring having four nitrogen atoms and one carbon atom,



Imino: =NR, wherein R is an imino substituent, for example, for example, hydrogen, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably H or a C₁₋₇alkyl group. Examples of

imino groups include, but are not limited to, =NH, =NMe, and =NEt.

Amidine (amidino): $-C(=NR)NR_2$, wherein each R is an amidine substituent, for example, hydrogen, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably H or a C_{1-7} alkyl group. Examples of amidine groups include, but are not limited to, $-C(=NH)NH_2$, $-C(=NH)NMe_2$, and $-C(=NMe)NMe_2$.

10 Nitro: $-NO_2$.

Nitroso: $-NO$.

Azido: $-N_3$.

15

Cyano (nitrile, carbonitrile): $-CN$.

Isocyano: $-NC$.

20 Cyanato: $-OCN$.

Isocyanato: $-NCO$.

Thiocyano (thiocyanato): $-SCN$.

25

Isothiocyano (isothiocyanato): $-NCS$.

Sulfhydryl (thiol, mercapto): $-SH$.

30 Thioether (sulfide): $-SR$, wherein R is a thioether substituent, for example, a C_{1-7} alkyl group (also referred to as a C_{1-7} alkylthio group), a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of C_{1-7} alkylthio groups include, but are not limited to, $-SCH_3$ and $-SCH_2CH_3$.

35

Disulfide: $-SS-R$, wherein R is a disulfide substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group (also referred to herein as C_{1-7} alkyl disulfide). Examples of C_{1-7} alkyl disulfide groups
5 include, but are not limited to, $-SSCH_3$ and $-SSCH_2CH_3$.

Sulfine (sulfinyl, sulfoxide): $-S(=O)R$, wherein R is a sulfine substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group.
10 Examples of sulfine groups include, but are not limited to, $-S(=O)CH_3$ and $-S(=O)CH_2CH_3$.

Sulfone (sulfonyl): $-S(=O)_2R$, wherein R is a sulfone substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a
15 C_{5-20} aryl group, preferably a C_{1-7} alkyl group, including, for example, a fluorinated or perfluorinated C_{1-7} alkyl group. Examples of sulfone groups include, but are not limited to, $-S(=O)_2CH_3$ (methanesulfonyl, mesyl), $-S(=O)_2CF_3$ (triflyl), $-S(=O)_2CH_2CH_3$ (esyl), $-S(=O)_2C_4F_9$ (nonafllyl), $-S(=O)_2CH_2CF_3$ (tresyl),
20 $-S(=O)_2CH_2CH_2NH_2$ (tauryl), $-S(=O)_2Ph$ (phenylsulfonyl, besyl), 4-methylphenylsulfonyl (tosyl), 4-chlorophenylsulfonyl (closyl), 4-bromophenylsulfonyl (brosyl), 4-nitrophenyl (nosyl), 2-naphthalenesulfonate (napsyl), and 5-dimethylamino-naphthalen-1-ylsulfonate (dansyl).

25

Sulfinic acid (sulfino): $-S(=O)OH$, $-SO_2H$.

Sulfonic acid (sulfo): $-S(=O)_2OH$, $-SO_3H$.

30 Sulfinate (sulfinic acid ester): $-S(=O)OR$; wherein R is a sulfinate substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of sulfinate groups include, but are not limited to, $-S(=O)OCH_3$ (methoxysulfinyl; methyl sulfinate) and
35 $-S(=O)OCH_2CH_3$ (ethoxysulfinyl; ethyl sulfinate).

Sulfonate (sulfonic acid ester): $-S(=O)_2OR$, wherein R is a sulfonate substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of sulfonate groups include, but are not limited to, $-S(=O)_2OCH_3$ (methoxysulfonyl; methyl sulfonate) and $-S(=O)_2OCH_2CH_3$ (ethoxysulfonyl; ethyl sulfonate).

Sulfinyloxy: $-OS(=O)R$, wherein R is a sulfinyloxy substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of sulfinyloxy groups include, but are not limited to, $-OS(=O)CH_3$ and $-OS(=O)CH_2CH_3$.

Sulfonyloxy: $-OS(=O)_2R$, wherein R is a sulfonyloxy substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of sulfonyloxy groups include, but are not limited to, $-OS(=O)_2CH_3$ (mesylate) and $-OS(=O)_2CH_2CH_3$ (esylate).

Sulfate: $-OS(=O)_2OR$; wherein R is a sulfate substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of sulfate groups include, but are not limited to, $-OS(=O)_2OCH_3$ and $-SO(=O)_2OCH_2CH_3$.

Sulfamyl (sulfamoyl; sulfinic acid amide; sulfinamide): $-S(=O)NR^1R^2$, wherein R^1 and R^2 are independently amino substituents, as defined for amino groups. Examples of sulfamyl groups include, but are not limited to, $-S(=O)NH_2$, $-S(=O)NH(CH_3)$, $-S(=O)N(CH_3)_2$, $-S(=O)NH(CH_2CH_3)$, $-S(=O)N(CH_2CH_3)_2$, and $-S(=O)NHPh$.

Sulfonamido (sulfinamoyl; sulfonic acid amide; sulfonamide): $-S(=O)_2NR^1R^2$, wherein R^1 and R^2 are independently amino substituents, as defined for amino groups. Examples of sulfonamido groups include, but are not limited to, $-S(=O)_2NH_2$,

$-S(=O)_2NH(CH_3)$, $-S(=O)_2N(CH_3)_2$, $-S(=O)_2NH(CH_2CH_3)$, $-S(=O)_2N(CH_2CH_3)_2$,
and $-S(=O)_2NHPh$.

5 Sulfamino: $-NR^1S(=O)_2OH$, wherein R^1 is an amino substituent, as
defined for amino groups. Examples of sulfamino groups include,
but are not limited to, $-NHS(=O)_2OH$ and $-N(CH_3)S(=O)_2OH$.

10 Sulfonamino: $-NR^1S(=O)_2R$, wherein R^1 is an amino substituent, as
defined for amino groups, and R is a sulfonamino substituent, for
example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20}
aryl group, preferably a C_{1-7} alkyl group. Examples of sulfonamino
groups include, but are not limited to, $-NHS(=O)_2CH_3$ and
 $-N(CH_3)S(=O)_2C_6H_5$.

15 Sulfinamino: $-NR^1S(=O)R$, wherein R^1 is an amino substituent, as
defined for amino groups, and R is a sulfinamino substituent, for
example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20}
aryl group, preferably a C_{1-7} alkyl group. Examples of sulfinamino
groups include, but are not limited to, $-NHS(=O)CH_3$ and
20 $-N(CH_3)S(=O)C_6H_5$.

Phosphino (phosphine): $-PR_2$, wherein R is a phosphino substituent,
for example, $-H$, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a
 C_{5-20} aryl group, preferably $-H$, a C_{1-7} alkyl group, or a C_{5-20} aryl
25 group. Examples of phosphino groups include, but are not limited
to, $-PH_2$, $-P(CH_3)_2$, $-P(CH_2CH_3)_2$, $-P(t-Bu)_2$, and $-P(Ph)_2$.

Phospho: $-P(=O)_2$.

30 Phosphinyl (phosphine oxide): $-P(=O)R_2$, wherein R is a phosphinyl
substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl
group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group or a C_{5-20}
aryl group. Examples of phosphinyl groups include, but are not
limited to, $-P(=O)(CH_3)_2$, $-P(=O)(CH_2CH_3)_2$, $-P(=O)(t-Bu)_2$, and
35 $-P(=O)(Ph)_2$.

Phosphonic acid (phosphono): $-P(=O)(OH)_2$.

Phosphonate (phosphono ester): $-P(=O)(OR)_2$, where R is a phosphonate substituent, for example, -H, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably -H, a C_{1-7} alkyl group, or a C_{5-20} aryl group. Examples of phosphonate groups include, but are not limited to, $-P(=O)(OCH_3)_2$, $-P(=O)(OCH_2CH_3)_2$, $-P(=O)(O-t-Bu)_2$, and $-P(=O)(OPh)_2$.

10 Phosphoric acid (phosphonooxy): $-OP(=O)(OH)_2$.

Phosphate (phosphonooxy ester): $-OP(=O)(OR)_2$, where R is a phosphate substituent, for example, -H, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably -H, a C_{1-7} alkyl group, or a C_{5-20} aryl group. Examples of phosphate groups include, but are not limited to, $-OP(=O)(OCH_3)_2$, $-OP(=O)(OCH_2CH_3)_2$, $-OP(=O)(O-t-Bu)_2$, and $-OP(=O)(OPh)_2$.

Phosphorous acid: $-OP(OH)_2$.

20

Phosphite: $-OP(OR)_2$, where R is a phosphite substituent, for example, -H, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably -H, a C_{1-7} alkyl group, or a C_{5-20} aryl group. Examples of phosphite groups include, but are not limited to, $-OP(OCH_3)_2$, $-OP(OCH_2CH_3)_2$, $-OP(O-t-Bu)_2$, and $-OP(OPh)_2$.

25

Phosphoramidite: $-OP(OR^1)-NR^2_2$, where R^1 and R^2 are phosphoramidite substituents, for example, -H, a (optionally substituted) C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably -H, a C_{1-7} alkyl group, or a C_{5-20} aryl group. Examples of phosphoramidite groups include, but are not limited to, $-OP(OCH_2CH_3)-N(CH_3)_2$, $-OP(OCH_2CH_3)-N(i-Pr)_2$, and $-OP(OCH_2CH_2CN)-N(i-Pr)_2$.

30

35 Phosphoramidate: $-OP(=O)(OR^1)-NR^2_2$, where R^1 and R^2 are phosphoramidate substituents, for example, -H, a (optionally

substituted) C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably -H, a C₁₋₇ alkyl group, or a C₅₋₂₀ aryl group. Examples of phosphoramidate groups include, but are not limited to, -OP(=O)(OCH₂CH₃)-N(CH₃)₂, -OP(=O)(OCH₂CH₃)-N(i-Pr)₂, and

5 -OP(=O)(OCH₂CH₂CN)-N(i-Pr)₂.

Alkylene

C₃₋₁₂ alkylene: The term "C₃₋₁₂ alkylene", as used herein, pertains to a bidentate moiety obtained by removing two hydrogen atoms,

10 either both from the same carbon atom, or one from each of two different carbon atoms, of a hydrocarbon compound having from 3 to 12 carbon atoms (unless otherwise specified), which may be aliphatic or alicyclic, and which may be saturated, partially unsaturated, or fully unsaturated. Thus, the term "alkylene"

15 includes the sub-classes alkenylene, alkynylene, cycloalkylene, etc., discussed below.

Examples of linear saturated C₃₋₁₂ alkylene groups include, but are not limited to, -(CH₂)_n- where n is an integer from 3 to 12, for

20 example, -CH₂CH₂CH₂- (propylene), -CH₂CH₂CH₂CH₂- (butylene), -CH₂CH₂CH₂CH₂CH₂- (pentylene) and -CH₂CH₂CH₂CH₂CH₂CH₂CH₂- (heptylene).

Examples of branched saturated C₃₋₁₂ alkylene groups include, but are not limited to, -CH(CH₃)CH₂-, -CH(CH₃)CH₂CH₂-,

25 -CH(CH₃)CH₂CH₂CH₂-, -CH₂CH(CH₃)CH₂-, -CH₂CH(CH₃)CH₂CH₂-, -CH(CH₂CH₃)-, -CH(CH₂CH₃)CH₂-, and -CH₂CH(CH₂CH₃)CH₂-.

Examples of linear partially unsaturated C₃₋₁₂ alkylene groups (C₃₋₁₂ alkenylene, and alkynylene groups) include, but are not limited

30 to, -CH=CH-CH₂-, -CH₂-CH=CH₂-, -CH=CH-CH₂-CH₂-, -CH=CH-CH₂-CH₂-CH₂-, -CH=CH-CH=CH-, -CH=CH-CH=CH-CH₂-, -CH=CH-CH=CH-CH₂-CH₂-, -CH=CH-CH₂-CH=CH-, -CH=CH-CH₂-CH₂-CH=CH-, and -CH₂-C≡C-CH₂-.

Examples of branched partially unsaturated C₃₋₁₂ alkylene groups

35 (C₃₋₁₂ alkenylene and alkynylene groups) include, but are not

limited to, $-\text{C}(\text{CH}_3)=\text{CH}-$, $-\text{C}(\text{CH}_3)=\text{CH}-\text{CH}_2-$, $-\text{CH}=\text{CH}-\text{CH}(\text{CH}_3)-$ and $-\text{C}\equiv\text{C}-\text{CH}(\text{CH}_3)-$.

5 Examples of alicyclic saturated C_{3-12} alkylene groups (C_{3-12} cycloalkylenes) include, but are not limited to, cyclopentylene (e.g. cyclopent-1,3-ylene), and cyclohexylene (e.g. cyclohex-1,4-ylene).

10 Examples of alicyclic partially unsaturated C_{3-12} alkylene groups (C_{3-12} cycloalkylenes) include, but are not limited to, cyclopentenylene (e.g. 4-cyclopenten-1,3-ylene), cyclohexenylene (e.g. 2-cyclohexen-1,4-ylene; 3-cyclohexen-1,2-ylene; 2,5-cyclohexadien-1,4-ylene).

15 The term " C_{1-3} alkylene" as used herein, is defined in a similar manner to the above group, but with from 1 to 3 carbon atoms.

Solvents

20 Solvents may conveniently be classified according to one or more of their physical or chemical properties.

For example, solvents may be classified according to their polarity, that is, their permanent dipole moment. Examples of highly polar solvents include dimethylformamide (DMF),
25 dimethylacetamide, and acetonitrile (ACN). Examples of moderately polar solvents include acetone, methanol, tetrahydrofuran (THF), ethyl acetate (AcOEt), and water. Examples of relatively non-polar solvents include diethyl ether, chloroform, and dichloromethane (DCM). Examples of non-polar and
30 virtually non-polar solvents include alkanes, benzene, toluene, and carbon tetrachloride.

Solvents may also be classified as "protic" or "aprotic" according to their proton-exchange properties. Protic solvents
35 accept and/or donate protons. Examples of protic solvents include water, alcohols, carboxylic acids (e.g., acetic acid),

and amines (e.g., ammonia, pyridine). Aprotic solvents neither accept nor donate protons. Examples of aprotic solvents include carbon tetrachloride, chloroform, dichloromethane (DCM), acetonitrile (ACN), ethyl acetate (AcOEt), dimethylacetamide, tetrahydrofuran (THF), dimethylformamide (DMF), toluene, benzene, acetone, ethers (e.g., diethyl ether), alkanes (e.g., hexane), dimethylsulfoxide (DMSO), sulfur dioxide, hexamethylphosphoramide (HMPA), and, tetramethylurea. Amphoteric solvents, such as water, are capable of both accepting and donating protons.

Solvents may be classified as "hydroxylic" or "non-hydroxylic" according to whether they contain one or more hydroxyl, i.e. -OH, groups. Hydroxylic solvents include water and alcohols (e.g. methanol, ethanol), and non-hydroxylic solvents include dichloromethane and toluene.

Solvents may also be classified as "organic" or "inorganic" according to their chemical composition. Conventionally, organic solvents comprise, at least, carbon atoms, while inorganic solvents do not. Examples of inorganic solvents include water, ammonia, and sulfur dioxide.

Anhydrous solvents are solvents which contain less than 0.1% by weight of water, and preferably less than 0.01% or 0.001% by weight of water.

Further Preferences


Preferred methods of the invention may include any appropriate combination of method steps as described above.

Preferences for the reaction conditions of the method steps of the invention have been described above.

Preferences for the various groups defined above are expressed below, and may be combined with each other as appropriate.

R^2

R^2 is preferably selected from R and =CH-R (wherein, in one aspect, R is preferably optionally substituted phenyl). If there is a double bond between C1 and C2 or C2 and C3, R^2 is preferably a group of formula X:



wherein z is selected from cyano, R, carboxy, ester and amido.

 R^3

R^3 is preferably H.

 R^6

R^6 is preferably selected from H and C_{1-7} alkoxy, and more preferably H and methoxy, with H being the most preferred.

 R^7

R^7 is preferably selected from H and OR, where OR is preferably optionally substituted C_{1-7} alkoxy (e.g. methoxy, benzyloxy).

 R^8

R^8 is preferably selected from either: H and OR, where OR is preferably optionally substituted C_{1-7} alkoxy (e.g. methoxy, benzyloxy); or is a dimer link.

 R^9

R^9 is preferably H.

 R^{11}

R^{11} is preferably H, but may be C_{1-7} alkyl.

 R^{12}

R^{12} is preferably methyl.

ExamplesGeneral Experimental Methods


The progress of reactions was monitored by thin-layer chromatography (TLC) using Merck grade 7749 silica gel containing
5 binding and fluorescence indicators, on glass plates.

Visualization of TLC plate was achieved with UV light, unless otherwise stated. Flash column chromatography was performed using Merck silica gel 60 (0.040-0.063). The majority of organic solvents and reagents used were bought from Fischer, Lancaster
10 and Aldrich Chemical Co. and inorganic drying agents from BDH.


^1H and ^{13}C NMR spectra were obtained on a Bruker 250 MHz/52mm; IR spectra were recorded with a FT-IR Spectrometer Spectrum 1000. The optical rotation of compounds was determined at ambient
15 temperature with an ADP 220 polarimeter. Mass Spectrometry was carried out on a Micromass platform using either electrospray or Atmospheric Pressure chemical ionisation. Microanalysis was performed using a Carlo Erba 1108 elemental analyser.

Synthesis of monomer isocyanates

- (i) [2-(tert-Butyl-dimethyl-silanyloxymethyl)-pyrrolidin-1-yl]-(2-isocyanato-4,5-dimethoxy-phenyl)-methanone; and
(ii) (2-Hydroxymethyl-pyrrolidin-1-yl)-(2-isocyanato-4,5-dimethoxy-phenyl)-methanone (8)



(4,5-Dimethoxy-2-nitro-phenyl)-(2-hydroxymethyl-pyrrolidin-1-yl)-methanone (2)




5

Oxalyl chloride (9.22 g, 6.4 mL, 72.6 mmol, 1.1 eq) and DMF (cat) were added to a suspension of 4,5-dimethoxy-2-nitrobenzoic acid (1, 15.0 g, 66 mmol) in anhydrous CH₂Cl₂ (150 mL) under a N₂ atmosphere. The suspension was stirred at room temperature for 18 hours. The resultant solution was added dropwise to a solution of (S)-(+)-2-pyrrolidine-methanol (7.33 g, 7.16 mL, 72.6 mmol, 1.1 eq) and triethylamine (14.77 g, 20.21 mL, 145 mmol, 2.2 eq) in

10

anhydrous CH_2Cl_2 (100 mL) at -40°C (dry ice/ CH_3CN) under a N_2 atmosphere. The reaction mixture was allowed to come to room temperature and stirred for 18 h. The mixture was washed with 1 M HCl (3 x 200 mL), H_2O (2 x 200 mL), satd $\text{NaCl}_{(\text{aq})}$ (200 mL), dried (MgSO₄) and evaporated *in vacuo* to give a yellow foam. Trituration with 3% MeOH/EtOAc gave a white solid. Filtration and concentration of the filtrate gave a second crop of white solid. Total yield (18.13g, 88.5%). mp $124.4 - 127.8^\circ\text{C}$; $[\alpha]^{25}_{\text{D}} -109.0^\circ$ ($c = 1.0$, CHCl_3); ^1H NMR (CDCl_3) δ 7.71 (s, 1H), 6.61 (s, 1H), 4.44 - 4.39 (m, 1H), 4.00 (s, 3H), 3.99 (s, 3H), 3.98 - 3.76 (m, 2H), 3.18 (m, 2H), 2.23 - 2.13 (m, 3H), 1.92 - 1.69 (m, 1H); ^{13}C NMR (CDCl_3) δ 164.4, 154.5, 149.2, 137.1, 127.8, 109.0, 107.2, 65.7, 61.3, 56.8, 56.5, 49.5, 28.3, 24.3; IR (neat) 3343, 2940, 1605, 1530, 1337, 1276, 1109, 1064, 992, 862, 788, 756 cm^{-1} ; HRMS m/z calcd for $\text{C}_{14}\text{H}_{18}\text{N}_2\text{O}_7$ 310.1234 (M+H) found 311.1243.

[2-(*tert*-Butyl-dimethyl-silanyloxymethyl)-pyrrolidin-1-yl]-(4,5-dimethoxy-2-nitro-phenyl)-methanone (3)



A solution of *t*-butyldimethylsilyl chloride (9.04 g, 60 mmol, 1.2 eq), imidazole (8.51 g, 125 mmol, 2.5 eq) and nitro-alcohol 2 (15.55 g, 50 mmol, 1 eq) in anhydrous DMF (30 mL) was stirred at room temperature under a N_2 atmosphere for 16 hours. The reaction mixture was diluted with H_2O (500 mL) and extracted with EtOAc (2 x 200 mL). The combined organic extracts were washed with H_2O (2 x 200 mL), satd $\text{NaCl}_{(\text{aq})}$ (2 x 200 mL), dried (MgSO₄) and evaporated *in vacuo*. Purification by flash column chromatography (2% MeOH/ CHCl_3) gave the product as a yellow foam (13.95 g, 66%). $[\alpha]^{25}_{\text{D}} -99.5^\circ$ ($c = 1.0$, CHCl_3); ^1H NMR (CDCl_3) δ 7.68 (s, 1H), 6.75 (s, 1H), 3.96 (s, 3H), 3.88 (s, 3H), 3.90 - 3.88 (m, 2H), 3.13 - 3.08 (m, 2H), 2.07 - 2.03 (m, 3H), 2.01 - 1.81 (m, 1H), 0.91 - 0.77 (m, 9H), 0.10 - 0.07 (m, 6H); ^{13}C NMR (CDCl_3) δ 166.7, 154.6, 149.2, 137.6, 137.6, 128.9, 109.4, 107.4, 64.1, 58.9, 57.0, 56.9,


49.4, 27.7, 26.2, 24.6, 18.5, -4.97; MS (AP) m/z 425 (M^+); IR (neat) 3343, 2979, 2738, 2626, 1736, 1654, 1533, 1474, 1355, 1288, 1230, 1131, 880, 794, 669 cm^{-1} .

- 5 [2-(Acetyloxymethyl)-pyrrolidin-1-yl]-(4,5-dimethoxy-2-nitro-phenyl)-methanone (4)



- Pyridine (9.03 mL, 111.7 mmol, 1.1 eq) and acetic anhydride (10.5 mL, 111.7 mmol, 1.1 eq) were added to a solution of the nitro-
 10 alcohol **2** (31.5 g, 101.5 mmol, 1eq) in anhydrous THF (300 mL) under a N_2 atmosphere. DMAP (2.48 g, 20.3 mmol, 0.2 eq) was added portion wise and the mixture was stirred at room temperature for 2.5 h. The solvent was removed *in vacuo*, the residue was treated with 1 M HCl (300 mL) and extracted with EtOAc (300 mL). The
 15 organic extract was washed with 1 M HCl (2 x 200 mL), H_2O (3 x 200 mL), satd NaCl (aq) (2 x 200 mL), dried (MgSO_4) and evaporated *in vacuo* to give the product as a yellow foam (34.5 g, 96%): $[\alpha]_D^{27} - 89.0$ (c 1.0, CHCl_3); ^1H NMR (CDCl_3) δ 7.69 (s, 1H), 6.82 (s, 1H), 4.05-3.95 (m 9H), 3.24-3.08 (m, 2H), 2.11 (s, 3H), 2.00-1.41 (m,
 20 4H); ^{13}C NMR (CDCl_3) δ 170.9, 170.2, 151.7, 141.5, 140.7, 112.5, 111.3, 100.7, 64.6, 56.8, 55.7, 55.5, 49.8, 27.9, 24.7, 20.9; IR (neat) 3629, 3464, 2982, 1751, 1659, 1585; HRMS m/z calcd for $\text{C}_{16}\text{H}_{21}\text{N}_2\text{O}_7$ 353.1355 ($M + \text{H}$), found 353.1349.


- 25 (2-Amino-4,5-dimethoxy-phenyl)-[2-(tert-butyl-dimethyl-silanyloxymethyl)-pyrrolidin-1-yl]-methanone (5)



- A solution of the nitro compound **3** (19.8 g, 46.6 mmol) in ethanol (180 mL) was hydrogenated (Parr apparatus) over 10% Palladium on carbon (2 g, 10 wt%), maintaining the H_2 pressure at 16 psi. The
 30 reaction was complete when no more H_2 was consumed. The mixture

was filtered through celite and the ethanol evaporated *in vacuo*. Purification by flash column chromatography (2% MeOH/EtOAc) gave the product as a yellow oil (16.8 g, 91%). $[\alpha]^{25}_D -149.6^\circ$ ($c = 1.0$, CHCl_3); ^1H NMR (CDCl_3) δ 6.75 (s, 1H), 6.24 (s, 1H), 4.45 - 4.32 (m, 1H), 3.84 (s, 3H), 3.78 (s, 3H), 3.64 - 3.50 (m, 4H), 2.08 - 2.00 (m, 3H), 1.93 - 1.74 (m, 1H), 0.89 (s, 9H), 0.09 - 0.01 (m, 6H); ^{13}C NMR (CDCl_3) δ 169.8, 151.8, 141.8, 141.0, 112.5, 100.9, 63.1, 58.7, 56.9, 56.0, 27.5, 26.5, 25.6, 18.5, -5.0; MS (ES+) m/z 395 (M+1); IR (neat) 3465, 3363, 3225, 2973, 2738, 1636, 1523, 1475, 1291 cm^{-1} .


(2-Amino-4,5-dimethoxy-phenyl)-[2-(acetoxymethyl)-pyrrolidin-1-yl]-methanone (6)



A solution of the nitro compound **4** (34.0 g, 96.5 mmol) in ethanol (80 mL) was hydrogenated (Parr apparatus) over 10% Palladium on carbon (3.4 g, 10 wt%) at 30 psi for 6 h. The mixture was filtered through celite and the ethanol evaporated *in vacuo*.

Purification by flash column chromatography (2% MeOH/EtOAc) gave the product as a yellow oil (16.2 g, 52%): $[\alpha]^{26}_D -168.5$ (c 1.0, CHCl_3); ^1H NMR (CDCl_3) δ 6.73 (s, 1H), 6.26 (s, 1H), 4.66-4.53 (bs, 2H), 4.33-4.16 (bs, 2H), 3.91-3.71 (m, 7H), 3.60-3.44 (m, 2H), 2.22-2.01 (m, 5H), 2.01-1.87 (m, 1H), 1.87-1.70 (m, 3H); ^{13}C NMR 170.9, 167.2, 154.4, 149.2, 137.3, 128.2, 109.2, 107.2, 63.9, 56.7, 56.5, 55.8, 48.4, 27.6, 24.1, 20.6; IR (neat) 3453, 3355, 3240, 2968, 2833, 1731, 1621, 1514; MS (ES+) m/z 323 ($\text{M}^+ + 1$).

[2-(*tert*-Butyl-dimethyl-silanyloxymethyl)-pyrrolidin-1-yl]-(2-isocyanato-4,5-dimethoxy-phenyl)-methanone (7)




5

A solution of triethylamine (1.35 eq.) in anhydrous toluene was added to the amine (5) (1 eq.) and triphosgene (0.36 eq.) in anhydrous toluene under a N₂ atmosphere. The reaction was finished after 2 hours. (monitored by IR, ν_{NCO} 2265 cm⁻¹). The product was used without further purification.

10

(2-Hydroxymethyl-pyrrolidin-1-yl)-(2-isocyanato-4,5-dimethoxy-phenyl)-methanone (8)




15


This was prepared from (6) in the same manner as above for (7).

Synthesis of protecting group precursors:

(i) 2-[3-(4-Hydroxymethyl-phenyl)ureido]-pentanedioic acid diallyl ester (35)




5 *tert*-Butyl-dimethyl-(4-nitro-benzyloxy)-silane (32)



A solution of *t*-butyldimethylsilyl chloride (8.53 g, 56.3 mmol, 1.3 eq), imidazole (7.38 g, 108.3 mmol, 2.5 eq) and 4-nitrobenzyl alcohol (6.64 g, 43.3 mmol, 1 eq) in anhydrous DMF (25 mL) was stirred at room temperature under a N₂ atmosphere for 72 h. The reaction mixture was diluted with H₂O (500 mL) and extracted with EtOAc (4 x 100 mL). The combined organic extracts were washed with H₂O (100 mL), satd NaCl_(aq) (100 mL), dried (MgSO₄) and evaporated *in vacuo*. The residue was triturated with *n*-hexane and filtered. The filtrate was evaporated *in vacuo* to give the product as a yellow oil which crystallised (11.02 g, 95%). ¹H NMR (CDCl₃) δ 8.2 (d, *J* = 8.25 Hz, 2H), 7.47 (d, *J* = 8.02 Hz, 2H), 4.8 (s, 2H), 0.96 (s, 9H), 0.12 (s, 6H). IR (neat) 2955, 2930, 1605

and 1522 cm⁻¹. HRMS *m/z* calcd for C₁₃H₂₂NO₃ Si 268.1369 (M + H), found 268.1376

4-(*tert*-Butyl-dimethyl-silanyloxymethyl)-phenylamine (33)




5

Ammonium formate was added to a solution of the nitro compound **32** (8.86 g, 33.1 mmol, 1 eq) in ethanol (175 mL) over 10% Palladium on carbon (2.66 g, 30 wt%) [caution exothermic] and the mixture was stirred at room temperature for 2.5 h. The reaction mixture was filtered through celite and the solvent evaporated *in vacuo*. The residue was partitioned between EtOAc (100 mL) and H₂O (100 mL), the organic portion was washed with H₂O (100 mL), satd NaCl_(aq) (100 mL), dried (MgSO₄) and evaporated to give the product as a yellow oil (7.3 g, 92%). ¹H NMR (CDCl₃) δ 7.08 (d, *J* = 7.8 Hz, 2H), 6.63 (d, *J* = 7.8 Hz, 2H), 4.6 (s, 2H), 3.58 (bs, 2H), 0.9 (s, 9H), 0.07 (s, 6H). IR (neat) 3451, 3361, 3005, 2954, 1625 cm⁻¹. HRMS *m/z* calcd for C₁₃H₂₃NO Si 237.1549 (M⁺), found 237.1552.

15

2-{3[4-(*tert*-Butyl-dimethyl-silanyloxymethyl)-phenyl]-ureido}-pentanedioic acid diallyl ester (34)




20

A solution of triethylamine (0.24 g, 0.33 mL, 2.4 mmol, 2 eq) in anhydrous CH₂Cl₂ (10 mL) was added dropwise to a solution of diallyl-L-glutamate tosylate (0.48 g, 1.2 mmol, 1eq) and triphosgene (0.12 g, 0.4 mmol, 0.3 eq) in anhydrous CH₂Cl₂ (40 mL) stirring at -80°C under a N₂ atmosphere. The mixture was stirred at -80°C for 1 h then allowed to reach room temperature. A solution of the amino-silyl ether **33** (0.28 g, 1.2 mmol, 1 eq) and triethylamine (0.12 g, 0.17 mL, 1.2 mmol, 1 eq) in anhydrous

25


CH₂Cl₂ (10 ml) was added dropwise (16 min) and the resulting solution stirred at room temperature for 18 h. The solvent was removed *in vacuo* and the residue triturated with toluene and filtered. The filtrate was evaporated to give the crude product as a yellow oil. Purification by flash column chromatography (20% EtOAc/80% *n*-hexane) gave the product as a colourless oil (0.35 g, 61%). ¹H NMR (CDCl₃) δ 7.26 (s, 4H), 6.83 (s, 1H), 5.9 (m, 2H), 5.61 (d, *J* = 8Hz, 1H), 5.3 (m, 4H), 4.68 (s, 2H), 4.60 (m, 5H), 2.5 (m, 2H), 2.25 (m, 1H), 2.0 (m, 1H), 0.95 (s, 9H) 0.07 (s, 6H). IR (neat) 3349, 2954, 2929, 2856, 1739, 1650, 1603, 1553 cm⁻¹. HRMS *m/z* calcd for C₂₅H₃₉N₂O₆ 491.2577 Si (M+H), found 491.2554.

2-[3-(4-Hydroxymethyl-phenyl)ureido]-pentanedioic acid diallyl ester (35)




A solution of the TBDMS ether **34** (0.32 g, 0.65 mmol) in AcOH/THF/H₂O (9 mL/3 mL/3 mL) was stirred at room temperature for 2 h. The reaction mixture was cooled (ice bath) and neutralised with NaHCO_{3(aq)} (13.2 g, 15.7 mmol) in H₂O (150 mL). The mixture was extracted with EtOAc (4 x 30 mL) and the combined extracts were washed with H₂O (100 mL), satd NaCl_(aq) (100 mL), dried (MgSO₄) and evaporated *in vacuo*. Purification by flash column chromatography (60% EtOAc/40% *n*-hexane) gave the product as a colourless oil (0.22 g, 91%). ¹H NMR (*d*₆ DMSO) δ 8.5 (s, 1H), 7.31 (d, *J* = 8.5Hz, 2H), 7.16 (d, *J* = 8.12 Hz, 2H), 6.55 (d, *J* = 8.1Hz), 5.92 (m, 2H), 5.3 (m, 4H), 5.0 (t, *J* = 5.55Hz, 2H), 4.6 (m, 4H), 4.35 (m, 1H), 2.5 (m, 2H), 2.11 (m, 1H), 1.9 (m, 1H). IR (neat) 3353, 1738, 1659, 1602, 1551cm⁻¹. HRMS *m/z* calcd for C₁₉H₂₅N₂O₆ 377.1713 (M+H), found 377.1705.

(ii) 2-(4-Hydroxymethyl-phenoxy-carbonylamino)-pentanedioic acid diallyl ester (42)




2-[4-(tert-Butyl-dimethyl-silanyloxymethyl)-
5 phenoxy-carbonylamino]-pentanedioic acid diallyl ester (41)



A solution of triethylamine (3.19 g, 4.4 mL, 31.6 mmol, 2.1 eq) in anhydrous CH_2Cl_2 (20 mL) was added dropwise to a solution of diallyl-L-glutamate tosylate (6.0 g, 15.0 mmol, 1eq) and triphosgene (1.6 g, 5.4 mmol, 0.36 eq) in anhydrous CH_2Cl_2 (40 mL) stirring at -80°C under a N_2 atmosphere. The mixture was stirred at -80°C for 1.75 h then allowed to reach room temperature. A solution of hydroxyl-silyl ether **40**, prepared using a literature procedure, (3.6 g, 15.0mmol 1 eq) and triethylamine (1.7 g, 2.3 mL, 16.5 mmol, 1.1 eq) in anhydrous CH_2Cl_2 (35 mL) was added dropwise and the resulting solution was stirred at room temperature for 18 h. The solvent was removed *in vacuo* and the residue triturated with toluene and filtered. The filtrate was evaporated to give the crude product as a yellow oil. Purification by flash column chromatography (20% EtOAc/80% *n*-hexane) gave the product as a colourless oil (3.6 g, 46%). ^1H NMR

(CDCl₃) δ 7.3 (d, J = 8.5 Hz, 2H), 7.08 (d, J = 8.5 Hz, 2H), 5.92 (m, 2H), 5.70 (d, J = 8 Hz, 1H), 4.7 (s, 2H), 4.68 (d, J = 5.8 Hz, 2H), 4.60 (d, J = 5.8 Hz, 2H), 4.5 (m, 1H), 2.5 (m, 2H), 2.3 (m, 1H), 2.1 (m, 1H), 0.93 (s, 9H), 0.09 (s, 6H). IR (neat) 3350, 2954, 2930, 2865, 2857, 1738, 1531, 1503 cm⁻¹. HRMS m/z calcd for C₂₅H₃₈NO₇ Si 492.2418 (M+H), found 492.2411.

2-(4-Hydroxymethyl-phenoxy-carbonylamino)-pentanedioic acid diallyl ester (42)




10


A solution of the TBDMS ether **41** (3.23 g, 6.56 mmol) in AcOH/THF/H₂O (18 mL/6 mL/6 mL) was stirred at room temperature for 2 h. The reaction mixture was cooled (ice bath) and neutralised with Na₂CO_{3(aq)} (16.6 g, 15.6 mmol) in H₂O (135 mL). The mixture was extracted with EtOAc (4 x 150 mL) and the combined extracts were washed with H₂O (250 mL), satd NaCl_(aq) (250 mL), dried (MgSO₄) and evaporated *in vacuo*. Purification by flash column chromatography (50% EtOAc/50% *n*-hexane) gave the product as a colourless oil (2.28 g, 92%). ¹H NMR (CDCl₃) δ 7.34 (d, J = 8.5 Hz, 2H), 7.11 (d, J = 8.5 Hz, 2H), 5.92 (m, 2H), 5.79 (m, 2H), 5.79 (d, J = 8.1 Hz, 1H), 5.3 (m, 4H), 4.65 (m, 6H), 4.49 (m, 1H), 2.50 (m, 2H), 2.35 (m, 1H), 2.1 (m, 1H). IR (neat) 3349, 3080, 3028, 2943, 2879, 1731, 1535, 1503 cm⁻¹. HRMS m/z calcd for C₁₉H₂₄NO₇ 378.1553 (M+H), found 378.1559.

25

(iii) 4-(4-hydroxymethyl-2-methoxy-5-nitrophenoxy)butyric acid allyl ester (52)




4-(4-formyl-2-methoxyphenoxy)-butyric acid methyl ester (48)



5


A solution of vanillin (**47**) (40.00 g, 262.89 mmol) and methyl-4-bromobutyrate (50.00 g, 276.18 mmol) in DMF (200 mL) was allowed to stir over potassium carbonate (51.53 g, 372.40 mmol) for 16 hours. Water was added to the reaction mixture at which time the product crystallised. The resulting mixture was filtered and dried *in vacuo* for 16 hours to afford the keto-ester (**48**) as a white solid (41.3g, 66%). MP = 57–59°C. ^1H NMR (250 MHz, CDCl_3) δ 9.80 (s, 1H), 7.46–7.40 (m, 2H), 6.97 (d, J = 8.1 Hz, 1H), 4.16 (t, J = 6.3 Hz, 2H), 3.92 (s, 3H), 3.70 (s, 3H), 2.57 (t, J = 7.2 Hz, 2H), 2.20 (pent, J = 6.7 Hz, 2H). ^{13}C NMR (67.8 MHz, CDCl_3) 188.2 (C1), 173.7 (C12), 153.8 (Cquat.), 152.0 (Cquat.), 144.1 (Cquat.), 125.8 (Cmethine), 110.3 (C3), 108.5 (C6), 69.0 (C9), 57.0 (C8), 52.2 (C13), 30.6 (C11), 24.5 (C10). It was decided to adopt the numbering system shown in the figure below for the molecule for ease of peak assignment in ^{13}C NMR.



IR (cm^{-1}) 3450, 3332, 2952, 1737, 1685, 1587, 1467, 1407, 1006, 938, 864, 813, 730, 656. MS (M^+) 253. Anal. Calcd for $\text{C}_{13} \text{H}_{16} \text{O}_5$: C, 61.90; H, 6.39. Found: C, 61.50; H, 6.39.


5

4-(4-formyl-2-methoxy-5-nitro-phenoxy)-butyric acid methyl ester (49)




A solution of the keto-ester (48) (20.00 g, 79.3 mmol) in acetic anhydride (80 mL) was added dropwise to a stirring solution of HNO_3 (400 mL) and Ac_2O (80 mL) at 0°C . After stirring for 2.5 hours the reaction mixture was poured into iced water (3L) and allowed to stand at 4°C for a further 16 hours. The precipitate was collected by filtration and dried under vacuum to provide the nitro compound (49) as a yellow crystalline solid (14.52 g, 62%). Melting Point $70-73^\circ\text{C}$. ^1H NMR (250 MHz, CDCl_3) δ 10.4 (s, 2H), 7.61 (s, 1H), 7.40 (s, 1H), 4.21 (t, $J = 6.2$ Hz, 2H), 4.00 (s, 3H), 3.71 (s, 3H), 2.58 (t, $J = 7.1$ Hz, 2H), 2.23 (pent, $J = 6.3$ Hz, 2H). ^{13}C NMR (67.8 MHz, CDCl_3) 188.2 (C1), 173.7 (C12), 153.8 (Cquat.), 152.1 (Cquat.), 144.1 (Cquat.), 125.8 (Cquat.), 110.2 (C6), 108.5 (C3), 69.0 (C9), 57.0 (C8), 52.2 (C13), 30.6 (C11), 24.4 (C10). IR (cm^{-1}) 3571, 3485, 2951, 1725, 1689, 1573, 1329, 1172, 1064, 1002, 936, 896, 858, 820, 766, 738, 688, 624. MS ($M+1$) 298.0. Anal. Calcd for $\text{C}_{13} \text{H}_{15} \text{NO}_7$: C, 52.53; H, 5.09; N, 4.71. Found: C, 52.80; H, 5.03; N, 4.75.

4-(4-hydroxymethyl-2-methoxy-5-nitrophenoxy)butyric acid methyl ester (50)



Sodium borohydride (2.69 g, 71.3 mmol) was added to a stirred
5 solution of the ester (49) (10.0 g, 33.6 mmol) in THF (50 mL)
under an N₂ atmosphere at room temperature. Effervescence was
observed upon addition of the reducing agent. TLC (EtOAc) after
16 hours revealed the complete loss of starting material. The
solution was concentrated and redissolved in EtOAc (100 mL). The
10 organic layer was washed with sat. NH₄Cl (5 x 100 mL) and
concentrated *in vacuo*. Purification by flash chromatography (1%
MeOH/CHCl₃) yielded the product (50) as a yellow solid (6.46g,
64%). MP = 98–102°C. ¹H NMR (250 MHz, CDCl₃) δ 7.70 (s, 1H),
7.16 (s, 1H), 4.95 (d, *J* = 6.5 Hz, 2H), 4.12 (t, *J* = 6.2 Hz, 2H),
15 3.98 (s, 3H), 3.70 (s, 3H), 2.71 (t, *J* = 6.5 Hz, 1H), 2.56 (t, *J*
= 7.1 Hz, 2H), 2.19 (pent, *J* = 6.7 Hz, 2H). ¹³C NMR (67.8 MHz,
CDCl₃) 173.9 (C12), 154.6 (Cquat.), 147.3 (Cquat.), 139.6
(Cquat.), 133.2 (Cquat.), 111.0 (C6), 109.8 (C3), 68.6 (C9), 62.7
(C1), 56.7 (C8), 52.1 (C13), 30.7 (C11), 24.6 (C10). IR (cm⁻¹)
20 3286, 2937, 2881, 1737, 1577, 1533, 1368, 1332, 1282, 1162, 1008,
979, 950, 872, 821, 755, 651. MS (M⁺) 299.0. Anal. Calcd for C₁₃
H₁₇NO₇: C, 52.17; H, 5.73; N, 4.68. Found: C, 52.41; H, 5.86; N,
4.67.


4-(4-hydroxymethyl-2-methoxy-5-nitrophenoxy)butyric acid (51)



A solution of the ester (**50**) (10.00 g, 33.4 mmol) in methanol (100 mL) was added dropwise to a stirring solution of 1M NaOH (100 mL) and H₂O (50 mL). TLC (1:10:100 Acetic acid: MeOH: CHCl₃) after 16 hours revealed the complete loss of starting material. The solution was acidified to pH1 with conc. HCl. The resulting yellow precipitate was collected by vacuum filtration to provide the product (**51**) as a yellow solid (8.58g, 90%). MP = 172-175°C.

¹H NMR (250 MHz, CDCl₃) δ 7.71 (s, 1H), 7.40 (s, 1H), 4.99 (s, 2H), 4.13 (t, *J* = 6.3 Hz, 2H), 3.98 (s, 3H), 2.52 (t, *J* = 7.1 Hz, 2H), 2.15 (pent, *J* = 6.7 Hz, 2H). ¹³C NMR (67.8 MHz, CDCl₃) 174.5 (C12), 154.2 (Cquat.), 146.4 (Cquat.), 138.5 (Cquat.), 134.7 (Cquat.), 109.8 (C6), 109.3 (C3), 68.3 (C9), 60.9 (C1), 56.2 (C8), 30.2 (C11), 24.3 (C10). IR (cm⁻¹) 3533, 2976, 2634, 1709, 1617, 1577, 1520, 1411, 1286, 1214, 1019, 990, 888, 876, 814, 756, 677. MS (M⁺ -OH) 268.0. Anal. Calcd for C₁₂ H₁₅NO₇: C, 50.53; H, 5.30; N, 4.91. Found: C, 50.48; H, 5.22; N, 4.88.

4-(4-hydroxymethyl-2-methoxy-5-nitrophenoxy)butyric acid allyl ester (52)




A mixture of compound **51** (7.00 g 24.50 mmol), allyl alcohol (80 mL) and *p*-tosic acid (742 mg, 3.90 mmol) was heated at reflux under a N₂ atmosphere for 4 hours, at which time TLC (2% MeOH/CHCl₃) indicated that reaction had gone to completion. Excess allyl alcohol was evaporated *in vacuo* to afford the crude

compound (52), which was partitioned between NaHCO₃ (50 mL) and EtOAc (50 mL). The organic layer was washed with water (3 x 50 mL), brine (3 x 50 mL) and then dried (MgSO₄), and concentrated *in vacuo*. Purification by flash chromatography (CHCl₃) yielded the product as an orange-brown solid (5.78 g, 72%). MP = 73–75°C ¹H NMR (250 MHz, CDCl₃) δ 7.70 (s, 1H), 7.16 (s, 1H), 6.00–5.84 (m, 1H), 5.36–5.21 (m, 2H), 4.94 (d, *J* = 6.3 Hz), 4.62–4.59 (m, 2H), 4.13 (t, *J* = 6.2 Hz, 2H), 3.97 (s, 3H), 2.67–2.56 (m, 3H), 2.20 (pent, *J* = 6.7 Hz, 2H). ¹³C NMR δ 173.1 (C12), 154.7 (Cquat.), 147.3 (Cquat.), 139.6 (Cquat.), 133.2 (Cquat.), 132.4 (C14), 118.7 (C15), 111.1 (C6), 109.9 (C3), 68.6 (C9), 65.6 (C13), 62.7 (C1), 56.7 (C8), 30.9 (C11), 24.6 (C10). IR (cm⁻¹) 3329.4, 3100.0, 2972.1, 1734.5, 1647.9, 1577.4, 1508.1, 1281.5, 932.8, 884.0, 815.8, 758.2, 662.2. MS (M⁺ -OH) 308. Anal. Calcd for C₁₆ H₁₉NO₇: C, 55.38; H, 5.89; N, 4.31. Found: C, 52.41; H, 5.86; N, 4.67.

20


Synthesis of Monomer Carbamates

General method



A solution of the appropriate alcohol (1 eq) and triethylamine (1.1 eq) in either anhydrous toluene or anhydrous CH₂Cl₂ was added dropwise to a solution of the appropriate isocyanate (1 eq) in anhydrous toluene. The reaction was monitored by IR (disappearance of the ν_{NCO} 2265 cm⁻¹ peak). The reaction mixture was filtered and the filtrate evaporated *in vacuo*. The product was purified by flash column chromatography.


[2-[2-(*tert*-Butyl-dimethyl-silanyloxymethyl)-pyrrolidine-1-carbonyl]-4,5-dimethoxy-phenyl]-carbamic acid-benzyl ester (9)



5 A solution of anhydrous benzyl alcohol (0.19 g, 0.18 mL, 1.7 mmol) and triethylamine (0.19 g, 0.26 mL, 1.85 mmol) in anhydrous toluene (5 mL) was added to a solution of the isocyanate **7** prepared from the amine **5** (0.522 g, 1.32 mmol), triphosgene (0.14 g, 0.48 mmol) and triethylamine (0.18 g, 0.25 mL, 1.8 mmol) in
 10 anhydrous toluene (15 mL). The reaction was complete in 16 hours. The product was obtained (flash column chromatography 20% EtOAc/80% *n*-hexane) as a colourless oil (0.49 g, 70%): $\nu_{\max}/\text{cm}^{-1}$ (film) 1727 (C=O, carbamate); $[\alpha]_D^{24.2} - 80.6^\circ$ ($c = 0.217$, CHCl_3) ^1H NMR (CDCl_3) δ 9.2 (bs, 1H), 7.9 (s, 1H), 7.4 (m, 5H), 6.83 (s, 1H), 5.18 (s, 2H), 4.35 (s, 1H), 4.0 (s, 1H), 3.94 (s, 3H), 3.82
 15 (s, 3H), 3.65 (m, 1H), 3.50 (m, 2H), 2.11 (m, 2H), 1.95 (m, 1H), 1.75 (m, 1H), 0.9 (s, 9H), 0.07 (s, 6H). IR (neat) 3302, 2953, 2852, 1729, 1620, 1598, 1528, cm^{-1} .

20


[2-[2-(*tert*-Butyl-dimethyl-silanyloxymethyl)-pyrrolidine-1-carbonyl]-4,5-dimethoxy-phenyl]-carbamic acid-4-methoxy-benzyl ester (10)



25

A solution of 4-methoxybenzyl alcohol (0.164 g, 1.19 mmol) and triethylamine (0.132 g, 0.18 mL, 1.3 mmol) in anhydrous toluene (10 mL) was added to a solution of the isocyanate **7** prepared from the amine **5** (0.47 g, 1.19 mmol), triphosgene (0.127 g, 0.43 mmol) and triethylamine (0.162 g, 0.22 mL, 1.6 mmol) in anhydrous toluene (20 mL). The reaction was complete in 20 hours. The product was obtained (flash column chromatography 40% EtOAc/60% *n*-hexane) as a colourless oil (0.45 g, 69%): $\nu_{\max}/\text{cm}^{-1}$ (film) 1727 (C=O, carbamate); $[\alpha]_D^{25.7} - 71.27^\circ$ ($c = 0.225$, CHCl_3) ^1H NMR (CDCl_3) δ 9.15 (s, 1H), 7.9 (s, 1H), 7.33 (d, $J = 6.56$ Hz, 2H), 6.9 (d, $J = 6.6$ Hz, 2H), 6.81 (s, 1H), 5.10 (d, $J = 11.92$ Hz, 2H), 4.34 (m, 1H), 3.99 (m, 1H), 3.93 (s, 3H), 3.81 (s, 6H), 3.65 (m, 1H), 2.03 (m, 2H), 1.95 (m, 1H), 1.7 (m, 1H), 0.89 (s, 9H), 0.04 (s, 6H). IR (CHCl_3) 2953, 1727, 1598, 1556 cm^{-1} . HRMS m/z calcd for $\text{C}_{29}\text{H}_{42}\text{N}_2\text{O}_7\text{Na}$ 581.2659 ($\text{M}+\text{Na}$), found 581.2663.

[2-[2-(tert-Butyl-dimethyl-silanyloxymethyl)-pyrrolidine-1-carbonyl]-4,5-dimethoxy-phenyl]-carbamic acid-2-trimethylsilanylethyl ester (11)



20


A solution of 2-trimethylsilyl ethanol (0.168 g, 0.2 mL, 1.42 mmol) and triethylamine (0.156 g, 0.22 mL, 1.55 mmol) in anhydrous toluene (10 mL) was added to a solution of the isocyanate **7** prepared from the amine **5** (0.509 g, 1.29 mmol), triphosgene (0.138 g, 0.46 mmol) and triethylamine (0.176 g, 0.24 mL, 1.74 mmol) in anhydrous toluene (25 mL). The reaction was complete in 21 hours. The product was obtained (flash column chromatography 40%EtOAc/60% *n*-hexane) as a colourless oil (0.417 g, 60%): $\nu_{\max}/\text{cm}^{-1}$ (film) (C=O, carbamate);); $[\alpha]_D^{22.6} - 96.15^\circ$ ($c = 0.21$, CHCl_3), ^1H NMR (CDCl_3) δ 9.03 (bs, 1H), 7.87 (s, 1H), 7.87 (s, 1H), 6.82 (s, 1H), 4.35 (m, 1H), 4.2 (m, 2H), 4.01 (m, 1H),

30

3.93 (s, 3H), 3.82 (s, 3H), 3.70 (m, 1H), 3.50 (m, 2H), 2.10 (m, 2H), 1.98 (m, 1H), 1.70 (m, 1H), 1.10 (m, 2H), 0.9 (s, 9H), 0.08 (s, 15H), IR (neat) 3305, 2953, 2857, 1727, 1622, 1599, 1522 cm^{-1} .


5

[2-[2-(*tert*-Butyl-dimethyl-silanyloxymethyl)-pyrrolidine-1-carbonyl]-4,5-dimethoxy-phenyl]-carbamic acid-3-(4-nitrophenyl)-allyl ester (12)




10 A solution of 3-(4-nitrophenyl)-prop-2-en-1-ol (0.222 g, 1.24 mmol) and triethylamine (0.138 g, 0.19 mL, 1.37 mmol) in anhydrous CH_2Cl_2 (10 mL) was added to a solution of the isocyanate 7 prepared from the amine 5 (0.491 g, 1.24 mmol), triphosgene (0.132 g, 0.45 mmol) and triethylamine (0.17 g, 0.23 mL, 1.68 mmol) in anhydrous toluene (20 mL). The reaction was complete in 15 20 hours. The product was obtained (flash column chromatography 50% EtOAc/50% *n*-hexane) as a yellow oil which crystallised (0.432g, 58%): $\nu_{\text{max}}/\text{cm}^{-1}$ (film) (C = O, carbamate); $[\alpha]_{\text{D}}^{25.3} - 65.0^\circ$ (c = 0.24, CHCl_3), ^1H NMR (CDCl_3) δ 9.39 (bs, 1H), 7.89 ((s, 1H), 8.19 (d, J = 8.8 Hz, 2H), 7.53 (d, J = 9 Hz, 2H), 6.85 (s, 1H), 6.73 (d, J = 15.9 Hz, 1H), 6.52 (dt, J = 5.8, 15.9 Hz, 1H) 4.86 (m, 2H) 4.38 (m, 1H), 4.01 (m, 1H), 3.94 (s, 3H), 3.83 (s, 3H), 3.70 (m, 1H), 3.52 (m, 2H), 2.06 (m, 2H), 1.95 (m, 1H), 1.72 (m, 1H), 0.9 (s, 9H), 0.08 (s, 6H). IR (neat) 3340, 2930, 1729, 1597, 1519 cm^{-1} . HRMS m/z calcd for $\text{C}_{30}\text{H}_{31}\text{N}_3\text{O}_8\text{SiNa}$ 622.2561 (M+Na), 25 found 622.2542.

{2-[-(tert-Butyl-dimethyl-silanyloxymethyl)-pyrrolidine-1-carbonyl]-4,5-dimethoxy-phenyl}-carbamic acid 2-benzenesulfonyl-ethyl ester (13)



- 5 A solution of phenylsulfonylethanol (0.26 g, 0.167 mL 1.39 mmol) and triethylamine (0.13 g, 0.18 mL, 1.29 mmol) in anhydrous toluene (10 mL) was added to a solution of the isocyanate **7** prepared from the amine **5** (0.5 g, 1.27 mmol), triphosgene (0.135 g, 0.34 mmol) and triethylamine (0.17 g, 0.24 mL, 1.72 mmol) in
10 anhydrous toluene (20 mL). The reaction was complete in 96 hours. The product was obtained (flash column chromatography 60% EtOAc/40% *n*-hexane) as a yellow oil (0.3 g, 39%). $[\alpha]_D^{24.1} = 81.5^\circ$ ($c = 0.23$, CHCl_3), ^1H NMR (CDCl_3) δ 9.1 (s, 1H), 7.95 (d, $J = 8$ Hz, 2H), 7.72 (s, 1H), 7.58 (m, 3H), 6.82 (s, 1H), 4.45 (t, $J =$
15 6.3 Hz, 2H), 4.35 (m, 1H), 3.95 (m, 1H), 3.91 (s, 3H), 3.82 (s, 3H), 3.70 (m, 1H), 3.5 (m, 4H), 2.1 (m, 2H), 1.95 (m, 1H), 1.7 (m, 1H), 0.9 (s, 9H), 0.05 (s, 6H).


- Acetic acid 1-[2-(4,5-dimethoxy-2-nitro-benzyloxycarbonylamino)-4,5-dimethoxy-benzoyl]-pyrrolidin-2-ylmethyl ester (14)



- A solution of nitroveratryl alcohol (1.98 g, 9.3 mmol) and triethylamine (0.94 g, 1.29 mL, 9.3 mmol) in anhydrous CH_2Cl_2 (30 mL) was added to a solution of the isocyanate **8** prepared from the
25 amine **6** (3.0 g, 9.3 mmol), triphosgene (0.99 g, 3.4 mmol) and triethylamine (1.27 g, 1.75 mL, 12.6 mmol) in anhydrous toluene

(60 mL). The reaction was complete in 16 h. The product was obtained (flash column chromatography 40% EtOAc/60% *n*-hexane) as a yellow foam (4.15 g, 69%). $[\alpha]^{25}_D -62.5^\circ$ ($c = 1.0$, CHCl_3); ^1H NMR (CDCl_3) δ 9.16 (s, 1H), 7.80 (s, 1H), 7.74 (s, 1H), 7.10 (s, 1H), 6.83 (s, 1H), 5.65 (d, $J = 15.2$ Hz, 1H), 5.55 (d, $J = 15.2$ Hz, 1H), 4.58 (bs, 1H), 4.29 (bs, 2H), 3.99 – 3.86 (m, 12H), 3.66 – 3.46 (m, 2H), 2.07 (s, 3H), 2.03 – 1.90 (m, 1H), 1.90 – 1.67 (m, 3H); ^{13}C NMR (CDCl_3) δ 169.5, 153.7, 153.2, 151.3, 148.1, 143.9, 139.6, 132.2, 127.9, 115.3, 111.2, 109.9, 108.2, 104.4, 64.4, 63.6, 56.5, 56.4, 56.4, 56.0, 55.9, 50.8, 27.7, 25.0, 20.8; MS (AP) m/z (relative intensity) 584 (M+Na), 562 (M+1); IR (neat) 3333, 2939, 1735, 1672, 1600, 1520, 1462, 1395, 1327, 1274, 1221, 1173, 1114, 1072, 1036, 873, 795.1, 756.1 (cm^{-1}); HRMS m/z calcd for $\text{C}_{26}\text{H}_{32}\text{N}_3\text{O}_{11}$ 562.2033 (M+H) found 562.2037.


4-{4-[2-(2-Acetoxymethyl-pyrrolidine-1-carbonyl)-4,5-dimethoxy-phenylcarbamoyloxymethyl]-2-methoxy-5-nitro-phenoxy}butyric acid allyl ester (15)



A solution of linker alcohol (52) (3.02 g, 9.3 mmol) and triethylamine (0.94 g, 1.29 mL, 9.3 mmol) in anhydrous CH_2Cl_2 /toluene (20 mL/10 mL) was added to a solution of the isocyanate 8 prepared from the amine 6 (3.0 g, 9.3 mmol), triphosgene (0.99 g, 3.4 mmol) and triethylamine (1.27 g, 1.75 mL, 12.6 mmol) in anhydrous toluene (100 mL). The reaction was complete in 16 hours. The product was obtained (flash column chromatography 60% EtOAc/40% *n*-hexane) as a yellow foam (1.84 g, 30%). $[\alpha]^{25}_D -54.5^\circ$ ($c = 1.0$, CHCl_3); ^1H NMR (CDCl_3) δ 9.15 (s, 1H), 7.80 (s, 1H), 7.73 (s, 1H), 7.09 (s, 1H), 6.83 (s, 1H), 5.98 – 5.87 (m, 1H), 5.69 (d, $J = 15.2$ Hz, 1H), 5.53 (d, $J = 15.2$ Hz, 1H), 5.35 – 5.22 (m, 2H), 4.62 – 4.58 (m, 3H), 4.29 (bs, 2H),

4.18 - 4.11 (m, 2H), 3.97 (s, 3H), 3.92 (s, 3H), 3.89 (s, 3H),
 3.58 - 3.51 (m, 2H), 2.59 (t, $J = 7.2$ Hz, 2H), 2.24 - 2.15 (m,
 2H), 2.06 (s, 3H), 1.98 - 1.79 (m, 4H); ^{13}C NMR (CDCl_3) δ 172.5,
 170.9, 169.4, 154.1, 153.2, 151.2, 147.3, 143.9, 139.5, 132.1,
 5 128.0, 118.4, 115.3, 111.2, 110.1, 109.6, 104.4, 68.2, 65.3,
 64.5, 63.7, 56.6, 56.4, 56.0, 55.9, 50.9, 30.6, 27.6, 25.0, 24.2,
 20.9; MS (AP) m/z (relative intensity) 673 (M^+ , 15), 515 (14),
 487 (4), 400 (3), 349 (9), 322 (22), 308 (30), 289 (8), 247 (4),
 224 (6); IR (neat) 2940, 1735, 1600, 1520, 1465, 1395, 1326,
 10 1275, 1228, 1173, 1114, 1069, 1037, 993, 939, 871, 755 cm^{-1} ; HRMS
 m/z calcd for $\text{C}_{32}\text{H}_{39}\text{N}_3\text{O}_{13}$ 673.2494 (M^+) found 673.2483.


2-[3-(4-{2-[2-(*tert*-Butyl-dimethyl-silanyloxymethyl)-pyrrolidine-
 1-carbonyl]-4,5-dimethoxy-phenylcarbamoyloxymethyl}-phenyl)-
 15 ureido]-pentanedioic acid diallyl ester (36)



A solution of the urea progroup **35** (2.03 g, 5.4 mmol) and
 triethylamine (0.6 g, 0.83 mL, 5.95 mmol) in anhydrous CH_2Cl_2 (55
 mL) was added to a solution of the isocyanate **7** prepared from the
 20 amine **5** (2.13 g, 5.4 mmol), triphosgene (0.58 g, 1.95 mmol) and
 triethylamine (0.74 g, 1.01 mL, 7.3 mmol) in anhydrous toluene
 (70 mL). The reaction was complete in 20 h. The product was
 obtained (flash column chromatography 60% EtOAc/40% *n*-hexane) as
 a white foam (1.94 g, 45%). $[\alpha]_D^{24.8} - 40.6^\circ$ ($c = 0.234$, CHCl_3), ^1H
 25 NMR (CDCl_3) δ 9.1 (bs, 1H), (7.85 (s, 1H), 7.31 (s, 1H), 6.87 (s,
 1H), 6.82 (s, 1H), 5.90 (m, 2H), 5.62 (d, $J = 11.7$ Hz, 1H), 5.25
 (m, 4H), 5.11 (s, 2H), 4.63 (m, 5H), 4.35 (m, 1H), 3.99 (m, 1H),
 3.92 (s, 3H), 3.81 (s, 3H), 3.63 (m, 1H), 3.51 (m, 2H), 2.50 (m,
 2H), 2.25 (m, 1H), 2.00 (m, 3H), 1.70 (m, 1H), 0.9 (s, 9H), 0.05


(s, 6H). IR (neat) 3349, 2952, 2856, 1732, 1664, 1600, 1520 cm^{-1} . HRMS m/z calcd for $\text{C}_{40}\text{H}_{56}\text{N}_4\text{O}_{11}\text{SiCs}$ 929.2769 (M+Cs), found 929.2727.

2-(4-{2-[2-(*tert*-Butyl-dimethyl-silanyloxymethyl)-pyrrolidine-1-carbonyl]-4,5-dimethoxy-phenylcarbamoyloxymethyl}-phenoxycarbonylamino)-pentanedioic acid diallyl ester (43)




A solution of the carbamate progroup **42** (1.48 g, 3.92 mmol) and triethylamine (0.45 g, 0.6 mL, 4.3 mmol) in anhydrous CH_2Cl_2 (30 mL) was added to a solution of the isocyanate **7** prepared from the amine **5** (1.54 g, 3.92 mmol), triphosgene (0.42 g, 1.4 mmol) and triethylamine (0.535 g, 0.74 mL, 5.3 mmol) in anhydrous toluene (50 mL). The reaction was complete in 4 h. The product was obtained (flash column chromatography 40% EtOAc/60% *n*-hexane) as a colourless oil (1.76 g, 56). ^1H NMR (CDCl_3) δ 9.22 (bs, 1H), 7.87 (s, 1H), 7.40 (d, J = 10 Hz, 2H), 7.13 (d, J = 7.5 Hz, 2H), 6.83 (s, 1H), 5.93 (m, 2H), 5.74 (d, J = 8.3 Hz, 1H), 5.30 (m, 4H), 5.17 (d, J = 12.5 Hz, 1H), 5.15 (d, J = 12.5 Hz, 1H), 4.68 (d, J = 5 Hz, 2H), 4.61 (d, J = 5 Hz, 1H), 4.48 (m, 1H), 4.35 (m, 1H), 3.95 (s, 3H), 3.82 (s, 3H), 3.65 (m, 1H), 3.50 (m, 2H), 2.55 (m, 2H), 2.30 (m, 1H), 2.1 (m, 3H), 1.95 (m, 1H), 1.8 (m, 1H), 0.9 (s, 9H), 0.04 (s, 6H). IR (neat) 3338, 2953, 2857, 1735, 1615, 1597, 1522 cm^{-1} .

{2-[2-tert-Butyl-dimethyl-silanyloxymethyl]-pyrrolidine-1-carbonyl}-4,5-dimethoxy-phenyl}-carbamic acid methyl ester (77)



A solution of methanol (0.39 g, 0.5 mL 12.3 mmol) and triethylamine (0.3 g, 0.41 mL, 2.95 mmol) in anhydrous toluene (10 mL) was added to a solution of the isocyanate 7 prepared from the amine 5 (0.97 g, 2.5 mmol), triphosgene (0.263 g, 0.89 mmol) and triethylamine (0.335 g, 0.46 mL, 3.32 mmol) in anhydrous toluene (30 mL). The reaction was complete in 18 hours. The product was obtained (flash column chromatography 60% EtOAc/40% n-hexane) as a colourless oil (0.694 g, 62.5%): $[\alpha]_D^{25} -122^\circ$ ($c = 0.24$, CHCl_3); ^1H NMR (CDCl_3) δ 9.1 (bs, 1H), 7.86 (s, 1H), 6.83 (s, 1H), 4.35 (bs, 1H), 4.05 (m, 1H), 3.93 (s, 3H), 3.82 (s, 3H), 3.74 (s, 3H), 3.67 (m, 1H), 3.5 (m, 2H), 2.07 (m, 2H), 1.95 (m, 1H) 1.72 (m, 1H), 0.90 (s, 9H), 0.04 (s, 6H); MS (ES+) m/z (relative intensity) 475.2 ($\text{M}^+ + \text{Na}$, 5), 453.2 ($\text{M}^+ + 1$, 100); IR (neat) 2953, 1733, 1598, 1524, 1396 cm^{-1} .


{2-[2-tert-Butyl-dimethyl-silanyloxymethyl]-pyrrolidine-1-carbonyl}-4,5-dimethoxy-phenyl}-carbamic acid tert-butyl ester (78)



A solution of t-butanol (0.99 g, 1.25 mL 13.3 mmol) and triethylamine (0.292 g, 0.4 mL, 2.9 mmol) in anhydrous toluene (10 mL) was added to a solution of the isocyanate 7 prepared from the amine 5 (1.05 g, 2.66 mmol), triphosgene (0.284 g, 0.96 mmol) and triethylamine (0.36 g, 0.5 mL, 3.6 mmol) in anhydrous toluene (30 mL). The reaction was stirred at room temperature for 18 hours then heated under reflux for 18 h. The product was obtained

(flash column chromatography 60% EtOAc/40% *n*-hexane) as a colourless oil (0.392 g, 30%): $[\alpha]_D^{23.5} - 90.7^\circ$ ($c = 0.193$, CHCl_3); ^1H NMR (CDCl_3) δ 8.58 (bs, 1H), 7.91 (s, 1H), 6.82 (s, 1H), 4.37 (bs, 1H), 4.13 (m, 1H), 3.95 (s, 3H), 3.82 (s, 3H), 3.68 (m, 1H), 3.51 (m, 2H), 2.05 (m, 2H), 1.93 (m, 1H), 1.74 (m, 1H), 1.61 (s, 9H), 0.97 (s, 9H), 0.04 (s, 6H); MS (ES+) m/z (relative intensity) 517.2 ($\text{M}^+ + \text{Na}$, 5), 495.2 ($\text{M}^+ + 1$, 100); IR (neat) 2930, 1723, 1600, 1521, 1420, 1394 cm^{-1} .

10 {2-[2-*tert*-Butyl-dimethyl-silanyloxymethyl]-pyrrolidine-1-carbonyl}-4,5-dimethoxy-phenyl}-carbamic acid 2,2,2-trichloroethyl ester (79)




15

A solution of 2,2,2-trichloroethanol (0.48 g, 0.31 mL 3.2 mmol) and triethylamine (0.36 g, 0.49 mL, 3.5 mmol) in anhydrous toluene (10 mL) was added to a solution of the isocyanate 7 prepared from the amine 5 (1.15 g, 2.92 mmol), triphosgene (0.31 g, 1.05 mmol) and triethylamine (0.398 g, 0.55 mL, 3.94 mmol) in anhydrous toluene (30 mL). The reaction was complete in 18 h. The product was obtained (flash column chromatography 60% EtOAc/40% *n*-hexane) as a colourless oil (1.075 g, 65%): $[\alpha]_D^{24.2} - 90.5^\circ$ ($c = 0.21$, CHCl_3); ^1H NMR (CDCl_3) δ 9.48 (bs, 1H), 7.85 (s, 1H), 6.87 (s, 1H), 4.83 (d, $J = 11.97$ Hz, 1H), 4.76 (d, $J = 12.0$ Hz, 1H), 4.39 (bs, 1H), 3.99 (m, 1H), 3.94 (s, 3H), 3.84 (s, 3H), 3.68 (m, 1H), 3.56 (m, 2H), 2.1 (m, 2H), 1.98 (m, 1H), 1.74 (m, 1H), 0.91 (s, 9H), 0.04 (s, 6H); MS (ES+) m/z (relative intensity) 593.0 ($\text{M}^+ + \text{Na}$, 5), 571.1 ($\text{M}^+ + 1$, 100); IR (neat) 2953, 1746, 1599, 1524, 1462, 1422, 1397 cm^{-1} .

30

{2-[2-*tert*-Butyl-dimethyl-silanyloxymethyl]-pyrrolidine-1-carbonyl}-4,5-dimethoxy-phenyl}-carbamic acid 4-nitro benzyl ester (80)




5

A solution of 4-nitro-benzyl alcohol (0.42 g, 2.75 mmol) and triethylamine (0.3 g, 0.42 mL, 3.0 mmol) in anhydrous dichloromethane (20 mL) was added to a solution of the isocyanate 7 prepared from the amine 5 (0.985 g, 2.5 mmol), triphosgene (0.265 g, 0.895 mmol) and triethylamine (0.34 g, 0.47 mL, 3.36 mmol) in anhydrous toluene (40 mL). The reaction was complete in 18 h. The product was obtained (flash column chromatography 40% EtOAc/60% *n*-hexane) as a yellow oil (0.87 g, 61%): $[\alpha]_D^{21.0} - 85.15^\circ$ ($c = 0.23$, CHCl_3); ^1H NMR (CDCl_3) δ 9.48 (bs, 1H), 8.22 (d, $J = 8.8$ Hz, 2H), 7.87 (s, 1H), 7.56 (d, $J = 8.8$ Hz, 2H), 6.86 (s, 1H), 5.26 (2d, $J = 13.5$ Hz, 2H), 4.36 (bs, 1H), 4.0 (m, 1H), 3.93 (s, 3H), 3.83 (s, 3H), 3.67 (m, 1H), 3.55 (m, 2H), 2.06 (m, 2H), 1.97 (m, 1H), 1.75 (m, 1H), 0.90 (s, 9H), 0.03 (s, 6H); MS (ES+) m/z (relative intensity) 482.2 ($\text{M}^+ + \text{Na}$, 100), 460.3 ($\text{M}^+ + 1$, 60); IR (neat) 2953, 1728, 1600, 1519, 1397, 1346 cm^{-1} .

15

20


{2-[2-*tert*-Butyl-dimethyl-silanyloxymethyl]-pyrrolidine-1-carbonyl}-4,5-dimethoxy-phenyl}-carbamic acid 9H-fluorenyl-9-ylmethyl ester (81)



25

A solution of 9-fluorenylmethanol (0.54 g, 2.7 mmol) and triethylamine (0.3 g, 0.4 mL, 3.0 mmol) in anhydrous toluene (20 mL) was added to a solution of the isocyanate **7** prepared from the amine **5** (0.98 g, 2.5 mmol), triphosgene (0.265 g, 0.895 mmol) and triethylamine (0.34 g, 0.47 mL, 3.36 mmol) in anhydrous toluene (40 mL). The reaction was complete in 18 h. The product was obtained (flash column chromatography 20% EtOAc/80% *n*-hexane) as a yellow oil (1.04 g, 68%): $[\alpha]_D^{20.8} - 72.96^\circ$ ($c = 0.23$, CHCl_3); ^1H NMR (CDCl_3) δ 9.32 (bs, 1H), 7.86 (s, 1H), 7.78 (d, $J = 7.5$ Hz, 2H), 7.66 (m, 2H), 7.42 (d, $J = 7.4$ Hz, 2H), 7.34 (d, $J = 7.4$ Hz, 2H), 6.9 (s, 1H), 4.51–4.28 (m, 4H), 4.05 (m, 1H), 3.94 (s, 3H), 3.85 (s, 3H), 3.72 (m, 1H), 3.55 (m, 2H), 2.09 (m, 2H), 1.98 (m, 1H), 1.75 (m, 1H), 0.93 (s, 9H), 0.07 (s, 6H); MS (ES+) m/z (relative intensity) 525.2 ($\text{M}^+ + \text{Na}$, 100), 503.3 ($\text{M}^+ + 1$, 55); IR (neat) 2953, 1727, 1600, 1522, 1397, 1346 cm^{-1} .

{2-[2-tert-Butyl-dimethyl-silanyloxymethyl]-pyrrolidine-1-carbonyl}-4,5-dimethoxy-phenyl}-carbamic acid allyl ester (82)



A solution of allyl alcohol (3.73 g, 4.36 mL, 64.15 mmol) and triethylamine (1.56 g, 2.14 mL, 15.4 mmol) in anhydrous toluene (40 mL) was added to a solution of the isocyanate **7** prepared from the amine **5** (5.06 g, 12.8 mmol), triphosgene (1.37 g, 4.62 mmol) and triethylamine (1.75 g, 2.41 mL, 17.3 mmol) in anhydrous toluene (120 mL). The reaction was complete in 48 h. The product was obtained (flash column chromatography 30% EtOAc/70% *n*-hexane) as a pale yellow oil (4.23 g, 69%): $[\alpha]_D^{20.2} - 106.7^\circ$ ($c = 0.45$, CHCl_3); ^1H NMR (CDCl_3) δ 9.16 (bs, 1H), 7.88 (s, 1H), 6.84 (s, 1H), 6.00–5.93 (m, 1H), 5.38–5.23 (m, 2H), 4.66–4.63 (m, 2H), 4.36 (bs, 1H), 4.0 (m, 1H), 3.94 (s, 3H), 3.83 (s, 3H), 3.7 (m, 1H), 3.52 (m, 2H), 2.08–2.04 (m, 2H), 1.97 (m, 1H), 1.75 (m, 1H), 0.91 (s, 9H), 0.04 (s, 6H); MS (ES+) m/z (relative intensity)

501.1 (M^+ +Na, 3), 479.1 (M^+ +1, 100); Ir (neat) 2953, 2857, 1731, 1622, 1599, 1524, 1397 cm^{-1}

Deprotection of alcohols

5 General methods for the deprotection of monomer *tert*-butyldimethylsilyl ethers and acetates

Method A (TBDMS ethers)

10 A 1.0 M THF solution of *tetra*-N-butyl-ammonium fluoride (1.2 eq.) was added *via* syringe to a solution of the TBDMS ether (1 eq.) in THF at 0°C. The reaction was stirred at room temperature until reaction was complete (TLC). The solvent was removed *in vacuo* and the product purified by flash column chromatography.


15 Method B (TBDMS ethers)

A solution of the TBDMS ether in a mixture of AcOH/THF/H₂O (3/1/1) was stirred at room temperature until reaction was complete (TLC). The reaction mixture was cooled (ice bath) and carefully neutralised with NaHCO₃ (aq) (1 eq). The mixture was extracted with 20 EtOAc (x3) the combined extracts were washed with water (x1), satd NaCl (aq) (x1), dried (MgSO₄) and evaporated *in vacuo*. The product was purified by flash column chromatography.

Method C (acetates)


25 A solution of K₂CO₃ (5 eq) in H₂O was added dropwise to a solution of the acetate (1 eq) in MeOH/CHCl₃. The mixture was stirred at room temperature until reaction was complete (TLC). The solvent was evaporated *in vacuo* and the aqueous portion washed with EtOAc (x3). The combined organic extracts were washed with satd NaCl (aq) 30 (x3), dried (MgSO₄) and evaporated *in vacuo*. The product was purified by flash column chromatography.

[2-(2-Hydroxymethyl-pyrrolidine-1-carbonyl)-4,5-dimethoxy-phenyl]-carbamic acid-benzyl ester (16)




The TBDMS ether **9** (0.517 g, 0.98 mmol) in THF (15 mL) was
 5 deprotected (Method A: Bu₄NF (1.2 mL, 1.2 mmol)) to give the
 product (flash column chromatography 90% EtOAc/10% *n*-hexane) as a
 colourless oil (0.3 g, 75%).); $[\alpha]_D^{20.2} - 80.6^\circ$ ($c = 0.18$,
 CHCl₃), ¹H NMR (CDCl₃) δ 8.8 (bs, 1H), 7.80 (s, 1H), 7.40 (m, 5H),
 6.81 (s, 1H), 5.18 (m, 2H), 4.45 (m, 1H), 4.25 (m, 1H), 3.93 (s,
 10 3H), 3.85 (m, 4H), 3.70 (m, 1H), 3.60 (m, 1H), 3.50 (m, 1H), 2.19
 (m, 1H), 1.90 (m, 1H), 1.70 (m, 2H). IR (neat) 3338, 2959, 1727,
 1598, 1523 cm⁻¹.

[2-(2-Hydroxymethyl-pyrrolidine-1-carbonyl)-4,5-dimethoxy-
 15 phenyl]-carbamic acid-4-methoxy-benzyl ester (17)




The TBDMS ether **10** (0.37 g, 0.66 mmol) in THF (20 mL) was
 deprotected (Method A: Bu₄NF (0.8 mL, 0.8 mmol)) to give the
 product (flash column chromatography 80% EtOAc/20% *n*-hexane, then
 20 EtOAc) as a colourless oil (0.29 g, 97%). $[\alpha]_D^{22.1} - 69.6^\circ$ ($c =$
 0.23, CHCl₃), ¹H NMR (CDCl₃) δ 8.72 (s, 1H), 7.76 (s, 1H), 7.34
 (d, $J = 8.6$ Hz, 2H), 6.90 (d, $J = 8.6$ Hz, 2H), 6.80 (s, 1H),
 5.10 (m, 2H), 4.40 (m, 1H), 4.30 (m, 1H), 3.92 (s, 3H), 3.83 (s,
 3H), 3.80 (m, 4H), 3.7 (m, 1H), 3.58 (m, 1H), 3.45 (m, 1H), 2.15
 25 (m, 1H), 1.90 (m, 1H), 1.70 (m, 2H). IR (neat) 3338, 2958, 2837,
 1726, 1599 cm⁻¹.

[2-(2-Hydroxymethyl-pyrrolidine-1-carbonyl)-4,5-dimethoxy-phenyl]-carbamic acid 2-trimethylsilanyl-ethyl ester (18)



The TBDMS ether **11** (0.354 g, 0.66 mmol) was deprotected (Method
 5 B: AcOH (6 mL)/THF (2 mL)/H₂O (2 mL) then NaHCO₃ (8.77 g, 104.4
 mmol) in H₂O (100 mL)) to give the product (flash column
 chromatography 80% EtOAc/20% n-hexane) as a colourless oil (0.27
 g, 95%). $[\alpha]_D^{22.0} - 91.0^\circ$ (c = 0.21, CHCl₃), ¹H NMR (CDCl₃) δ 8.62
 (s, 1H), 7.80 (s, 1H), 6.81 (s, 1H), 4.42 (m, 1H), 4.30 (m, 1H),
 10 4.22 (m, 2H), 3.93 (s, 3H), 3.85 (m, 4H), 3.70 (m, 1H), 3.60 (m,
 1H), 3.50 (m, 1H), 2.20 (m, 1H), 1.90 (m, 1H), 1.70 (m, 2H), 1.09
 (m, 2H), 0.08 (s, 9H). IR (neat) 3340, 2953, 1726, 1597, 1520
 cm⁻¹.


15 [2-(2-Hydroxymethyl-pyrrolidine-1-carbonyl)-4,5-dimethoxy-
 phenyl]-carbamic acid-3-(4-nitrophenyl)-allylester (19)



The TBDMS ether **12** (0.346 g, 0.58 mmol) was deprotected (Method
 B: AcOH (6 mL)/THF (2 mL)/H₂O (2 mL) then NaHCO₃ (8.77 g, 104.4
 20 mmol) in H₂O (100 mL)) to give the product (flash column
 chromatography EtOAc) as a yellow foam (0.26 g, 92%). $[\alpha]_D^{21.9} -$
 61.2° (c = 0.24, CHCl₃), ¹H NMR (CDCl₃) δ 8.95 (s, 1H), 8.20 (d, J =
 8.8 Hz, 2H), 7.81 (s, 1H), 7.53 (d, J = 8.8 Hz, 2H), 6.84 (s,
 1H), 6.75 (d, J = 16 Hz, 1H), 6.50 (dt, J = 5.8, 16 Hz, 1H), 4.84


(m, 2H), 4.43 (m, 1H), 4.25 (m, 1H), 3.94 (s, 3H), 3.86 (m, 4H), 3.75 (m, 1H), 3.65 (m, 1H), 3.55 (m, 1H), 2.70 (m, 2H), 2.20 (m, 1H), 1.90 (m, 1H). IR (neat) 3340, 2939, 1728, 1597, 1519 cm^{-1} .

5 [2-(2-Hydroxymethyl-pyrrolidine-1-carbonyl)-4,5-dimethoxy-phenyl]-carbamic acid 2-benzenesulfonyl-ethyl ester (20)



The TBDMS ether **13** (0.3 g, 0.49 mmol) was deprotected (Method B: AcOH (9 mL)/THF (6 mL)/H₂O (3 mL) then NaHCO₃ (13.16 g, 156.6
10 mmol) in H₂O (175 mL)) to give the product (flash column chromatography 80% EtOAc/20% *n*-hexane) as a colourless oil (0.13 g, 54%). $[\alpha]_D^{22.0} - 50.7^\circ$ ($c = 0.22$, CHCl₃), ¹H NMR (CDCl₃) δ 8.79 (s, 1H), 7.80 (s, 1H), 7.40 (m, 4H), 6.82 (s, 1H), 5.20 (d, $J = 12.3$ Hz, 1H), 5.16 (d, $J = 12.3$ Hz, 1H), 4.40 (m, 1H), 4.25 (m,
15 1H), 3.93 (s, 3H), 3.85 (m, 4H), 3.70 (m, 1H), 3.60 (m, 1H), 3.50 (m, 3H), 2.20 (m, 1H), 1.90 (m, 1H), 1.70 (m, 2H). IR (neat) 3337, 2938, 1729, 1598, 1524 cm^{-1} .


20 [2-(2-Hydroxymethyl-pyrrolidine-1-carbonyl)-4,5-dimethoxy-phenyl]-carbamic acid 4,5-dimethoxy-2-nitro-benzyl ester (21)



The acetate **14** (2.0 g, 3.5 mmol) in MeOH/CHCl₃ (80 mL/30 mL) was deprotected (Method C: K₂CO₃ (2.45 g, 18.0 mmol) in H₂O (50 mL))
25 to give the product (flash column chromatography 2% MeOH/98% CHCl₃) as a yellow foam (1.6 g, 86%).

$[\alpha]^{25}_D -59.0^\circ$ ($c = 1.0$, CHCl_3); ^1H NMR (CDCl_3) δ 8.99 (s, 1H), 7.72 (s, 2H), 7.10 (s, 1H), 6.83 (s, 1H), 5.63 (d, $J = 15.2$ Hz, 1H), 5.52 (d, $J = 15.2$ Hz, 1H), 4.38 (bs, 2H), 4.08 – 3.80 (m, 13H), 3.73 – 3.44 (m, 2H), 2.25 – 2.08 (m, 1H), 2.03 – 1.60 (m, 3H); ^{13}C NMR (CDCl_3) δ 170.6, 153.7, 153.1, 151.1, 148.1, 144.1, 139.6, 131.4, 127.7, 110.7, 110.0, 108.2, 104.6, 66.0, 63.8, 60.8, 56.5, 56.4, 56.0, 51.4, 28.2, 25.0; MS (FAB) m/z 652 (M+Cs), 520 (M+1); IR (neat) 3362, 2960, 1735, 1613, 1519, 1454, 1397, 1321, 1279, 1220, 1174, 1119, 1072, 1034, 990, 958, 880, 847, 795, 758, 708 cm^{-1} ; HRMS m/z calcd for $\text{C}_{24}\text{H}_{30}\text{N}_3\text{O}_{10}$ 520.1946 (M+H) found 520.1931.

4-{4-[2-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-4,5-dimethoxy-phenylcarbamoyloxymethyl]-2-methoxy-5-nitro-phenoxy}-butyric acid methyl ester (22)




15

The acetate **15** (1.80 g, 2.7 mmol) in $\text{MeOH}/\text{CHCl}_3$ (80 mL/30 mL) was deprotected (Method C: K_2CO_3 (1.83 g, 13.3 mmol) in H_2O (50 mL)) to give the methyl ester product as a yellow foam (1.06 g, 63%). $[\alpha]^{24}_D -50.0^\circ$ ($c = 1.0$, CHCl_3); ^1H NMR (CDCl_3) δ 8.98 (s, 1H), 7.72 (s, 2H), 7.08 (s, 1H), 6.83 (s, 1H), 5.63 (d, $J = 15.2$ Hz, 1H), 5.52 (d, $J = 15.0$ Hz, 1H), 4.41 – 4.31 (m, 1H), 4.18 – 4.09 (m, 3H), 3.97 (s, 3H), 3.91 (s, 3H), 3.85 (s, 3H), 3.66 (s, 3H), 3.62 – 3.50 (m, 2H), 2.59 – 2.54 (m, 2H), 2.19 (pent., $J = 6.7$ Hz, 2H), 1.91 – 1.66 (m, 4H); ^{13}C NMR (CDCl_3) δ 174.3, 171.7, 154.9, 154.1, 151.9, 148.2, 144.8, 140.2, 132.2, 128.5, 119.0, 111.3, 110.8, 110.1, 105.2, 68.3, 66.2, 63.8, 60.9, 56.5, 56.4, 56.0, 51.7, 51.5, 30.3, 28.3, 25.1, 24.2; MS (FAB) m/z 628 (M+Na) 606 (M+1); IR (neat) 3342, 2953, 2615, 1740, 1601, 1531, 1398, 1333, 1285, 1116, 1072, 996, 943, 870, 814, 755 cm^{-1} .


30

2-(3-{4-[2-(2-Hydroxymethyl-pyrrolidine-1-carbonyl)-4,5-dimethoxy-phenylcarbamoyloxymethyl]-phenyl}-ureido)-pentanedioic acid diallyl ester (37)



- 5 The TBDMS ether **36** (1.88g, 2.36 mmol) was deprotected (Method B: AcOH (18 mL)/THF (6 mL)/H₂O (6 mL) then NaHCO₃ (26.3 g, 313.0 mmol) in H₂O (270 mL)) to give the product (flash column chromatography 99% EtOAc/MeOH 1%) as a white foam (1.6 g, 99 %). $[\alpha]_D^{23.4} - 45.9^\circ$ ($c = 0.21$, CHCl₃), ¹H NMR (CDCl₃) δ 8.69 (s, 1H),
 10 7.75 (s, 1H), 7.30 (m, 4H), 7.12 (s, 1H), 6.80 (s, 1H), 5.90 (m, 2H), 5.74 (d, $J = 12.8$ Hz, 1H), 5.30 (m, 4H), 5.10 (s, 2H), 4.60 (s, 5H), 4.40 (m, 1H), 4.20 (m, 1H), 3.90 (m, s, 3H), 3.84 (m, 4H), 3.70 (m, 1H), 3.50 (m, 2H), 2.50 (m, 2H), 2.10 (m, 2H), 1.90 (m, 1H), 1.70 (m, 2H). IR (neat) 3350, 2951, 2856, 1734, 1660,
 15 1601, 1518 cm⁻¹. HRMS m/z calcd for C₃₉H₄₃N₄O₁₁Na 705.2748 (M+Na), found 705.2721.


2-(4-{2-[2-(2-Hydroxymethyl-pyrrolidine-1-carbonyl)-4,5-dimethoxy-phenylcarbamoyloxymethyl]-phenoxy-carbonylamino}-pentanedioic acid
 20 diallyl ester (44)



The TBDMS ether **43** (2.17 g, 2.72 mmol) was deprotected (Method B: AcOH (21 mL)/THF (7 mL)/H₂O (7 mL) then NaHCO₃ (30.66 g, 365.0 mmol) in H₂O (400 mL)) to give the product (flash column


chromatography EtOAc) as a white foam (1.7 g, 91 %). ^1H NMR (CDCl₃) δ 8.77 (s, 1H), 7.68 (s, 1H), 7.42 (d, J = 7.5 Hz, 2H), 7.13 (d, J = 7.5 Hz, 2H), 6.79 (s, 1H), 5.95 (m, 2H), 5.78 (d, J = 6.25 Hz, 1H), 5.30 (m, 4H), 5.17 (d, J = 9.4 Hz, 1H), 5.13 (d, J = 9.4 Hz, 1H), 4.70 (m, 4H), 4.50 (m, 1H), 4.40 (m, 1H), 4.25 (m, 1H), 3.93 (s, 3H), 3.84 (m, 4H), 3.70 (m, 1H), 3.55 (m, 2H), 2.55 (m, 2H), 2.40 (m, 1H), 2.10 (m, 2H), 1.90 (m, 1H), 1.70 (m, 2H). IR (neat) 3345, 2950, 2856, 1736, 1615, 1598, 1522 cm⁻¹.

10 [2-(2-Hydroxymethyl-pyrrolidine-1-carbonyl)-4,5-dimethoxy-phenyl]-carbamic acid methyl ester (83)



The TBDMS ether **77** (0.67 g, 1.5 mmol) in THF (30 mL) was deprotected (Method A: Bu₄NF (1.74 mL, 1.74 mmol)) to give the product (flash column chromatography 99% EtOAc/1% MeOH) as a colourless oil (0.46 g, 99%): $[\alpha]_D^{25.5}$ - 125.0° (c = 0.22, CHCl₃); ^1H NMR (CDCl₃) δ 8.72 (bs, 1H), 7.76 (s, 1H), 6.81 (s, 1H), 4.42-4.14 (m, 2H), 3.92 (s, 3H), 3.84 (s + m, 4H), 3.6-3.4 (m, 2H), 2.17 (m, 1H), 1.90-1.62 (m, 3H); MS (ES+) m/z (relative intensity) 361.0 (M^+ + Na, 20), 339.1 (M^+ + 1, 100); IR (neat) 3339, 2953, 1730, 1598, 1524, 1458, 1397 cm⁻¹.


[2-(2-Hydroxymethyl-pyrrolidine-1-carbonyl)-4,5-dimethoxy-phenyl]-carbamic acid tert-butyl ester (84)



25 The TBDMS ether **78** (0.34 g, 0.69 mmol) in THF (20 mL) was deprotected (Method A: Bu₄NF (0.83 mL, 0.83 mmol)) to give the product (flash column chromatography EtOAc) as a colourless oil (0.26 g, 99%): $[\alpha]_D^{24.6}$ - 90.4° (c = 0.19, CHCl₃); ^1H NMR (CDCl₃) δ

8.42 (bs, 1H), 7.81 (s, 1H), 6.80 (s, 1H), 4.43 (m, 1H), 4.28 (bs, 1H), 3.94 (s, 3H), 3.84 (s + m, 4H), 3.76 (m, 1H), 3.62 (m, 1H), 3.51 (m, 1H), 2.17 (m, 1H), 1.91 (m, 1H) 1.85–1.62 (m, 2H), 1.51 (s, 9H); MS (ES+) m/z (relative intensity) 403.1 ($M^+ + Na$, 15), 381.1 ($M^+ + 1$, 100); IR (neat) 3340, 2975, 1721, 1597, 1522, 1456, 1395 cm^{-1} .

[2-(2-Hydroxymethyl-pyrrolidine-1-carbonyl)-4,5-dimethoxy-phenyl]-carbamic acid 2,2,2-trichloro-ethyl ester (85)




10

The TBDMS ether **79** (1.03 g, 1.8 mmol) was deprotected (Method B: AcOH (15 mL)/THF (5 mL)/H₂O (5 mL) then NaHCO₃ (21.9 g, 261 mmol) in H₂O (300 mL)) to give the product (crystallised from 80% EtOAc/20% n-hexane) as a white solid (0.8 g, 97%): $[\alpha]_D^{24.3} - 91.4^\circ$ ($c = 0.19$, CHCl₃); ¹H NMR (CDCl₃) δ 9.04 (bs, 1H), 7.73 (s, 1H), 6.85 (s, 1H), 4.83 (d, $J = 12.0$ Hz, 1H), 4.78 (d, $J = 12.0$ Hz, 1H), 4.44 (m, 1H), 4.05 (m, 1H), 3.93 (s, 3H), 3.86 (s + m, 4H), 3.73 (m, 1H), 3.61–3.5 (m, 2H), 2.04 (m, 1H), 1.92 (m, 1H), 1.73 (m, 2H); MS (ES+) m/z (relative intensity) 477.0 ($M^+ + Na$, 30), 455.0 ($M^+ + 1$, 100); IR (neat) 3306, 2954, 1743, 1599, 1524, 1432, 1396 cm^{-1} .

15

20

[2-(2-Hydroxymethyl-pyrrolidine-1-carbonyl)-4,5-dimethoxy-phenyl]-carbamic acid 4-nitro-benzyl ester (86)




25

The TBDMS ether **80** (0.81 g, 1.4 mmol) was deprotected (Method B: AcOH (15 mL)/THF (5 mL)/H₂O (5 mL) then NaHCO₃ (21.9 g, 261 mmol)


in H₂O (300 mL)) to give the product (flash column chromatography EtOAc) as a pale yellow oil (0.61 g, 94%): $[\alpha]_D^{22.0} - 60.42^\circ$ ($c = 0.24$, CHCl₃); ¹H NMR (CDCl₃) δ 9.05 (bs, 1H), 8.23 (d, $J = 8.8$ Hz, 2H), 7.78 (s, 1H), 7.56 (d, $J = 8.8$ Hz, 2H), 6.84 (s, 1H), 5.27 (m, 2H), 4.42 (m, 1H), 4.15 (m, 1H), 3.93 (s, 3H), 3.85 (s + m, 4H), 3.71 (m, 1H), 3.62 (m, 1H), 3.51 (m, 1H), 2.17 (m, 1H), 1.91 (m, 1H) 1.71 (m, 2H); MS (ES+) m/z (relative intensity) 482.2 ($M^{+} + Na$, 100), 460.3 ($M^{+} + 1$, 60); IR (neat) 3322, 2941, 1727, 1596, 1517, 1453, 1428, 1395, 1343 cm⁻¹.

[2-(2-Hydroxymethyl-pyrrolidine-1-carbonyl)-4,5-dimethoxy-phenyl]-carbamic acid 9H-fluoren-9-ylmethyl ester (87)



The TBDMS ether **81** (0.98 g, 1.6 mmol) was deprotected (Method B: AcOH (15 mL)/THF (5 mL)/H₂O (5 mL) then NaHCO₃ (21.9 g, 261 mmol) in H₂O (300 mL)) to give the product (flash column chromatography EtOAc) as a colourless oil (0.79 g, 99%): $[\alpha]_D^{21.6} - 60.5^\circ$ ($c = 0.314$, CHCl₃); ¹H NMR (CDCl₃) δ 8.8 (bs, 1H), 7.78 (d, $J = 7.5$ Hz, 2H), 7.75 (bs, 1H), 7.65 (m, 2H), 7.42 (t, $J = 7.5$ Hz, 2H), 7.33 (t, $J = 7.5$ Hz, 2H), 6.85 (s, 1H), 4.55-4.38 (m, 3H), 4.3 (m, 1H), 4.05 (m, 1H), 3.93 (s, 3H), 3.86 (s + m, 4H), 3.7 (m, 1H), 3.59 (m, 1H), 3.45 (m, 1H), 2.2 (m, 1H), 1.92 (m, 1H), 1.82-1.65 (m, 2H); MS (ES+) m/z (relative intensity) 525.2 ($M^{+} + Na$, 100), 503.3 ($M^{+} + 1$, 60); IR (neat) 3328, 2948, 1722, 1596, 1520, 1449, 1394 cm⁻¹.

[2-(2-Hydroxymethyl-pyrrolidine-1-carbonyl)-4,5-dimethoxy-phenyl]-carbamic acid allyl ester (88)



The TBDMS ether **82** (1.44 g, 3.0 mmol) in THF (30 mL) was
 5 deprotected (Method A: Bu₄NF (13.6 mL, 3.6 mmol)) to give the
 product (flash column chromatography 80% EtOAc/20% *n*-hexane) as a
 colourless oil (0.996 g, 91%): $[\alpha]_D^{24.1} = -101.7^\circ$ ($c = 0.35$, CHCl₃);
¹H NMR (CDCl₃) δ 8.74 (bs, 1H), 7.79 (s, 1H), 6.82 (s, 1H), 5.96
 (m, 1H), 5.27 (m, 2H), 4.86 (m, 2H), 4.41 (m, 1H), 4.15 (m, 1H),
 10 3.93 (s, 3H), 3.84 (s + m, 4H), 3.80–3.45 (m, 3H), 2.2 (m, 1H),
 1.95–1.60 (m, 3H); HRMS m/z calcd for C₁₈H₂₅N₂O₆ 365.1713 (M+H)
 found 365.1699; IR (neat) 3337, 2940, 1728, 1598, 1524, 1455,
 1396 cm⁻¹.

15 Cyclisation of monomer alcohols

General methods:


Method A

The alcohol (1 eq), (diacetoxyiodo)benzene (1.1 eq) and TEMPO
 (0.1 eq) were dissolved in CH₂Cl₂ and the mixture stirred at room
 20 temperature until reaction was complete (TLC). The reaction
 mixture was washed with satd NaHSO₃ (aq) (x1) and the NaHSO₃ portion
 was then washed with CH₂Cl₂ (x4). The combined organic extracts
 were washed with satd NaHCO₃ (aq) (x2), satd NaCl (aq) (x1), dried
 (MgSO₄) and evaporated *in vacuo*. The product was purified by
 25 either flash column chromatography or recrystallisation.

Method B


The alcohol (1 eq), pyridinium dichromate (1.2 eq) and 4Å
 molecular sieves (0.5 g/mmol alcohol) in anhydrous CH₂Cl₂ were
 30 stirred at room temperature under a N₂ atmosphere until reaction
 was complete (TLC). The reaction mixture was filtered through
 celite, washing with EtOAc. The solvent was evaporated *in vacuo*
 and the product purified by flash column chromatography.

(11*S*,11*aS*)-7,8-Dimethoxy-11-hydroxy-5-oxo-1,2,3,10,11,11*a*-hexahydro-5*H*-pyrrolo[2,1-*c*][1,4]benzodiazepine-10-carboxylic acid benzyl ester (23)



5 The alcohol **16** (0.136 g, 0.33 mmol) was reacted (Method A) with DAIB (0.127 g, 0.39 mmol) and TEMPO (0.005 g, 0.033 mmol) in CH₂Cl₂ (6 mL). The product was obtained (flash column chromatography 90% EtOAc/10% *n*-hexane) as a white foam (0.095 g, 70%). $[\alpha]_D^{20.2} + 195.7^\circ$ ($c = 0.23$, CHCl₃), ¹H NMR (CDCl₃) δ 7.30 (m, 3H), 7.24 (m, 3H), 6.52 (s, 1H), 5.64 (m, 1H), 5.50 (d, $J = 12.3$ Hz, 1H), 4.85 (d, $J = 12.3$ Hz, 1H), 3.92 (s, 3H), 3.70 (m, 5H), 3.60 (m, 1H), 3.50 (m, 1H), 2.15 (m, 2H), 2.00 (m, 2H). IR (neat) 3563, 3294, 2953, 1698, 1597, 1573, 1515 cm⁻¹.


15 (11*S*,11*aS*)-7,8-Dimethoxy-11-hydroxy-5-oxo-1,2,3,10,11,11*a*-hexahydro-5*H*-pyrrolo[1,2-*c*][1,4]benzodiazepine-10-carboxylic acid 4-methoxy-benzyl ester (24)



The alcohol **17** (0.214 g, 0.48 mmol) was reacted (Method A) with DAIB (0.175 g, 0.55 mmol) and TEMPO (0.007 g, 0.048 mmol) in CH₂Cl₂ (6 mL). The product was obtained (flash column chromatography 80% EtOAc/20% *n*-hexane) as a colourless foam (0.201 g, 94%). $[\alpha]_D^{21.5} + 185.8^\circ$ ($c = 0.22$, CHCl₃), ¹H NMR (CDCl₃) δ 7.27 (s, 1H), 7.17 (d, $J = 7.5$ Hz, 2H), 6.83 (d, $J = 8$ Hz, 2H), 6.49 (s, 1H), 5.62 (m, 1H), 5.32 (d, $J = 12$ Hz, 1H), 4.79 (d, $J = 12$ Hz, 1H), 3.92 (s, 3H), 3.78 (s, 3H), 3.70 (m, 4H), 3.55 (m,


1H), 3.45 (m, 1H), 2.15 (m, 2H), 2.00 (m, 2H), IR (neat) 3369, 2958, 1705, 1606, 1515 cm^{-1} .

(11*S*,11*aS*)-7,8-Dimethoxy-11-hydroxy-5-oxo-1,2,3,10,11,11*a*-
 5 hexahydro-5*H*-pyrrolo[1,2-*c*][1,4]benzodiazepine-10-carboxylic acid
 2-trimethylsilanyl-ethyl ester (25)



The alcohol **18** (0.110 g, 0.26 mmol) was reacted (Method A) with
 DAIB (0.092 g, 0.285 mmol) and TEMPO (0.004 g, 0.026 mmol) in
 10 CH_2Cl_2 (3 mL). The product was obtained (flash column
 chromatography 80% EtOAc/20% *n*-hexane) as a colourless oil (0.106
 g, 97%). $[\alpha]_D^{21.9} + 145.0^\circ$ ($c = 0.21$, CHCl_3), ^1H NMR (CDCl_3) δ 7.23
 (s, 1H), 6.66 (s, 1H), 5.62 (m, 1H), 4.25 (m, 1H), 4.15 (m, 1H),
 3.92 (s, 3H), 3.88 (s, 3H), 3.70 (m, 2H), 3.50 (m, 2H), 2.15 (m,
 15 2H), 2.10 (m, 2H), 0.9 (m, 2H), 0.0 (s, 9H). IR (neat) 3370,
 2953, 1704, 1623, 1605, 1515. cm^{-1} .


(11*S*,11*aS*)-7,8-Dimethoxy-11-hydroxy-5-oxo-1,2,3,10,11,11*a*-
 hexahydro-5*H*-pyrrolo[1,2-*c*][1,4]benzodiazepine-10-carboxylic acid
 20 3-(4-nitro-phenyl)-allyl ester (26)



The alcohol **19** (0.253 g, 0.52 mmol) was reacted (Method A) with
 DAIB (0.185 g, 0.57 mmol) and TEMPO (0.008 g, 0.052 mmol) in
 CH_2Cl_2 (4 mL). The product was recrystallised (EtOAc/*n*-hexane) to
 25 give a pale yellow solid (0.24 g, 94%). $[\alpha]_D^{23.8} + 172.3^\circ$ ($c =$
 0.21, CHCl_3), ^1H NMR (CDCl_3) δ 8.17 (d, $J = 8.5$ Hz, 2H), 7.44 (d,
 $J = 7.9$ Hz, 2H) 7.27 (s, 1H) 6.71 (s, 1H), 6.47 (m 1H), 6.3 (m,


1H), 5.67 (m, 1H), 4.77 (s, 2H), 3.94 (s, 3H), 3.85 (s, 3H), 3.70 (m, 2H), 3.60 (m, 1H), 3.55 (m, 1H), 2.15 (m, 2H), 2.05 (m, 2H), IR (neat) 3369, 2957, 1709, 1602, 1516. cm^{-1}

- 5 (11*S*,11*aS*)-7,8-Dimethoxy-11-hydroxy-5-oxo-1,2,3,10,11,11*a*-hexahydro-5*H*-pyrrolo[1,2-*c*][1,4]benzodiazepine-10-carboxylic acid 2-benzenesulfonyl-ethyl ester (27)



The alcohol **20** (0.102 g, 0.21 mmol) was reacted (Method A) with
 10 DAIB (0.080 g, 0.25 mmol) and TEMPO (0.003 g, 0.021 mmol) in CH_2Cl_2 (5 mL). The product was obtained (flash column chromatography 80% EtOAc/20% *n*-hexane) as a colourless oil (0.072 g, 72%). $[\alpha]_D^{24.3} + 127.5^\circ$ ($c = 0.22$, CHCl_3), ^1H NMR (CDCl_3) δ 7.75 (m, 5H), 7.22 (m, 1H), 6.95 (m, 1H), 5.65 (m, 1H), 4.70 (m, 2H),
 15 3.95 (s, 6H), 3.60 (m, 5H), 3.25 (m, 1H), 2.15 (m, 2H), 2.05 (m, 2H), IR (neat) 3369, 2971, 1710, 1622, 1604, 1516. cm^{-1}

- (11*S*,11*aS*)-7,8-Dimethoxy-11-hydroxy-5-oxo-1,2,3,10,11,11*a*-hexahydro-5*H*-pyrrolo[2,1-*c*][1,4]benzodiazepine-10-carboxylic acid
 20 4,5-dimethoxy-2-nitro-benzyl ester (28)




The alcohol **21** (1.70 g, 3.3 mmol) was reacted (Method B) with pyridinium dichromate (1.47 g, 3.9 mmol) and 4Å molecular sieves (1.63 g) in anhydrous CH_2Cl_2 (50 mL). The product was obtained

(flash column chromatography 50% EtOAc/50% *n*-hexane) as a yellow foam (1.04 g, 62%).

$[\alpha]^{26}_D +99.0^\circ$ ($c = 1.0$, CHCl_3); ^1H NMR (CDCl_3) δ 7.65 (s, 1H), 7.25 (s, 1H), 6.83 (s, 1H), 6.51 (s, 1H), 5.74 – 5.72 (m, 1H), 5.51 (d, $J = 15.4$ Hz, 1H), 5.44 (d, $J = 15.5$ Hz, 1H), 4.51 (bs, 1H), 3.92 – 3.87 (m, 9H), 3.68 (s, 3H), 3.54 – 3.50 (m, 2H), 2.16 – 2.02 (m, 4H); ^{13}C NMR (CDCl_3) δ 166.8, 155.4, 153.8, 150.9, 148.5, 148.0, 138.8, 128.2, 126.8, 126.1, 112.5, 110.3, 109.2, 107.9, 86.1, 65.3, 60.1, 56.3, 56.2, 56.2, 56.1, 46.4, 28.6, 23.0; MS (FAB) m/z 650 ($\text{M}+\text{Cs}$), 540 ($\text{M}+\text{Na}$, 20), 518 ($\text{M}+1$); IR (neat) 3362, 2941, 2616, 1715, 1620, 1523, 1436, 1284, 1134, 1104, 1068, 969, 924, 873, 837, 792, 768, 736, 684, 646 cm^{-1} ; HRMS (FAB) m/z calcd for $\text{C}_{24}\text{H}_{28}\text{N}_3\text{O}_{10}$ 518.1761 ($\text{M}+\text{H}$) found 518.1775.

(11*S*,11*aS*)-7,8-dimethoxy-11-hydroxy-5-oxo-1,2,3,10,11,11*a*-hexahydro-5*H*-pyrrolo[1,2-*c*][1,4]benzodiazepine-10-carboxylic acid 5-methoxy-4-(3-methoxycarbonyl-propoxy)-2-nitro-benzyl ester (29)




The alcohol **22** (1.06 g, 1.7 mmol) was reacted (Method B) with pyridinium dichromate (0.76 g, 2.0 mmol) and 4Å molecular sieves (0.84 g) in anhydrous CH_2Cl_2 (70 mL). The product was obtained (flash column chromatography 50% EtOAc/50% *n*-hexane) as a yellow foam (0.553 g, 52%).

$[\alpha]^{25}_D +92.5^\circ$ ($c = 1.0$, CHCl_3); ^1H NMR (CDCl_3) δ 7.64 (s, 1H), 7.25 (s, 1H), 6.82 (s, 1H), 6.50 (s, 1H), 5.74 – 5.71 (m, 1H), 5.49 (d, $J = 15.3$ Hz, 1H), 5.44 (d, $J = 15.0$ Hz, 1H), 4.17 – 4.05 (m, 4H), 3.96 – 3.83 (m, 7H), 3.73 – 3.65 (m, 6H), 3.59 – 3.48 (m, 2H), 2.58 – 2.50 (m, 2H), 2.19 – 2.10 (m, 4H); ^{13}C NMR (CDCl_3) δ 172.3, 170.1, 165.8, 154.4, 153.2, 149.9, 147.5, 146.2, 137.7, 127.3, 125.1, 111.5, 109.4, 108.5, 108.4, 85.2, 67.2, 64.3, 55.2, 55.1, 50.7, 45.4, 29.2, 27.7, 23.2, 22.1; MS (FAB) m/z 626

(M+Na), 604 (M+1); IR (neat) 3385, 2955, 2616, 1734, 1638, 1523, 1285, 1104, 1066, 970, 942, 873, 836, 818, 789, 767, 735, 683, 646 cm^{-1} .


- 5 2-{3-[4-((1*S*,11*aS*)-7,8-dimethoxy-11-hydroxy-5-oxo-1,2,3,10,11,11*a*-hexahydro-5*H*-pyrrolo[2,1-*c*][1,4]benzodiazepine-10-carboxymethyl)-phenyl]-ureido}-pentanedioic acid diallyl ester (38)



- 10 The alcohol **37** (0.99 g, 1.45 mmol) was reacted (Method B) with pyridinium dichromate (0.66 g, 1.74 mmol) and 4Å molecular sieves (0.87 g) in anhydrous CH_2Cl_2 (9 mL). The product was obtained (flash column chromatography 90% EtOAc/10% *n*-hexane) as a white foam (0.565 g, 57%). $[\alpha]_{\text{D}}^{25.6} + 90.0^\circ$ ($c = 0.19$, CHCl_3), ^1H NMR (CDCl₃) δ 7.40 (s, 1H), 7.15 (m, 5H), 6.85 (s, 1H), 5.90 (m, 3H), 5.65 (m, 1H), 5.35 (m, 5H), 4.85 (d, $J = 11.4$ Hz, 1H), 4.60 (m, 4H), 4.25 (m, 1H), 4.11 (d, 7.1 Hz, 1H), 3.91 (m, 3H), 3.60 (m, 7H), 2.5 (m, 2H), 2.25 (m, 1H), 2.05 (m, 4H). HRMS m/z calcd for $\text{C}_{34}\text{H}_{41}\text{N}_4\text{O}_{11}$ 681.2772 (M+H), found 681.2755.
- 15


2-[4-((11*S*,11*aS*)-7,8-dimethoxy-11-hydroxy-5-oxo-1,2,3,10,11,11*a*-hexahydro-5*H*-pyrrolo[2,1-*c*][1,4]benzodiazepine-10-carboxyloxymethyl)-phenoxy-carbonylamino]-pentanedioic acid diallyl ester (45)

5



The alcohol **44** (0.55 g, 0.8 mmol) was reacted (Method B) with pyridinium dichromate (0.36 g, 0.96 mmol) and 4Å molecular sieves (0.4 g) in anhydrous CH₂Cl₂ (4 mL). The product was obtained (flash column chromatography 80% EtOAc/20% *n*-hexane) as a white foam (0.36 g, 66%). ¹H NMR (CDCl₃) δ 7.22 (m, 3H), 7.07 (d, *J* = 7.5 Hz, 2H), 6.50 (s, 1H), 5.95 (m, 3H), 5.70 (dd, *J* = 3, 10 Hz, 1H); 5.30 (m, 5H), 4.90 (d, *J* = 13 Hz, 1H), 4.60 (m, 4H), 4.45 (m, 1H), 3.92 (s, 3H), 3.55 (m, 8H), 2.50 (m, 2H), 2.30 (m, 1H), 2.10 (m, 4H).


(11*S*,11*aS*)-7,8-Dimethoxy-11-hydroxy-5-oxo-1,2,3,10,11,11*a*-hexahydro-5*H*-pyrrolo[1,2-*c*][1,4]benzodiazepine-10-carboxylic acid methyl ester (89)



The alcohol **83** (0.41 g, 1.2 mmol) was reacted (Method A) with DAIB (0.47 g, 1.45 mmol) and TEMPO (0.02 g, 0.12 mmol) in CH₂Cl₂ (30 mL). The product was obtained (trituration with Et₂O) as a white solid (0.34 g, 84%): [α]_D^{21.3} + 173.6° (*c* = 0.24, CHCl₃); ¹H NMR (CDCl₃) δ 7.3 (s, 1H), 6.68 (s, 1H), 5.66 (m, 1H), 3.96 (s, 3H), 3.91 (s, 3H), 3.85-3.65 (m, 4H), 3.6 (m, 1H), 3.49 (m, 1H), 2.14 (m, 2H), 2.02 (m, 2H), 1.85 (bs, 1H); MS (ES+) *m/z* (relative


intensity) 337.1 ($M^+ + 1$, 100); IR (neat) 3216, 2957, 1719, 1604, 1519, 1477, 1437, 1316 cm^{-1} .

(11*S*,11*aS*)-7,8-Dimethoxy-11-hydroxy-5-oxo-1,2,3,10,11,11*a*-
 5 hexahydro-5*H*-pyrrolo[1,2-*c*][1,4]benzodiazepine-10-carboxylic acid
 tert-butyl ester (90)



The alcohol **84** (0.23 g, 0.6 mmol) was reacted (Method A) with
 DAIB (0.234 g, 0.73 mmol) and TEMPO (0.009 g, 0.06 mmol) in CH_2Cl_2
 10 (10 mL). The product was obtained (flash column chromatography
 EtOAc) as a white foam (0.205 g, 89%): $[\alpha]_D^{20.9} + 162.4^\circ$ ($c = 0.19$,
 CHCl_3); ^1H NMR (CDCl_3) δ 7.22 (s, 1H), 6.62 (s, 1H), 5.45 (dd, $J =$
 3.2 Hz, 9.5 Hz, 1H), 3.93 (s, 3H), 3.89 (s, 3H), 3.8–3.69 (m,
 2H), 3.58 (m, 1H), 3.45 (m, 1H), 2.12 (m, 2H), 2.0 (m, 2H), 1.39
 15 (s, 9H); (ES+) m/z (relative intensity) 379.1 ($M^+ + 1$, 100); IR
 (neat) 3300, 2970, 1701, 1603, 1513, 1432, 1323 cm^{-1} .


(11*S*,11*aS*)-7,8-Dimethoxy-11-hydroxy-5-oxo-1,2,3,10,11,11*a*-
 hexahydro-5*H*-pyrrolo[1,2-*c*][1,4]benzodiazepine-10-carboxylic acid
 20 2,2,2-trichloro-ethyl ester (91)



The alcohol **85** (0.715 g, 1.57 mmol) was reacted (Method A) with
 DAIB (0.61 g, 1.88 mmol) and TEMPO (0.025 g, 0.16 mmol) in CH_2Cl_2
 (30 mL). The product was obtained (crystallised from Et_2O) as a
 25 white solid (0.56 g, 78%): $[\alpha]_D^{20.7} + 129.2^\circ$ ($c = 0.24$, CHCl_3); ^1H
 NMR (CDCl_3) δ 7.25 (s, 1H), 6.80 (s, 1H), 5.66 (dd, $J = 4.22$ Hz,
 9.8 Hz, 1H), 5.26 (d, $J = 12$ Hz, 1H), 4.23 (d, $J = 12$ Hz, 1H),
 3.93 (s, 3H), 3.91 (s, 3H), 3.79 (d, $J = 4.4$ Hz, 1H), 3.7 (m,


1H), 3.5 (m, 2H), 2.14 (m, 2H), 2.02 (m, 2H); (ES+) m/z (relative intensity) 452.9 ($M^+ + 1$, 100); IR (neat) 3307, 2958, 1722, 1617, 1599, 1512, 1453, 1432, 1408 cm^{-1} .

- 5 (11*S*,11*aS*)-7,8-Dimethoxy-11-hydroxy-5-oxo-1,2,3,10,11,11*a*-hexahydro-5*H*-pyrrolo[1,2-*c*][1,4]benzodiazepine-10-carboxylic acid 4-nitro-benzyl ester (92)



- The alcohol **86** (0.7 g, 1.5 mmol) was reacted (Method A) with DAIB
 10 (0.585 g, 1.82 mmol) and TEMPO (0.024 g, 0.15 mmol) in CH_2Cl_2 (40 mL). The product was obtained (flash column chromatography EtOAc) as a yellow foam (0.49 g, 71%): $[\alpha]_D^{21.3} + 174^\circ$ ($c = 0.2$, CHCl_3); ^1H NMR (CDCl_3) δ 8.16 (d, $J = 8.3$ Hz, 2H), 7.32 (d, $J = 8.0$ Hz, 2H), 6.63 (s, 1H), 5.66 (dd, $J = 4.3$ Hz, 9.6 Hz, 1H), 5.32 (d, $J =$
 15 13.5 Hz, 1H), 5.08 (d, $J = 13.6$ Hz, 1H), 3.94 (s, 3H), 3.80 (s, 3H), 3.7 (m, 1H), 3.51 (m, 3H), 2.14 (m, 2H), 1.99 (m, 2H); (ES+) m/z (relative intensity) 480.0 ($M^+ + \text{Na}$, 38) 458.1 ($M^+ + 1$, 100); IR (neat) 3312, 2968, 1709, 1602, 1513, 1431, 1402 cm^{-1} .


- 20 (11*S*,11*aS*)-7,8-Dimethoxy-11-hydroxy-5-oxo-1,2,3,10,11,11*a*-hexahydro-5*H*-pyrrolo[1,2-*c*][1,4]benzodiazepine-10-carboxylic acid 9*H*-fluoren-9-ylmethyl ester (93)



- The alcohol **87** (0.735 g, 1.46 mmol) was reacted (Method A) with
 25 DAIB (0.565 g, 1.75 mmol) and TEMPO (0.023 g, 0.15 mmol) in CH_2Cl_2

(40 mL). The product was obtained (flash column chromatography EtOAc) as a yellow oil (0.64 g, 88%): $[\alpha]_D^{21.5} + 113.3^\circ$ ($c = 0.20$, CHCl_3); $^1\text{H NMR}$ (CDCl_3) δ 7.72 (m, 2H), 7.48–7.0 (m, 7H), 6.68 (s, 1H), 5.7 (m, 1H), 4.55 (m, 1H), 4.15–3.9 (m, 5H), 3.85–3.65 (m, 4H), 3.65–3.45 (m, 3H), 2.14 (m, 2H), 2.03 (m, 2H); (ES+) m/z (relative intensity) 501.1 ($\text{M}^+ + 1$, 100); IR (neat) 3307 2961, 1702, 1602, 1512, 1450, 1406 cm^{-1} .

(11*S*,11*aS*)-7,8-Dimethoxy-11-hydroxy-5-oxo-1,2,3,10,11,11*a*-
 10 hexahydro-5*H*-pyrrolo[1,2-*c*][1,4]benzodiazepine-10-carboxylic acid
 allyl ester (94)




Dimethyl sulfoxide (1.16 g, 1.1 mL, 14.9 mmol, 5 eq) was added to a solution of cyanuric chloride (0.55 g, 3.0 mmol 1.2 eq) in
 15 anhydrous THF (20 mL) at -30°C under a nitrogen atmosphere. The solution was stirred at -30°C for 30 min. A solution of the alcohol **88** in anhydrous THF (10 mL) was added dropwise followed by triethylamine (1.25 g, 1.73 mL, 12.4 mmol, 5 eq). After 15 min at -30°C the solution was allowed to reach room temperature.
 20 The solvent was evaporated *in vacuo* and the residue dissolved in dichloromethane (50 mL), extracted with 1M HCl (3 x 30 mL), H_2O (2 x 30 mL), brine (50 mL), dried (MgSO_4) and evaporated *in vacuo* to give a white foam. The product was recrystallised (EtOAc) to give white needles (0.57 g, 64%) Mp $211-212^\circ\text{C}$; $[\alpha]_D^{23.6} + 178.6^\circ$ ($c =$
 25 0.2, CHCl_3); $^1\text{H NMR}$ (CDCl_3) δ 7.24 (s, 1H), 6.68 (s, 1H), 5.80 (m, 1H), 5.63 (m, 1H), 5.13 (m, 2H), 4.67 (m, 1H) 4.43 (m, 1H), 3.92 (2s, 4H), 3.76 (s, 3H), 3.69 (m, 1H), 3.60–3.44 (m, 2H), 2.11 (m, 2H), 2.01 (m, 2H); HRMS m/z calcd for $\text{C}_{18}\text{H}_{23}\text{N}_2\text{O}_6$ 33.1556 ($\text{M}+\text{H}$), found 363.1564.

Deprotection of groups in compounds 38 and 45


2-{3-[4-((11*S*,11*aS*)-7,8-Dimethoxy-11-hydroxy-5-oxo-1,2,3,10,11,11*a*-hexahydro-5*H*-pyrrolo[2,1-*c*][1,4]benzodiazepine-10-carbonyloxymethyl)-phenyl]-ureido}-pentanedioic acid (39)

5



A solution of the diallyl ester **38** (0.5 g, 0.74 mmol, 1 eq), Pd(PPh₃)₄ (0.043 g, 0.037 mmol, 0.05 eq) and pyrrolidine (0.26 g, 0.31 mL, 3.7 mmol, 5 eq) in anhydrous CH₂Cl₂ (15 mL) was stirred at room temperature for 1 h and the solvent removed *in vacuo*. The residue was washed with EtOAc (3 x 15 mL), dissolved in MeOH (5 mL) and passed down an IRC 50, weakly acidic, ion exchange column, eluting with MeOH (100 mL). The solvent was removed *in vacuo* to give the product as a white foam (0.39 g, 87%). [α]_D^{26.4} + 146.0° (c = 0.21, EtOH), ¹H NMR (d₆ DMSO) δ 8.82 (s, 1H), 7.32 (d, *J* = 7.12 Hz, 2H), 7.11 (d, *J* = 7.52 Hz, 2H), 7.04 (s, 1H), 6.69 (s, 1H), 6.50 (d, *J* = 6.6 Hz, 1H), 5.47 (d, *J* = 9.16 Hz, 1H), 5.14 (d, *J* = 12 Hz, 1H), 4.75 (d, *J* = 12 Hz, 1H), 4.11 (m, 1H), 3.78 (m, 5H), 3.69 (s, 3H), 3.40 (m, 4H), 2.27 (t, *J* = 7.5 Hz, 2H), 1.95 (m, 4H). HRMS *m/z* calcd for C₂₈H₃₃N₄O₁₁ 601.2146 (M+H), found 601.2160.


2-[4-((11*S*,11*aS*)-7,8-Dimethoxy-11-hydroxy-5-oxo-1,2,3,10,11,11*a*-hexahydro-5*H*-pyrrolo[2,1-*c*][1,4]benzodiazepine-10-carbonyloxymethyl)-phenoxy-carbonylamino]-pentanedioic acid (46)



25

A solution of the diallyl ester **45** (0.596 g, 0.95 mmol, 1 eq), Pd(PPh₃)₄ (0.055 g, 0.047 mmol, 0.05 eq) and pyrrolidine (0.34 g, 0.39 mL, 4.7 mmol, 5 eq) in anhydrous CH₂Cl₂ (18 mL) was stirred at room temperature for 1 h and the solvent removed *in vacuo*. The residue was washed with EtOAc (3 x 15 mL), dissolved in MeOH (15 mL) and passed down an IRC 50, weakly acidic, ion exchange column, eluting with MeOH (80 mL). The solvent was removed *in vacuo* to give the product as a white foam (0.46 g, 88%). ¹H NMR (d₆ DMSO) δ 7.95 (d, *J* = 6.25 Hz, 1H), 7.33 (d, *J* = 8 Hz, 2H), 7.10 (m, 3H), 6.73 (s, 1H), 5.49 (d, *J* = 9.2 Hz, 1H), 5.2 (d, *J* = 12.5 Hz, 1H), 4.89 (d, *J* = 12.75 Hz, 1H), 4.00 (m, 1H), 3.80 (m, 7H), 3.45 (m, 4H), 2.30 (t, *J* = 7.5 Hz, 2H), 1.95 (m, 5H). MS (ES+) 602.2.

Deprotection of N-10 protected monomers to give (11aS)-7,8-dimethoxy-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5-one (30)



Deprotection of (11S,11aS)-7,8-Dimethoxy-11-hydroxy-5-oxo-1,2,3,10,11,11a-hexahydro-5H-pyrrolo[1,2-c][1,4]benzodiazepine-10-carboxylic acid 4-methoxy-benzyl ester (24)

The N-10 protected PBD (0.08 g, 0.18 mmol) was dissolved in 10% TFA/CH₂Cl₂ (4 mL) at 0°C. The solution was stirred at 0°C for 25 min then poured onto ice and neutralised with satd NaHCO₃ (aq). The aqueous portion was extracted with CH₂Cl₂ (3 x 20 mL) and the combined organic extracts were washed with H₂O (50 mL), satd NaCl (aq) (50 mL), dried (MgSO₄) and evaporated *in vacuo*. Purification by flash column chromatography (3% MeOH/97% CHCl₃) gave the product **30** as a yellow solid (0.022 g, 47%).

¹H NMR (CDCl₃) δ 7.61 (d, *J* = 4.3 Hz, 1H), 7.46 (s, 1H), 6.72 (s, 1H), 3.90 (s, 3H), 3.86 (s, 3H), 3.75 (m, 2H), 3.65 (m, 1H), 3.5 (m, 1H), 2.30 (m, 2H), 1.9 (m, 2H).

Deprotection of (11S,11aS)-7,8-Dimethoxy-11-hydroxy-5-oxo-1,2,3,10,11,11a-hexahydro-5H-pyrrolo[1,2-c][1,4]benzodiazepine-10-carboxylic acid 2-trimethylsilanyl-ethyl ester (25)

A 1.0 M THF solution of tetra-N-butyl-ammonium fluoride (0.295 mL, 0.295 mmol, 1.2 eq.) was added via syringe to a solution of the N-10 protected PBD (0.104 g, 0.25 mmol, 1 eq) in THF (5 mL) at 0°C. The reaction mixture was stirred at room temperature for 4 h. The solvent was removed *in vacuo* and the product purified by flash column chromatography (4% MeOH/CHCl₃) to give the product **30** as a yellow solid (0.052 g, 81%).

Deprotection of (11S,11aS)-7,8-Dimethoxy-11-hydroxy-5-oxo-1,2,3,10,11,11a-hexahydro-5H-pyrrolo[1,2-c][1,4]benzodiazepine-10-carboxylic acid 3-(4-nitro-phenyl)-allyl ester (26)

A solution of the N-10 protected PBD (0.12 g, 0.25 mmol, 1 eq), Pd(PPh₃)₄ (0.03 g, 0.025 mmol, 0.1 eq), PPh₃ (0.006 g, 0.025 mmol, 0.1 eq) and pyrrolidine (0.019 g, 0.023 mL, 2.73 mmol, 1.1 eq) in anhydrous THF (5 mL) was stirred at room temperature for 5 h. The solvent was removed *in vacuo* and the product purified by flash column chromatography (2% MeOH/98% CHCl₃) to give **30** as a yellow oil (0.048 g, 75%).

The N-10 protected PBD (0.05 g, 0.1 mmol, 1 eq) was dissolved in MeOH (5 mL) and 10% Palladium on carbon (0.015 g 30 wt%) and cyclohexadiene (0.016 g, 0.018 mL, 0.2 mmol, 2 eq) were added. The mixture was heated at reflux for 5 h, cooled, filtered through celite and the solvent evaporated *in vacuo*. Purification by flash column chromatography (3% MeOH/97% CHCl₃) gave the product **30** as a yellow solid (0.017 g, 65%).

Deprotection of (11S,11aS)-7,8-Dimethoxy-11-hydroxy-5-oxo-1,2,3,10,11,11a-hexahydro-5H-pyrrolo[1,2-c][1,4]benzodiazepine-10-carboxylic acid 2-benzenesulfonyl-ethyl ester (27)

A 2.0 M MeOH solution of dimethylamine (0.18 mL, 0.37 mmol, 3 eq.) was added via syringe to a solution of the N-10 protected PBD (0.06 g, 0.122 mmol, 1 eq) in MeOH (1 mL). The reaction

mixture was stirred at room temperature for 18 h. The solvent was removed *in vacuo* and the product purified by flash column chromatography (5% MeOH/CHCl₃) to give the product **30** as a colourless oil (0.028 g, 87%).

5

Deprotection of (11S,11aS)-7,8-Dimethoxy-11-hydroxy-5-oxo-1,2,3,10,11,11a-hexahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carboxylic acid 4,5-dimethoxy-2-nitro-benzyl ester (28)

A solution of the N-10 protected PBD (0.25 g) in MeOH (10 mL) was irradiated at 365 nm. The reaction was monitored by reversed phase HPLC (C18 column, 5 µm particle size, 250 mm x 4.6 mm; mobile phase 70% H₂O/30% CH₃CN/0.1% TFA; detection at 245 nm) against a standard sample of the parent PBD **30**. Aliquots of the reaction mixture (20 µL) were injected at 1 h intervals. The conversion to parent PBD was complete in 12 h.

15

MS (ES+) *m/z* 261 (M⁺)

Deprotection of 2-[4-((11S,11aS)-7,8-Dimethoxy-11-hydroxy-5-oxo-1,2,3,10,11,11a-hexahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carboxyloxymethyl)-phenoxy-carbonylamino]-pentanedioic acid (46)

20

An aliquot of a 10 mM stock solution of the carbamate monomer prodrug was diluted to 100 µM in Carboxypeptidase G2 (CPG2) assay buffer (100 mM Tris-HCl, pH 7.3; 260 µM ZnCl₂). CPG2 (1 unit) was added and the reaction was incubated at 37°C. The reaction was monitored by reversed phase HPLC (C18 column, 5 µm particle size, 250 mm x 4.6 mm; mobile phase 70% H₂O/30% CH₃CN/0.1% TFA; detection at 245 nm) with 20 µL aliquots being injected at 0, 10, 20, 30, 40, 50 and 60 min. The conversion of the prodrug to the parent imine **30** was complete in 60 minutes.

25

30

Deprotection of (11S,11aS)-7,8-Dimethoxy-11-hydroxy-5-oxo-1,2,3,10,11,11a-hexahydro-5H-pyrrolo[1,2-c][1,4]benzodiazepine-10-carboxylic acid allyl ester (94)


35

A solution of the N-10 protected PBD (0.35 g, 0.96 mmol, 1 eq), Pd(PPh₃)₄ (0.055 g, 0.05 mmol, 0.05 eq) and pyrrolidine (0.025 g,


0.1 mL, 1.2 mmol, 1.25 eq) in anhydrous CH_2Cl_2 (12 mL) was stirred at room temperature for 3.5 h and the solvent removed *in vacuo*. The product was purified by flash column chromatography (4% MeOH/96% CHCl_3) to give **30** as a yellow oil (0.176 g, 71%).

5

Synthesis of Dimer Isocyanates



(2*S*)-1,1'-[[[(Pentane-1,5-diyl)dioxy]bis[(2-nitro-5-methoxy-1,4-phenylene)carbonyl]]bis[(2-hydroxymethyl)pyrrolidine] (**54**)



10


Oxalyl chloride (12.44 g, 8.55 mL, 97.9 mmol, 2.5 eq) and DMF (cat) were added to a solution of dimer core **53** (19.37 g, 39.2 mmol, 1 eq) in anhydrous THF (200 mL) under a N_2 atmosphere. The solution was stirred at room temperature for 18 h. The resultant solution was added dropwise to a solution of (S)-(+)-2-pyrrolidine-methanol (9.89 g, 9.65 mL, 97.9 mmol, 2.5 eq) and triethylamine (16.62 g, 22.89 mL, 164 mmol, 4.2 eq) in anhydrous

15

THF (150 mL) at -25°C (dry ice/ethylene glycol) under a N₂ atmosphere. The reaction mixture was allowed to come to room temperature and stirred for 18 h. The solvent was removed *in vacuo* and the residue dissolved in CH₂Cl₂ (750 mL), washed with 1 M HCl (3 x 200 mL), satd NaHCO₃ (aq) (3 x 200 mL), H₂O (2 x 200 mL), satd NaCl (aq) (250 mL), dried (MgSO₄) and evaporated *in vacuo*. The product was purified by flash column chromatography (5% MeOH/95% EtOAc-10% MeOH/90% EtOAc) to give a yellow foam (11.81 g, 45.6%).

[α]_D^{24.7} -94.1° (*c* = 0.260, CHCl₃); ¹H NMR (CDCl₃) δ 7.69 (s, 2H), 6.81 (s, 2H), 4.5-4.35 (m, 4H), 4.15 (t, *J* = 6.6 Hz, 4H), 3.98 (s, 6H), 3.9 (m, 2H), 3.8 (m, 2H), 3.18 (t, *J* = 6.9 Hz, 4H), 2.2 (m, 2H), 2.0 (m, 4H), 1.9-1.65 (m, 8H); IR (neat) 3400, 2946, 2873, 1618, 1577, 1522, 1276 cm⁻¹; HRMS *m/z* calcd for C₃₁H₄₁N₄O₁₂ 661.2721 (M+H) found 661.2690.

(2*S*)-1,1'-[[[(Pentane-1,5-diyl)dioxy]bis[(2-nitro-5-methoxy-1,4-phenylene)carbonyl]]bis[2-(*tert*-butyldimethylsilyloxymethyl)pyrrolidine]] (55)




A solution of *t*-butyldimethylsilyl chloride (6.59 g, 43.56 mmol, 2.6 eq), imidazole (5.7 g, 83.8 mmol, 5 eq) and dimer nitro-alcohol **54** (11.07 g, 16.75 mmol, 1 eq) in anhydrous DMF (30 mL) was stirred at room temperature under a N₂ atmosphere for 96 h.

The reaction mixture was diluted with H₂O (500 mL) and extracted with EtOAc (4 x 250 mL). The combined organic extracts were washed with H₂O (2 x 250 mL), satd NaCl (aq) (250 mL), dried (MgSO₄) and evaporated *in vacuo*. Purification by flash column chromatography (60% EtOAc/40% *n*-hexane) gave the product as an off white foam (9.02 g, 60.5%). [α]_D^{24.9} -84.9° (*c* = 0.212, CHCl₃); ¹H NMR (CDCl₃) δ 7.68 (s, 2H), 6.76 (s, 2H), 4.37 (m, 2H), 4.13 (m, 4H), 3.94 (s, 6H), 4.0-3.85 (m, 4H), 3.12 (m, 4H), 2.15-1.9 (m, 4H), 0.91 (s, 18H), 0.12 (s, 12H); IR (neat) 2952, 2857,


1737, 1643, 1577, 1522 cm^{-1} ; HRMS m/z calcd for $\text{C}_{43}\text{H}_{69}\text{N}_4\text{O}_{12}\text{Si}_2$
889.4451 (M+H) found 889.4473.

(2*S*)-1,1'-[[[(Pentane-1,5-diyl)dioxy]bis[(2-amino-5-methoxy-1,4-
5 phenylene)carbonyl]]bis[2-(tert-
butyldimethylsilyloxymethyl)pyrrolidine] (56)



A solution of the dimer nitro compound **55** (9.0 g, 10.12 mmol) in
ethanol (100 mL) was hydrogenated (Parr apparatus) over 10%
10 Palladium on carbon (0.9 g, 10 wt%), maintaining the H_2 pressure
at 16 psi. The reaction was complete when no more H_2 was consumed.
The mixture was filtered through celite and the ethanol
evaporated *in vacuo*. Purification by flash column chromatography
(90% EtOAc/10% *n*-hexane) gave the product as a yellow foam (6.1
15 g, 73%). $[\alpha]_{\text{D}}^{25.5} -141.2^\circ$ ($c = 0.241$, CHCl_3); ^1H NMR (CDCl_3) δ 6.76
(s, 2H), 6.23 (s, 2H), 4.5-4.3 (m, 4H), 3.99 (t, $J = 6.6$ Hz, 4H)
3.75 (s, 6H), 3.67 (m, 2H), 3.53 (m, 4H), 2.05 (m, 4H), 1.95 (m,
6H), 1.7 (m, 8H), 0.9 (s, 18H), 0.04 (s, 12H); IR (neat) 3449,
3349, 2952, 2857, 1624, 1592, 1514, 1406 cm^{-1} ; HRMS m/z calcd for
20 $\text{C}_{43}\text{H}_{73}\text{N}_4\text{O}_8\text{Si}_2$ 829.4967 (M+H) found 829.4998.


(2*S*)-1,1'-[[[(Pentane-1,5-diyl)dioxy]bis[(2-isocyanato-5-methoxy-
1,4-phenylene)carbonyl]]bis[2-(tert-
butyldimethylsilyloxymethyl)pyrrolidine] (57)



25 A solution of triethylamine (2.7 eq.) in anhydrous toluene was
added to the amine (**56**) (1 eq.) and triphosgene (0.72 eq.) in
anhydrous toluene under a N_2 atmosphere. The reaction was finished
after 2 hours. (monitored by IR, ν_{NCO} 2265 cm^{-1}). The product was
30 used without further purification.

Synthesis of Dimer Carbamates


General Method



5

A solution of the appropriate alcohol (2 eq) and triethylamine (2.2 eq) in either anhydrous toluene or anhydrous CH_2Cl_2 was added dropwise to a solution of the isocyanate (**57**) (1 eq) in anhydrous toluene. The reaction was monitored by IR (disappearance of the ν_{NCO} 2265 cm^{-1} peak). The reaction mixture was filtered and the filtrate evaporated *in vacuo*. The product was purified by flash column chromatography.

(2*S*)-1,1'-[[[(Pentane-1,5-diyl)dioxy]bis[(2-allyloxycarbonylamino-5-methoxy-1,4-phenylene)carbonyl]]bis[2-(tert-butyl dimethylsilyloxymethyl)pyrrolidine] (**58**)




A solution of anhydrous allyl alcohol (0.09 g, 0.105 mL, 1.54 mmol, 2.4 eq) and triethylamine (0.143 g, 0.2 mL, 1.41 mmol) in anhydrous toluene (4 mL) was added to a solution of the isocyanate **57** prepared from the dimer amine **56** (0.533 g, 0.64 mmol), triphosgene (0.14 g, 0.46 mmol) and triethylamine (0.175 g, 0.24 mL, 1.74 mmol) in anhydrous toluene (20 mL). The reaction was complete in 16 h. The product was obtained (flash column chromatography 60% EtOAc/40% *n*-hexane) as a yellow oil (0.4 g, 62%).

$[\alpha]_{\text{D}}^{26.1} -105.7^\circ$ ($c = 0.227$, CHCl_3); ^1H NMR (CDCl_3) δ 9.18 (s, 2H), 7.85 (s, 2H), 6.83 (s, 2H), 6.0 (m, 2H), 5.3 (m, 4H), 4.65 (m, 4H), 4.35 (m, 2H), 4.15 (m, 4H), 4.05 (m, 2H), 3.8 (s, 6H), 3.7 (m, 2H), 3.5 (m, 4H), 2.05 (m, 4H), 1.95 (m, 6H), 1.7 (m, 4H),

30

0.9 (s, 18H), 0.07 (s, 12H); IR (neat) 3306, 2952, 2930, 2857, 1731, 1621, 1598, 1523, 1406 cm^{-1} ; HRMS m/z calcd for $\text{C}_{51}\text{H}_{81}\text{N}_4\text{O}_{12}\text{Si}_2$ 997.5390 (M+H) found 997.5336.

- 5 (2*S*)-1,1'-[[[(Pentane-1,5-diyl)dioxy]bis[(2-[N-(4-(diprop-2-enyl-L-glutamylcarbonyloxy)benzyloxycarbonyl)]amino-5-methoxy-1,4-phenylene)carbonyl]]bis[2-(tert-butyl)dimethylsilyloxymethyl]pyrrolidine] (62)




10

A solution of the carbamate progroup **42** (1.27 g, 3.4 mmol) and triethylamine (0.37 g, 0.515 mL) in anhydrous CH_2Cl_2 (25 mL) was added to a solution of the isocyanate **57** prepared from the dimer amine **56** (1.4 g, 1.7 mmol), triphosgene (0.36 g, 0.12 mmol) and triethylamine (0.46 g, 0.64 mL, 4.55 mmol) in anhydrous toluene (75 mL). The reaction was complete in 48 hours. The product was obtained (flash column chromatography 50% EtOAc/50% *n*-hexane) as a white foam (1.65 g, 60%). $[\alpha]_{\text{D}}^{22.7} -39.13^\circ$ ($c = 0.23$, CHCl_3); ^1H NMR (CDCl_3) δ 9.24 (s, 2H), 7.84 (s, 2H), 7.4 (m, 4H), 7.1 (m, 4H), 6.82 (s, 2H), 5.95 (m, 4H), 5.8 (d, $J = 7.6$ Hz, 2H), 5.3 (m, 8H), 5.16 (d, $J = 12.4$ Hz, 2H), 5.1 (d, $J = 12.3$ Hz, 2H), 4.65 (m, 8H), 4.5 (m, 2H), 4.35 (m, 2H), 4.15 (m, 4H), 4.05 (m, 2H), 3.8 (s, 6H), 3.7 (m, 2H), 3.5 (m, 4H), 2.55 (m, 4H), 2.3 (m, 2H), 2.05 (m, 6H), 1.95 (m, 4H), 1.6 (m, 6H), 0.9 (s, 18H), 0.07 (s, 12H); IR (neat) 3338, 2952, 2857, 1738, 1648, 1617, 1597, 1523 cm^{-1} .

(2S)-1,1'-[[[(Pentane-1,5-diyl)dioxy]bis[(2-[N-(4-(diprop-2-enyl-L-glutamylcarbonylamino)benzyloxycarbonyl)]amino-5-methoxy-1,4-phenylene)carbonyl]]bis[2-(tert-butyltrimethylsilyloxymethyl)pyrrolidine]] (63)


5



A solution of the urea progroup **35** (1.27 g, 3.4 mmol) and triethylamine (0.37 g, 0.515 mL) in anhydrous CH_2Cl_2 (25 mL) was added to a solution of the isocyanate **57** prepared from the dimer amine **56** (1.4 g, 1.7 mmol), triphosgene (0.36 g, 0.12 mmol) and triethylamine (0.46 g, 0.64 mL, 4.55 mmol) in anhydrous toluene (75 mL). The reaction was complete in 48 h. The product was obtained (flash column chromatography 50% EtOAc/50% *n*-hexane) as a white foam (1.65 g, 60%). $[\alpha]_{\text{D}}^{23.1} -50.7^\circ$ ($c = 0.217$, CHCl_3); ^1H NMR (CDCl_3) δ 9.0 (s, 2H), 7.68 (s, 2H), 7.25 (m, 10H), 6.8 (s, 2H), 5.9 (m, 6H), 5.25 (m, 8H), 5.05 (m, 4H), 4.6 (m, 10H), 4.35 (m, 2H), 4.15 (m, 2H), 4.05 (m, 4H), 3.78 (s, 6H), 3.65 (m, 2H), 3.5 (m, 4H), 2.45 (m, 4H), 2.2 (m, 2H), 2.1–1.8 (m, 10H), 1.7 (m, 6H), 0.9 (s, 18H), 0.07 (s, 12H); IR (neat) 3351, 2952, 1736, 1700, 1666, 1601, 1521, 1411, 1200 cm^{-1} .

20

(2S)-1,1'-[[[(Pentane-1,5-diyl)dioxy]bis[(2-(2-phenylthioethoxycarbonyl)-amino-5-methoxy-1,4-phenylene)carbonyl]bis[2-(tert-butyltrimethylsilyloxymethyl)pyrrolidine]] (95)




5

A solution of 2-(phenylthio)ethanol (0.65 mL, 4.8 mmol,) and triethylamine (0.74 mL, 5.3 mmol) in anhydrous toluene (10 mL) was added to a solution of the isocyanate **57** prepared from the dimer amine **56** (2.0 g, 2.4 mmol), triphosgene (0.515 g, 1.7 mmol) and triethylamine (0.907 mL, 6.5 mmol) in anhydrous toluene (100 mL). The reaction was complete in 90 h. The product was obtained (flash column chromatography 50% EtOAc/50% *n*-hexane) as a white foam (0.862 g, 30%): $[\alpha]_D^{26} = -2.6^\circ$ ($c = 0.4$, CHCl_3); ^1H NMR (CDCl_3) δ 9.13 (s, 2H), 7.77 (s, 2H), 7.40–7.32 (m, 4H), 7.30–7.21 (m, 4H), 7.19–7.10 (m, 2H), 6.79 (s, 2H), 4.32–4.17 (m, 6H), 4.15–3.84 (m, 4H), 3.83–3.32 (m, 14H), 3.23–2.99 (m, 4H), 2.13–1.80 (m, 10H), 1.78–1.51 (m, 4H), 0.86 (s, 18H), 0.01 (s, 12H); MS (ES) m/z (relative intensity) 1211 ($\text{M}^+ + \text{Na}$, 6), 1189 ($\text{M}^+ + 1$, 100); IR (neat) 2928, 1729, 1597, 1522, 1469, 1406, 1258, 1201 cm^{-1} .

20

(2*S*)-1,1'-[[[(Pentane-1,5-diyl)dioxy]bis[(2-(2-phenylsulfonylethyloxy)carbonyl)-amino-5-methoxy-1,4-phenylene)carbonyl]bis[2-(tert-butyl)dimethylsilyloxymethyl]pyrrolidine] (96)



A solution of 2-(phenylsulfonyl)ethanol (0.58 mL, 4.8 mmol,) and triethylamine (0.74 mL, 5.3 mmol) in anhydrous toluene (20 mL) was added to a solution of the isocyanate **57** prepared from the dimer amine **56** (2.0 g, 2.4 mmol), triphosgene (0.515 g, 1.7 mmol) and triethylamine (0.907 mL, 6.5 mmol) in anhydrous toluene (100 mL). The reaction was complete in 90 h. The product was obtained (flash column chromatography 50% EtOAc/50% *n*-hexane) as a white foam (2.17 g, 77%): $[\alpha]_D^{22} = -87.5^\circ$ ($c = 1.0$, CHCl_3); ^1H NMR (CDCl_3) δ 9.04 (s, 2H), 8.07–7.93 (m, 3H), 7.77–7.48 (m, 7H), 7.26 (s, 2H), 6.82 (s, 2H), 4.46–4.26 (m, 5H), 4.18–3.89 (m, 6H), 3.88–3.64 (m, 8H), 3.63–3.42 (m, 8H), 2.16–1.84 (m, 10H), 1.83–1.51 (m, 5H), 0.90 (s, 18H), 0.04 (s, 12H); MS (ES) m/z (relative intensity) 1256 ($\text{M}^+ + 1$, 100); IR (neat) 3299, 2952, 1735, 1602, 1528, 1326, 1025, 841 cm^{-1} .

Deprotection of alcohols

General methods for the deprotection of dimer tert-butyl dimethylsilyl ethers


Method A

A 1.0 M THF solution of tetra-*N*-butyl-ammonium fluoride (2.4 eq.) was added *via* syringe to a solution of the TBDMS ether (1 eq.) in THF at 0°C. The reaction was stirred at room temperature until reaction was complete (TLC). The solvent was removed *in vacuo* and the product purified by flash column chromatography.

Method B


A solution of the TBDMS ether in a mixture of AcOH/THF/H₂O (3/1/1) was stirred at room temperature until reaction was complete (TLC). The reaction mixture was cooled (ice bath) and carefully neutralised with NaHCO₃ (aq) (1 eq). The mixture was extracted with EtOAc (x3) the combined extracts were washed with water (x1), satd NaCl (aq) (x1), dried (MgSO₄) and evaporated *in vacuo*. The product was purified by flash column chromatography.

(2*S*)-1,1'-[[[(Pentane-1,5-diyl)dioxy]bis[(2-allyloxycarbonylamino-5-methoxy-1,4-phenylene)carbonyl]]bis[2-(hydroxymethyl)pyrrolidine] (59)




The TBDMS ether **58** (0.32 g, 0.32 mmol) in THF (20 mL) was deprotected (Method A: Bu₄NF (0.765 mL, 0.765 mmol)) to give the product (flash column chromatography 5% MeOH/95% EtOAc) as a white foam (0.23 g, 93%). $[\alpha]_D^{24.7} -93.5^\circ$ ($c = 0.214$, CHCl₃); ¹H NMR (CDCl₃) δ 8.8 (s, 2H), 7.8 (s, 2H), 6.82 (s, 2H), 6.0 (m, 2H), 5.3 (m, 4H), 4.67 (m, 4H), 4.4 (m, 2H), 4.1 (t, $J = 6.6$ Hz, 4H), 3.85 (m, 2H), 3.8 (s, 6H), 3.75 (m, 2H), 3.6 (m, 2H), 3.5 (m, 2H), 2.17 (m, 2H), 1.95 (m, 6H), 1.7 (m, 8H); IR (neat) 3338, 2951, 2873, 1731, 1597, 1524, 1408 cm⁻¹; HRMS m/z calcd for C₃₉H₅₂N₄O₁₂Na 791.3479 (M+Na) found 791.3499.

(2S)-1,1'-[[[(Pentane-1,5-diyl)dioxy]bis[(2-[N-(4-(diprop-2-enyl-L-glutamylcarbonyloxy)benzyloxycarbonyl)]amino-5-methoxy-1,4-phenylene)carbonyl]]bis[(2-hydroxymethyl)pyrrolidine] (64)



5 The TBDMS ether **62** (1.63 g, 0.99 mmol) was deprotected (Method B: AcOH (18 mL)/THF (6 mL)/H₂O (6 mL) then NaHCO₃ (26.31 g, 313.2 mmol) in H₂O (300 mL)) to give the product (flash column chromatography 2% MeOH/98% EtOAc) as a colourless oil (1.0 g, 72%). $[\alpha]_D^{22.7} -34.01^\circ$ ($c = 0.147$, CHCl₃); ¹H NMR (CDCl₃) δ 8.8 (s, 2H), 7.7 (s, 2H), 7.4 (m, 4H), 7.1 (m, 4H), 6.78 (s, 2H), 5.95 (m, 4H), 5.8 (m, 2H), 5.3 (m, 8H), 5.17 (d, $J = 12.4$ Hz, 2H), 5.10 (d, $J = 12.3$ Hz, 2H), 4.65 (m, 8H), 4.5 (m, 2H), 4.36 (m, 4H), 4.12 (m, 4H), 3.82 (m, 2H), 3.8 (s, 6H), 3.7 (m, 2H), 3.55 (m, 2H), 3.43 (m, 2H), 2.51 (m, 4H), 2.3 (m, 2H), 2.1 (m, 4H), 1.95 (m, 4H), 1.85 (m, 2H), 1.68 (m, 6H); IR (neat) 3326, 2946, 1731, 1597, 1524, 1203 cm⁻¹.


(2S)-1,1'-[[[(Pentane-1,5-diyl)dioxy]bis[(2-[N-(4-(diprop-2-enyl-L-glutamylcarbonylamino)benzyloxycarbonyl)]amino-5-methoxy-1,4-phenylene)carbonyl]]bis[(2-hydroxymethyl)pyrrolidine] (65)



The TBDMS ether **63** (1.075 g, 0.66 mmol) was deprotected (Method B: AcOH (12 mL)/THF (4 mL)/H₂O (4 mL) then NaHCO₃ (17.54 g, 209.0 mmol) in H₂O (250 mL)) to give the product (flash column


chromatography 3% MeOH/97% EtOAc) as a white foam (0.69 g, 75%).
 $[\alpha]_D^{21.6} -46.98^\circ$ ($c = 0.3299$, CHCl_3); $^1\text{H NMR}$ (CDCl_3) δ 8.6 (s, 2H),
 7.72 (m, 4H), 7.21 (m, 8H), 6.79 (s, 2H), 6.02 (d, $J = 7.8$ Hz,
 2H), 5.86 (m, 4H), 5.3 (m, 8H), 5.04 (s, 4H), 4.6 (m, 8H), 4.49
 5 (m, 2H), 4.39 (m, 2H), 4.01 (m, 4H), 3.83 (m, 2H), 3.78 (s, 6H),
 3.69 (m, 2H), 3.5 (m, 4H), 2.45 (m, 4H), 2.2 (m, 2H), 2.1 (m,
 2H), 2.0–1.8 (m, 10 H), 1.7 (m, 4H), 1.55 (m, 2H); IR (neat)
 3351, 2946, 2877, 1732, 1601, 1520, 1202 cm^{-1} .

10 (2*S*)-1,1'-[[*(Pentane-1,5-diyl)dioxy*]bis[(2-(2-
phenylthioethyloxycarbonyl)-amino-5-methoxy-1,4-
phenylene)carbonyl]bis[2-hydroxymethylpyrrolidine] (97)



The TBDMS ether **95** (0.862 g, 0.7 mmol) was deprotected (Method B:
 15 AcOH (6 mL)/THF (2 mL)/H₂O (2 mL) then NaHCO₃ (8.8 g, 104.8 mmol)
 in H₂O (400 mL)) to give the product (flash column chromatography
 EtOAc) as a pale yellow foam (0.486 g, 70%): $[\alpha]_D^{26} -64.0^\circ$ ($c =$
 1.0, CHCl_3); $^1\text{H NMR}$ (CDCl_3) δ 8.73 (s, 2H), 7.70 (s, 2H), 7.46–
 7.36 (m, 4H), 7.35–7.14 (m, 6H), 6.80 (s, 2H), 4.49–4.34 (bs,
 20 2H), 4.34–4.20 (m, 6H), 4.09 (t, $J = 7.0$ Hz, 4H), 3.93–3.78 (m,
 9H), 3.77–3.65 (m, 3H), 3.64–3.41 (m, 5H), 3.19 (t, $J = 7.0$ Hz,
 4H), 2.24–2.10 (m, 2H), 2.01–1.83 (m, 7H), 1.81–1.56 (m, 9H); MS
 (ES) m/z (relative intensity) 983 ($\text{M}^+ + \text{Na}$, 12), 961 ($\text{M}^+ + 1$, 100);
 IR (neat) 3331, 2943, 1718, 1654, 1560, 1508, 1458 cm^{-1} .

(2S)-1,1'-[[[(Pentane-1,5-diyl)dioxy]bis[(2-(2-phenylsulfonylethyloxycarbonyl)-amino-5-methoxy-1,4-phenylene)carbonyl]bis[2-hydroxymethylpyrrolidine]] (98)



5 The TBDMS ether **96** (2.14 g, 1.7 mmol) was deprotected (Method B: AcOH (6 mL)/THF (2 mL)/H₂O (2 mL) then NaHCO₃ (8.8 g, 104.8 mmol) in H₂O (600 mL)) to give the product (flash column chromatography 2% MeOH/98% EtOAc) as a white foam (1.39 g, 80%): [α]_D²⁵ -66.5° (c = 1.0, CHCl₃); ¹H NMR (CDCl₃) δ 8.65 (s, 2H), 7.95-7.89 (m, 3H),
10 7.71-7.53 (m, 9H), 6.81 (s, 2H), 4.53-4.19 (m, 9H), 4.02-3.88 (m, 2H), 3.81 (s, 6H), 3.74-3.62 (m, 2H), 3.60-3.40 (m, 9H), 2.25-2.10 (m, 2H), 2.00-1.59 (m, 15H); MS (ES) m/z (relative intensity) 1025 (M⁺, 50); IR (neat) 3329, 2929, 1727, 1595, 1520, 1144 cm⁻¹.

15

Cyclisation of dimer alcohols

General methods

Method A


The alcohol (1 eq), (diacetoxyiodo)benzene (2.3 eq) and TEMPO
20 (0.23 eq) were dissolved in CH₂Cl₂ and the mixture stirred at room temperature until reaction was complete (TLC). The reaction mixture was washed with satd NaHSO₃ (aq) (x1) and the NaHSO₃ portion was then washed with CH₂Cl₂ (x4). The combined organic extracts were washed with satd NaHCO₃ (aq) (x2), satd NaCl (aq) (x1), dried
25 (MgSO₄) and evaporated *in vacuo*. The product was purified by either flash column chromatography or recrystallisation.

Method B

The alcohol (1 eq), pyridinium dichromate (2.4 eq) and 4Å
30 molecular sieves (0.1 g/mmol alcohol) in anhydrous CH₂Cl₂ were stirred at room temperature under a N₂ atmosphere until reaction

was complete (TLC). The reaction mixture was filtered through celite, washing with EtOAc. The solvent was evaporated *in vacuo* and the product purified by flash column chromatography.


- 5 *1,1'-[[Pentane-1,5-diyl]dioxo]bis[(1*S*,11*aS*)-10-(allyloxycarbonyl)-11-hydroxy-7-methoxy-1,2,3,10,11,11*a*-hexahydro-5*H*-pyrrolo[2,1-*c*][1,4]benzodiazepine-5-one] (60)*



- The alcohol **59** (0.227 g, 0.295 mmol) was reacted (Method B) with
 10 pyridinium dichromate (0.27 g, 0.71 mmol) and 4Å molecular sieves (0.295 g) in anhydrous CH₂Cl₂ (5 mL). The product was obtained (flash column chromatography 5% MeOH/95% EtOAc) as a white foam (0.073 g, 32%).

- ¹H NMR (CDCl₃) δ 7.24 (s, 2H), 6.65 (s, 2H), 5.8 (m, 2H), 5.63 (d, *J* = 8.7 Hz, 2H), 5.12 (m, 4H), 4.66 (m, 2H), 4.44 (m, 2H), 4.17 (m, 2H), 4.01 (m, 4H), 3.9 (m, 8H), 3.69 (m, 2H), 3.50 (m, 4H), 2.12 (m, 4H), 2.02 (m, 4H), 1.91 (m, 4H), 1.64 (m, 2H); HRMS *m/z* calcd for C₃₉H₄₈N₄O₁₂Na 787.3166 (*M*+Na) found 787.3173.

- 20 *1,1'-[[Pentane-1,5-diyl]dioxo]bis[(1*S*,11*aS*)-10-[N-(4-(diprop-2-enyl-*L*-glutamylcarbonyloxy)benzyloxycarbonyl)]-11-hydroxy-7-methoxy-1,2,3,10,11,11*a*-hexahydro-5*H*-pyrrolo[2,1-*c*][1,4]benzodiazepine-5-one] (66)*




- 25 The alcohol **64** (1.0 g, 0.71 mmol) was reacted (Method A) with DAIB (0.53 g, 1.64 mmol) and TEMPO (0.025 g, 0.164 mmol) in CH₂Cl₂ (10 mL). The product was obtained (flash column chromatography 5%

MeOH/95% EtOAc) as a white foam (0.72 g, 72%). $[\alpha]_D^{22.6} +128.03^\circ$

($c = 0.289$, CHCl_3); ^1H NMR (CDCl_3) δ 7.23 (s, 2H), 7.16 (d, $J = 6.9$ Hz, 4H), 7.01 (d, $J = 6.8$ Hz, 4H), 6.55 (s, 2H), 6.01 (s, 2H), 5.89 (m, 4H), 5.63 (m, 2H), 5.3 (m, 10H), 4.83 (d, $J = 11.9$ Hz, 2H), 4.65 (m, 8H), 4.44 (m, 2H), 4.09 (m, 2H), 3.88 (m, 8H), 3.75 (m, 4H), 3.49 (m, 4H), 2.48 (m, 4H), 2.27 (m, 2H), 2.15–1.95 (m, 10H), 1.89 (m, 4H), 1.52 (m, 2H).


$[\alpha]_D^{22.6} +128.03^\circ$ ($c = 0.289$, CHCl_3); ^1H NMR (CDCl_3) δ 7.23 (s, 2H), 7.16 (d, $J = 6.9$ Hz, 4H), 7.01 (d, $J = 6.8$ Hz, 4H), 6.55 (s, 2H), 6.01 (s, 2H), 5.89 (m, 4H), 5.63 (m, 2H), 5.3 (m, 10H), 4.83 (d, $J = 11.9$ Hz, 2H), 4.65 (m, 8H), 4.44 (m, 2H), 4.09 (m, 2H), 3.88 (m, 8H), 3.75 (m, 4H), 3.49 (m, 4H), 2.48 (m, 4H), 2.27 (m, 2H), 2.15–1.95 (m, 10H), 1.89 (m, 4H), 1.52 (m, 2H).

1,1'-[[Pentane-1,5-diyl]dioxy]bis[(1*S*,11*aS*)-10-[N-(4-(diprop-2-enyl-L-glutamylcarbonylamino)benzyloxycarbonyl)]-11-hydroxy-7-methoxy-1,2,3,10,11,11*a*-hexahydro-5*H*-pyrrolo[2,1-*c*][1,4]benzodiazepine-5-one] (67)




The alcohol **65** (0.51 g, 0.36 mmol) was reacted (Method A) with DAIB (0.27 g, 0.83 mmol) and TEMPO (0.012 g, 0.083 mmol) in CH_2Cl_2 (8 mL). The product was obtained (flash column chromatography 5% MeOH/95% EtOAc) as a white foam (0.325 g, 64%). $[\alpha]_D^{21.1} +192.0^\circ$ ($c = 0.216$, CHCl_3); ^1H NMR (CDCl_3) δ 8.03 (s, 2H), 7.33 (m, 4H), 7.26 (s, 2H), 7.15 (d, $J = 7.6$ Hz, 4H), 6.35 (s, 2H), 5.85 (m, 8H), 5.64 (dd, $J = 4$ Hz, 9.9 Hz, 2H), 5.25 (m, 10H), 4.6 (m, 12H), 4.02 (m, 2H), 3.87 (m, 8H), 3.8 (m, 2H), 3.72 (m, 2H), 3.57 (m, 4H), 2.69 (m, 2H), 2.36 (m, 4H), 2.2–1.95 (m, 10H), 1.68 (m, 2H), 1.5–1.2 (m, 4H); IR (neat) 3359, 2949, 1737, 1707, 1603, 1547, 1515 cm^{-1} .

1,1'-[[Pentane-1,5-diyl]dioxy]bis[(11*S*,11*aS*)-10-[N-(2-phenylthioethyloxycarbonyl)]-11-hydroxy-7-methoxy-1,2,3,10,11,11*a*-hexahydro-5*H*-pyrrolo[2,1-*c*][1,4]benzodiazepine-5-one] (99)



Dess-Martin periodinane (0.15% v/v soln. in DCM, 1.55 mL, 0.55 mmol) was added to a solution of the dimer alcohol **97** (0.243 g, 0.25 mmol) in anhydrous DCM (10 mL). The reaction was monitored by HPLC and was complete in 1.5 h. The reaction mixture was washed with satd NaHCO₃ (3 x 50 mL), H₂O (3 x 50 mL), brine (3 x 50 mL), dried (MgSO₄) and the solvent evaporated *in vacuo*. Flash column chromatography (2% MeOH/98% CHCl₃) gave the product as a white foam (0.114 g, 50%): $[\alpha]_D^{26} = +97.5^\circ$ (c = 0.2, CHCl₃); ¹H NMR (CDCl₃) δ 7.40–7.15 (m, 12H), 6.74 (s, 2H), 5.68–5.60 (m, 2H), 4.45–4.24 (m, 6H), 4.05–3.78 (m, 8H), 3.76–3.38 (m, 6H), 3.12–3.07 (m, 2H), 2.97–2.87 (m, 2H), 2.31–1.66 (m, 12H), 1.57–1.55 (m, 2H); MS (ES) *m/z* (relative intensity) 979 (M⁺ + Na, 100), 957 (M⁺ + 1, 35); IR (neat) 3298, 2945, 1704, 1602, 1514, 1432, 1270 cm⁻¹.

1,1'-[[Pentane-1,5-diyl]dioxy]bis[(11*S*,11*aS*)-10-[*N*-(2-phenylsulfonylethyloxycarbonyl)]-11-hydroxy-7-methoxy-1,2,3,10,11,11*a*-hexahydro-5*H*-pyrrolo[2,1-*c*][1,4]benzodiazepine-5-one] (100)




The alcohol **98** (0.80 g, 0.78 mmol) was reacted (Method A) with DAIB (0.553 g, 1.72 mmol) and TEMPO (0.024 g, 0.16 mmol) in CH₂Cl₂ (5 mL). The product was obtained (flash column chromatography 2% MeOH/98% CHCl₃) as a white foam (0.641 g, 80%).

[α]_D²⁶ +73.0° (*c* = 1.0, CHCl₃); ¹H NMR (CDCl₃) δ 8.12–7.40 (m, 10H), 7.20 (s, 2H), 6.97–6.75 (m, 2H), 5.70–5.55 (m, 2H), 4.86 (bs, 2H), 4.81 (bs, 1H), 4.43 (bs, 1H), 4.22–3.97 (m, 6H), 3.88 (s, 6H), 3.75–3.16 (m, 11H), 2.21–1.82 (m, 12H), 1.72–1.54 (m, 2H); MS (ES) *m/z* (relative intensity) 1044 (*M*⁺ + Na, 60), 1043 (100), 1021 (*M*⁺, 23); IR (neat) 3345, 2953, 1748, 1628, 1319 cm⁻¹.

Deprotection of groups in compounds 66 and 67

1,1'-[[Pentane-1,5-diyl]dioxy]bis[(11*S*,11*aS*)-10-[*N*-(4-(*L*-glutamylcarbonyloxy)benzyloxycarbonyl)]-11-hydroxy-7-methoxy-1,2,3,10,11,11*a*-hexahydro-5*H*-pyrrolo[2,1-*c*][1,4]benzodiazepine-5-one] (68)




A solution of the bis-diallyl ester **66** (0.69 g, 0.49 mmol, 1 eq), Pd(PPh₃)₄ (0.08 g, 0.069 mmol, 0.14 eq) and morpholine (0.33 g, 0.33 mL, 3.8 mmol, 7.7 eq) in anhydrous CH₂Cl₂ (12 mL) was stirred at room temperature for 18 h. The solvent was decanted and the

solid residue was washed with EtOAc (2 x 15 mL), CH₂Cl₂ (2 x 15 mL), dissolved in MeOH (5 mL) and passed down an IRC 50, weakly acidic, ion exchange column, eluting with MeOH (100 mL). The solvent was removed *in vacuo* to give the product as a white foam


(0.48 g, 78%).
 $[\alpha]_D^{16.2} +98.9^\circ$ ($c = 0.273$, MeOH); $^1\text{H NMR}$ (CD₃OD) δ 7.21 (m, 4H), 7.07 (m, 6H), 6.72 (s, 2H), 5.66 (d, $J = 9$ Hz, 2H), 5.24 (d, $J = 12.2$ Hz, 2H), 4.22 (m, 2H), 3.93 (m, 6H), 3.84 (m, 8H), 3.62 (m, 4H), 3.45 (m, 4H), 2.43 (m, 4H), 2.21 (m, 2H), 2.15–1.95 (m, 10H), 1.8 (m, 4H), 1.6 (m, 2H).

1,1'-[[Pentane-1,5-diyl]dioxy]bis[(11S,11aS)-10-[N-(4-(diprop-2-enyl-L-glutamylcarbonylamino)benzyloxycarbonyl)]-11-hydroxy-7-methoxy-1,2,3,10,11,11a-hexahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5-one] (69)



A solution of the bis-diallyl ester **67** (0.29 g, 0.21 mmol, 1 eq), Pd(PPh₃)₄ (0.033 g, 0.028 mmol, 0.14 eq) and morpholine (0.14 g, 0.14 mL, 1.6 mmol, 7.7 eq) in anhydrous CH₂Cl₂ (5 mL) was stirred at room temperature for 18 h. The solvent was decanted and the solid residue was washed with EtOAc (2 x 15 mL), CH₂Cl₂ (2 x 15 mL), dissolved in MeOH (5 mL) and passed down an IRC 50, weakly acidic, ion exchange column, eluting with MeOH (100 mL). The solvent was removed *in vacuo* to give the product as an off-white solid (0.2 g 77%). $[\alpha]_D^{15.6} +143.2^\circ$ ($c = 0.234$, MeOH); $^1\text{H NMR}$ (CD₃OD) δ 7.33 (d, $J = 6.4$ Hz, 6H), 7.15 (m, 6H), 6.66 (s, 2H), 5.65 (d, $J = 9.4$ Hz, 2H), 5.26 (d, $J = 11.44$ Hz, 2H), 4.76 (d, $J = 11.8$ Hz, 2H), 4.36 (m, 2H), 4.15–3.8 (m, 12H), 3.65 (m, 4H), 2.39 (m, 4H), 2.25–1.9 (m, 12H), 1.8 (m, 4H), 1.55 (m, 2H).

Deprotection of N-10 protected dimers to give 1,1'-[(pentane-1,5-diyl)dioxy]bis[(11aS)-7-methoxy-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5-one] (61)




5

Deprotection of 1,1'-[[Pentane-1,5-diyl]dioxy]bis[(11S,11aS)-10-(allyloxycarbonyl)-11-hydroxy-7-methoxy-1,2,3,10,11,11a-hexahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5-one] (60)


- 10 A solution of the alloc protected dimer (0.068 g, 0.09 mmol, 1 eq), Pd(PPh₃)₄ (0.005 g, 0.08 mmol, 0.2 eq) and pyrrolidine (0.016 g, 0.018 mL, 0.22 mmol, 2.5 eq) in anhydrous CH₂Cl₂ (5 mL) was stirred at room temperature for 4 h and the solvent removed *in vacuo*. The product was purified by flash column chromatography
- 15 (5% MeOH/95% CHCl₃) to give **61** as a yellow solid (0.04 g, 82%).
¹H NMR (CDCl₃) δ 7.61 (d, *J* = 4.4 Hz, 2H), 7.44 (s, 2H), 6.73 (s, 2H), 4.04 (m, 4H), 3.87 (s, 6H), 3.8 (m, 2H), 3.69 (m, 2H), 3.5 (m, 2H), 2.24 (m, 4H), 2.05–1.85 (m, 8H), 1.6 (m, 2H).

- 20 *Deprotection of 1,1'-[[Pentane-1,5-diyl]dioxy]bis[(11S,11aS)-10-[N-(4-(L-glutamylcarbonyloxy)benzyloxycarbonyl)]-11-hydroxy-7-methoxy-1,2,3,10,11,11a-hexahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5-one] (68)*

- An aliquot of a 10 mM stock solution of the carbamate dimer
- 25 prodrug was diluted to 100 μM in Carboxypeptidase G2 (CPG2) assay buffer (100 mM Tris-HCl, pH 7.3; 260 μM ZnCl₂). CPG2 (1 unit) was added and the reaction was incubated at 37°C. The reaction was monitored by reversed phase HPLC (C18 column, 5 μM particle size, 250 mm x 4.6 mm; mobile phase 70% H₂O/30% CH₃CN/0.1% TFA;
- 30 detection at 245 nM) with 20 μL aliquots being injected at 0, 15, 30, 45, 60 and 75 min. The conversion of the prodrug to the parent imine **61** was complete in 75 min.

Synthesis of alternate monomer isocyanate**Methyl-2-isocyanatobenzoate (71)**

Triphosgene (5.8 g, 19.8 mmol) was added to a solution of methyl anthranilate (**70**) (1 g, 6.6 mmol) and pyridine (8.0 mL, 99 mmol) in CH₂Cl₂ and stirred at room temperature for 4 hours. The reaction mixture was washed in 1N HCl (3 x 50 mL), H₂O (3 x 50 mL), brine (3 x 50 mL) and dried over MgSO₄. Excess solvent was removed *in vacuo* to give a quantitative yield of pure material (**71**). ¹H NMR (250 MHz, CDCl₃) δ 8.02 (dd, 1H, *J* = 1.7, 7.9 Hz, aromatic H), 7.46 (dt, 1H, *J* = 1.5, 5.8, 7.7 Hz, aromatic H), 7.29–7.25 (m, 1H, H-3), 7.12 (dd, 1H, *J* = 1.2, 8.03 Hz, H-2), 3.96 (s, 3H, OMe); IR (neat) ν 3676, 3483, 3369, 2956, 2844, 2592, 2306, 2191, 2129, 1944, 1735, 1697, 1611, 1540, 1457, 1320, 1280, 1170, 1097, 1045, 968, 879, 831, 768, 704 cm⁻¹; MS *m/z* 178 9 (*M*⁺+1), 153, 152, 146, 121, 120, 92, 90.


Synthesis of alternate monomer carbamate**Methyl-2-((*E*)-3-phenyl-allyloxycarbonylamino)-benzoate (72)**

A solution of methyl-2-isocyanatobenzoate (**71**) (1 g, 5.6 mmol) in CH₂Cl₂ (100 mL) was cooled to 0°C and treated with pyridine (7 mL, 84 mmol). Cinnamyl alcohol (2.25 g, 1.68 mmol) in CH₂Cl₂ (150 mL) was added dropwise to the stirring solution over a period of 1 hour and the reaction mixture was allowed to stir for 12 hours, under nitrogen. The reaction mixture was washed in brine (100 mL). The aqueous phase was washed with CH₂Cl₂ (3 x 100 mL). The organic phases were combined and washed with 1N HCl (200 mL) and

dried over MgSO_4 . Purification was achieved through flash column chromatography (80% Pet ether:EtOAc) to furnish the carbamate (**72**) as a colourless solid (85%). ^1H NMR (250 MHz, CDCl_3) δ 10.9 (br, s, 1H, NH), 8.45 (dd, 1H, $J = 1.0, 8.5$ Hz, aromatic H), 8.01 (dd, 1H, $J = 1.66, 8.0$ Hz, aromatic H), 7.54 (ddd, 1H, $J = 1.67, 7.3, 8.5$ Hz, aromatic H), 7.5-7.2 (m, 5H, coc aromatic H), 7.03 (ddd, 1H, $J = 1.2, 8.0$ Hz, aromatic H), 6.71 (d, 1H, $J = 16$ Hz, 3'-H), 6.35 (dt, 1H, $J = 6.3, 16$ Hz, 2'-H), 4.48 (dd, 2H, $J = 1.3, 6.3$, 1'-H), 3.91 (s, 1H); ^{13}C NMR (62.9 MHz, CDCl_3) δ 169.0 (ester carbonyl), 153.5 (CO - carbamate), 141.9 (aromatic quat), 136.8 (aromatic quat), 135.0 (methine), 131.3 (methine), 129.0 (methine), 128.4 (methine), 127.1 (methine), 123.9 (alkenic methine), 122.0 (methine), 119.3 (methine), 114.8 (aromatic quat), 66.1 (methylene - Coc), 57.7 (OCH_3). IR (neat) ν 3295, 3116, 3025, 2957, 2242, 1956, 1927, 1814, 1732, 1697, 1592, 1532, 1450, 1305, 1245, 1165, 1090, 1038, 976, 913, 856, 836, 819, 766, 743, 692 cm^{-1} ; MS m/z 311 ($\text{M}^+ + 1$), 268, 212, 188, 152, 117.

Synthesis of protected PBD


20 2-((*E*)-3-phenyl-allyloxycarbonylamino)-benzoic acid (**73**)



Compound **72** (7.989 g, 26 mmol) was dissolved in aqueous methanol (3:1, 1200 mL) with THF (2-3 drops) to aid solubility. A solution of LiOH (3.12 g, 130 mmol) was added as a solid to the stirring reaction mixture at 0°C and stirred for 40 minutes. The reaction was allowed to return to room temperature and stirred for 16 hours, at which time TLC (70% Pet ether:EtOAc) revealed complete reaction. Excess methanol and THF were evaporated *in vacuo* and the remaining solution acidified to pH 2 with conc. HCl, to furnish a colourless precipitate (**73**), which was collected by filtration and dried (92%). ^1H NMR (250 MHz, CDCl_3)

δ 10.85 (s, 1H, acid OH), 10.80 (s, 1H, carbamate NH), 8.34–8.32 (d, 1H, aromatic H), 8.00 (dd, 1H, J = 1.5, 7.9 Hz, aromatic H), 7.70–7.55 (m, 1H, aromatic H), 7.53–7.10 (m, 5H, aromatic coc), 6.75 (d, 1H, J = 16 Hz, 3'-H), 6.46 (dt, 1H, J = 6.2, 16 Hz, 2'-H), 4.82 (d, 2H, J = 6.3 Hz, 1'-H); ^{13}C NMR (62.9 MHz, CDCl_3) δ 170.6 (ester carbonyl), 153.2 (CO carbamate), 142.0 (aromatic quat), 137.1 (aromatic quat), 135.1 (methine), 134.5 (alkenic methine), 132.5 (methine), 131.0 (methine), 127.7 (methine), 125.0 (alkenic methine), 122.6 (methine), 119.0 (methine), 116.5 (aromatic quat), 66.5 (methylene Coc). MS m/z 297 ($\text{M}^+ + 1$), 265, 252, 236, 224, 205, 189, 176, 149, 138, 117.

{2-[1-(3-hydroxymethyl-pyrrolidin-1-yl)-methanoyl]-phenyl} carbamic acid (E)-3-phenyl-allyl ester (74)




15

A solution of DCC (4.54 g, 22 mmol) dissolved in the minimum of CH_2Cl_2 was added dropwise to compound **73** (6 g, 0.020 mol) in CH_2Cl_2 at -5°C , whilst stirring, with a catalytic amount of DMF (10 drops). The reaction mixture was stirred for a further five minutes before HOBt (3.0 g, 22 mmol) in CH_2Cl_2 was added. The reaction mixture was allowed to stir for 1 hour at -5°C , then left to stir for 12 hours at room temperature. The colourless precipitate of DCU was removed by filtration and the remaining reaction mixture cooled to -5°C . (S)-pyrrolidinemethanol (2.37 mL, 24 mmol) was added and the reaction mixture allowed to warm to room temperature and, stirred for 12 hours. TLC (70% Pet ether/EtOAc) revealed reaction completion. The reaction mixture was washed with NaHCO_3 (4 x 100 mL), NH_4Cl (4 x 100 mL), H_2O (4 x 100 mL), brine (4 x 100 mL) and dried over MgSO_4 . Purification was achieved via flash column chromatography (60% pet ether/EtOAc) to furnish compound **74** as a stiff brown oil (95%).

¹H NMR (250 MHz, CDCl₃); δ 8.69 (s, 1H, NH), 8.13 (d, 1H, *J* = 8.2 Hz, aromatic H), 7.42-7.22 (m, 6H, Coc aromatic H and aromatic H), 7.06 (ddd, 1H, *J* = 1.07, 7.6, 7.5, aromatic H), 6.70 (d, 1H, *J* = 16 Hz, 3'-H), 6.34 (dt, 1H, *J* = 6.4, 18 Hz, 2'-H), 4.81 (dd, 2H, *J* = 1.1, 6.4, 1'-H), 4.40 (br, s, 1H, H-11a), 3.85-3.42 (m, 4H, H-11, H-3), 2.06-1.70 (m, 4H, 1-H, H-2); ¹³C NMR (62.9 MHz, CDCl₃) δ 171.3 (ester carbonyl), 136.6 (aromatic quat), 134.6 (methine), 131.3 (methine), 129.0 (methine), 128.5 (methine), 128.0 (methine), 127.1 (methine), 123.9 (alkenic methine), 122.7 (methine), 121.3 (methine), 67.0 (Coc, C-1), 66.2 (methylene Coc), 61.1 (methine, C-11a), 51.9 (methine, C-3), 28.8 (methine, C-1), 25.5 (methine, C-2); MS *m/z*; 381 (*M*⁺+1), 363, 337, 308, 279, 261, 247, 229, 203, 117.


(11*S*, 11a*S*)-11-hydroxy-10-((*E*)-3-phenyl-allyloxycarbonyl)hexahydro-5*H*-pyrrolo[2,1-*c*][1,4]benzodiazepin-5-one (75)



A solution of DMSO (4.6 mL 65 mmol) in CH₂Cl₂ was added over 20 minutes to a stirring solution of oxalyl chloride (16.5 mL, 33 mmol) in CH₂Cl₂ at -40°C and left to stir for a further 20 minutes. Compound **74** (7 g, 18 mmol) was dissolved in CH₂Cl₂ and added over a period of 45 minutes to the reaction mixture. Once addition was complete, the reaction mixture was stirred at -40°C for a further 60 minutes. Over a period of 30 minutes TEA (10.8 mL, 77 mmol) in CH₂Cl₂ was added and stirred for a further 30 minutes, and then warmed to room temperature. The reaction mixture was washed with 1N HCl (3 x 100 mL), H₂O (3 x 100 mL), brine (3 x 100 mL) and dried over MgSO₄. Purification was achieved via flash column chromatography (AcOH:MeOH:CDCl₃ 1:10:100) and excess solvent was removed *in vacuo* to yield compound **75** as a solid colourless powder (92% yield). [α]^{22.4}_D =

+256° (*c* = 1, CHCl₃); ¹H NMR (250 MHz, CDCl₃) δ 7.76 (dd, 1H, *J* = 1.6, 7.5 Hz, aromatic H), 7.60-7.30 (m, 5H, Coc aromatic H), 6.46 (d, 1H, *J* = 16 Hz, 3'-H), 6.30-5.94 (m, 1H, 2'-H), 5.71 (d, 1H, *J* = 9.7 Hz, H-11), 4.86-4.72 (m, 2H, 1'-H), 3.77-3.41 (m, 4H, 11a-H, H-3), 2.17-1.78 (m, 4H, 1-H, H-2); ¹³C NMR (62.9 MHz, DMSO) δ 163.9 (C=O amide), 155.8 (C=O carbinolamine), 136.7 (aromatic quat), 135.0 (aromatic quat), 131.8 (methine), 131.4 (methine), 129.5 (methine), 129.1 (methine), 128.8 (methine), 127.3 (methine), 86.0 (methine CC-11), 67.1 (methylene coc), 61.2 (methine C-11a), 46.8 (methylene C-3), 29.1 (methylene C-1), 23.5 (methylene C-2); MS *m/z* 379 (*M*⁺+1), 363, 317, 277, 245, 225, 117.

PBD Deprotection




15 A solution of Pd(PPh₃)₄ (0.038 g, 0.0325 mmol) in CH₂Cl₂ was added to a solution of **75** (0.5 g, 1.3 mmol), TPP (0.017 g, 0.065 mmol) and pyrrolidine (0.097 g, 1.37 mmol) in CH₂Cl₂. Flash column chromatography (2% MeOH/CDCl₃) furnished a colourless powder in a
20 76% yield as a mixture of carbinolamine methyl ether and imine forms. ¹H NMR (250 MHz, CDCl₃) δ 8.02 (dd, 1H, *J* = 1.6, 23.2 Hz, aromatic H), 7.78-7.75 (m, 1H, aromatic H), 7.68-7.23 (m, 1H, aromatic H), 7.20-7.15 (m, 1H, aromatic H), 6.86-6.81 (m, 1H, aromatic H), 6.61 (d, 1H, *J* = 8.2 Hz aromatic H), 5.66 (d, 1H, *J* = 8.7 Hz, N10-H, carbinolamine), 5.34 (d, 1H, *J* = 5.8 Hz, N10-H, methyl ether), 4.57 (d, 1H, *J* = 6.2 Hz 11-H, *R* diastereomer), 4.41 (d, 1H, *J* = 8.9 Hz, 11-H, *S* diastereomer), 3.91-3.32 (m, 3H, H-3, H-11a), 3.45 (s, 11-OMe, *R* diastereomer), 3.32 (s, 11-OMe, *S* diastereomer), 2.31-1.32 (m, 4H, 2-H, H-1); ¹³C NMR (62.9 MHz, CDCl₃) δ 165.2 (C=O amide), 164.9 (imine signal), 146.1 (aromatic quat), 131.8 (methine). 130.7 (methine). 127.2 (methine), 126.9

(methine), 85.8 (C-11, carbinolamine methyl ether), 60.0 (C-11a, 1H), 53.9 (methoxy - OMe), 47.1 (1H, C-3), 30.0 (1H, C-1), 24.6 (1H, C-2); MS m/z 201 ($M^{+}+1$ imine form), 188, 177, 132, 117, 100, 90.


CLAIMS

1. A method of synthesis of a compound of formula (I):




5 comprising the step of either:

(a) reacting a compound of formula (II) with a compound of formula (III) to yield a compound of formula (IV):



(b) reacting a compound of formula (V) with a compound of formula (III) to yield a compound of formula (VI):



wherein

the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3;

15 R^2 and R^3 are independently selected from -H, -OH, =O, =CH₂, -CN, -R, OR, =CH-R, O-SO₂-R, CO₂R and COR;

R^6 , R^7 and R^9 are independently H, R, OH, OR, SH, SR, NH₂, NHR, NRR', nitro, Me₃Sn and halo;

R^8 is either selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR', nitro, Me₃Sn and halo or the compound is a dimer with each monomer being the same or different and being of the relevant formula, where the R^8 groups of each monomer form together a bridge having the formula -X-R''-X-, where R'' is a C₃₋₁₂ alkylene group, which chain may be interrupted by one or more heteroatoms and/or aromatic rings, and each X is independently selected from O, S and NH;

R^{10} is such that R^{10} -OC(=O)- forms a nitrogen protecting group;

R^{11} is either H or R;


R^{12} is an optionally substituted C₁₋₄ alkyl group;

P and Q are such that -CPQ is a masked aldehyde group;

wherein R and R' are independently selected from optionally substituted C₁₋₂₀ alkyl, C₃₋₂₀ heterocyclyl, and C₅₋₂₀ aryl.


15

2. A method according to claim 1 comprising step (a), wherein the synthesis of the compound of formula (I) from the compound of formula (IV) is:




wherein T is O or S, and each R^{ac} is independently selected from C_{1-10} alkyl or together can be a C_{1-3} alkylene group.


3. A method according to either claim 1 or claim 2 comprising
 5 step (a) of claim 1, where the compound of formula (II) is synthesised by:




4. A method according to claim 1 comprising step (b), wherein
 10 the synthesis of the compound of formula (I) from the compound of formula (VI) is:



5. A method according to either claim 1 or claim 4 comprising
 15 step (b) of claim 1, wherein the compound of formula (IV) is synthesised by:



6. A compound of formula (IV):



(IV)

wherein:


R^6 , R^7 and R^9 are independently H, R, OH, OR, SH, SR, NH_2 , NHR, NRR', nitro, Me_3Sn and halo;

- 5 R^8 is either selected from H, R, OH, OR, SH, SR, NH_2 , NHR, NRR', nitro, Me_3Sn and halo or the compound is a dimer with each monomer being the same or different and being of the relevant formula, where the R^8 groups of each monomer form together a bridge having the formula $-X-R''-X-$, where R'' is a C_{3-12} alkylene group, which
- 10 chain may be interrupted by one or more heteroatoms and/or aromatic rings, and each X is independently selected from O, S and NH;

R^{10} is such that $R^{10}-OC(=O)-$ forms a nitrogen protecting group; and R^{12} is an optionally substituted C_{1-4} alkyl group,

- 15 wherein R and R' are independently selected from optionally substituted C_{1-20} alkyl, C_{3-20} heterocyclyl, and C_{5-20} aryl.

7. A compound of formula (VI):



(VI)

20 wherein:

R^2 and R^3 are independently selected from $-H$, $-OH$, $=O$, $=CH_2$, $-CN$, $-R$, OR, $=CH-R$, $O-SO_2-R$, CO_2R and COR;

R^6 , R^7 and R^9 are independently H, R, OH, OR, SH, SR, NH_2 , NHR, NRR', nitro, Me_3Sn and halo;

R^8 is either selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR', nitro, Me₃Sn and halo or the compound is a dimer with each monomer being the same or different and being of the relevant formula, where the R^8 groups of each monomer form together a bridge having
5 the formula -X-R''-X-, where R'' is a C₃₋₁₂ alkylene group, which chain may be interrupted by one or more heteroatoms and/or aromatic rings, and each X is independently selected from O, S and NH;

R^{10} is such that R^{10} -OC(=O)- forms a nitrogen protecting group;

10 R^{12} is an optionally substituted C₁₋₄ alkyl group; and

P and Q are such that -CPQ is a masked aldehyde group;

wherein R and R' are independently selected from optionally substituted C₁₋₂₀ alkyl, C₃₋₂₀ heterocyclyl, and C₅₋₂₀ aryl,

with the proviso that when R^2 , R^3 , R^6 , R^7 , R^8 and R^9 are H, P and Q
15 are -OCH₃, then R^{10} is not -CH₂-Si(CH₃)₃.

8. A method according to any one of claims 1 to 5, or a compound according to either claim 6 or claim 7, wherein R^{10} is an optionally substituted C₁₋₃₀ alkyl group, C₃₋₃₀ heterocyclyl group or
20 a C₅₋₃₀ aryl group or a divalent version of one of these groups linked to another moiety.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2004/003873

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D487/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 00/12507 A (UNIV PORTSMOUTH ; HOWARD PHILIP WILSON (GB); THURSTON DAVID EDWIN (GB)) 9 March 2000 (2000-03-09) cited in the application page 17, line 25 - page 21, line 14; figures 1-3	1-8
A	----- FUKUYAMA ET AL: "Total synthesis of (+)-porothramycin B" 1993, TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, PAGE(S) 2577-2580 , XP002135999 ISSN: 0040-4039 the whole document	1-8
A	----- EP 1 193 270 A (SPIROGEN LTD) 3 April 2002 (2002-04-03) page 8, line 45 - page 20, line 14; figures 1-28 -----	1-8

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

16 December 2004

Date of mailing of the international search report

23/12/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Kyriakakou, G

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2004/003873

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0012507	A	09-03-2000	AT 246687 T	15-08-2003
			AU 758398 B2	20-03-2003
			AU 5526199 A	21-03-2000
			CA 2341968 A1	09-03-2000
			DE 69910227 D1	11-09-2003
			DE 69910227 T2	17-06-2004
			DK 1109811 T3	24-11-2003
			EP 1109811 A2	27-06-2001
			ES 2205872 T3	01-05-2004
			WO 0012507 A2	09-03-2000
			JP 2002525284 T	13-08-2002
			NZ 510492 A	29-08-2003
			PT 1109811 T	31-12-2003
			US 2003195196 A1	16-10-2003
			US 6562806 B1	13-05-2003
EP 1193270	A	03-04-2002	EP 1193270 A2	03-04-2002
			EP 1413582 A1	28-04-2004
			AT 240334 T	15-05-2003
			AU 757510 B2	20-02-2003
			AU 5635199 A	21-03-2000
			CA 2341471 A1	09-03-2000
			DE 69907977 D1	18-06-2003
			DE 69907977 T2	22-07-2004
			DK 1193270 T3	15-09-2003
			EP 1109812 A2	27-06-2001
			ES 2199200 T3	16-02-2004
			WO 0012508 A2	09-03-2000
			JP 2002525285 T	13-08-2002
			NZ 510493 A	28-11-2003
			PT 1193270 T	31-10-2003
			US 2003120069 A1	26-06-2003